{"2af60a6edf5657d366fc1f0ee1f3fda18b9418a3": [["disease with high mortality.", [["disease", "PROBLEM", 0, 7], ["high mortality", "PROBLEM", 13, 27], ["high", "OBSERVATION_MODIFIER", 13, 17], ["mortality", "OBSERVATION", 18, 27]]], ["Recent emergence events exemplified by severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) in humans (1) and swine acute diarrhea syndrome coronavirus (SADS-CoV) in domestic pigs (2) have demonstrated how devastating these viruses can be within naive populations.", [["acute respiratory syndrome coronavirus", "DISEASE", 46, 84], ["SARS-CoV)", "DISEASE", 86, 95], ["Middle East respiratory syndrome coronavirus", "DISEASE", 100, 144], ["acute diarrhea syndrome coronavirus", "DISEASE", 180, 215], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 39, 84], ["SARS-CoV", "ORGANISM", 86, 94], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 100, 144], ["MERS-CoV", "ORGANISM", 146, 154], ["humans", "ORGANISM", 159, 165], ["swine acute diarrhea syndrome coronavirus", "ORGANISM", 174, 215], ["SADS-CoV", "ORGANISM", 217, 225], ["pigs", "ORGANISM", 239, 243], ["naive populations", "CELL_TYPE", 310, 327], ["humans", "SPECIES", 159, 165], ["swine", "SPECIES", 174, 179], ["acute diarrhea syndrome coronavirus", "SPECIES", 180, 215], ["pigs", "SPECIES", 239, 243], ["severe acute respiratory syndrome coronavirus", "SPECIES", 39, 84], ["SARS-CoV", "SPECIES", 86, 94], ["Middle East respiratory syndrome coronavirus", "SPECIES", 100, 144], ["MERS-CoV", "SPECIES", 146, 154], ["humans", "SPECIES", 159, 165], ["swine acute diarrhea syndrome coronavirus", "SPECIES", 174, 215], ["SADS-CoV", "SPECIES", 217, 225], ["Recent emergence events", "PROBLEM", 0, 23], ["severe acute respiratory syndrome coronavirus (SARS-CoV)", "PROBLEM", 39, 95], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 100, 144], ["swine acute diarrhea syndrome coronavirus", "PROBLEM", 174, 215], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory syndrome coronavirus", "OBSERVATION", 52, 84], ["Middle", "ANATOMY_MODIFIER", 100, 106], ["respiratory syndrome", "OBSERVATION", 112, 132], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["diarrhea", "OBSERVATION", 186, 194], ["viruses", "OBSERVATION", 288, 295]]], ["To date, there are no approved antivirals or effective vaccines that protect humans from coronavirus diseases.", [["coronavirus diseases", "DISEASE", 89, 109], ["humans", "ORGANISM", 77, 83], ["coronavirus", "ORGANISM", 89, 100], ["humans", "SPECIES", 77, 83], ["coronavirus", "SPECIES", 89, 100], ["humans", "SPECIES", 77, 83], ["antivirals", "TREATMENT", 31, 41], ["effective vaccines", "TREATMENT", 45, 63], ["coronavirus diseases", "PROBLEM", 89, 109], ["no", "UNCERTAINTY", 19, 21], ["coronavirus diseases", "OBSERVATION", 89, 109]]], ["Therefore, identifying viral factors that contribute to pathogenesis and characterizing novel targets for therapeutic interventions are two important approaches to facilitate the development of effective vaccines and antivirals.", [["viral factors", "PROTEIN", 23, 36], ["viral factors", "PROBLEM", 23, 36], ["pathogenesis", "PROBLEM", 56, 68], ["therapeutic interventions", "TREATMENT", 106, 131], ["effective vaccines", "TREATMENT", 194, 212], ["antivirals", "TREATMENT", 217, 227], ["viral", "OBSERVATION", 23, 28]]]], "PMC7524685": [["IntroductionThe COVID-19 pandemic has highlighted the importance of international solidarity and unity in the face of a dire global health and economic crisis.", [["economic crisis", "PROBLEM", 143, 158], ["economic crisis", "OBSERVATION", 143, 158]]], ["Although massive intervention measures (e.g., shutting down cities, extending holidays, and travel bans) have been implemented in China and many other countries, the spread of the disease is unlikely to be stopped worldwide in the near future.", [["massive intervention measures", "TREATMENT", 9, 38], ["the disease", "PROBLEM", 176, 187], ["massive", "OBSERVATION_MODIFIER", 9, 16], ["intervention", "OBSERVATION", 17, 29], ["disease", "OBSERVATION", 180, 187]]], ["No effective vaccines or antiviral drugs have been clinically approved so far.", [["effective vaccines", "TREATMENT", 3, 21], ["antiviral drugs", "TREATMENT", 25, 40], ["effective", "OBSERVATION_MODIFIER", 3, 12], ["vaccines", "OBSERVATION", 13, 21], ["antiviral drugs", "OBSERVATION", 25, 40]]], ["Our current understanding of the factors that impact SARS-CoV-2 transmission is still limited.IntroductionEnvironmental factors are associated with the seasonality of respiratory-borne disease epidemics (Sooryanarain and Elankumaran, 2015).", [["SARS", "DISEASE", 53, 57], ["respiratory-borne disease", "DISEASE", 167, 192], ["SARS-CoV-2", "ORGANISM", 53, 63], ["CoV-2 transmission", "TEST", 58, 76], ["respiratory-borne disease epidemics", "PROBLEM", 167, 202], ["respiratory", "ANATOMY", 167, 178]]], ["Some research has investigated both indoor and outdoor environmental nitrogen dioxide (NO2) pollution exposure to individuals (Salonen et al., 2019).", [["nitrogen dioxide", "CHEMICAL", 69, 85], ["NO2", "CHEMICAL", 87, 90], ["nitrogen dioxide", "CHEMICAL", 69, 85], ["NO2", "CHEMICAL", 87, 90], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 69, 85], ["NO2", "SIMPLE_CHEMICAL", 87, 90], ["environmental nitrogen dioxide", "TREATMENT", 55, 85]]], ["Previous cross-sectional and cohort research has provided evidence that ambient NO2 exposure had longitudinal effects on growth in lung function (Molter et al., 2013), causing pulmonary insufficiency (e.g., lung volume, expiratory flow).", [["lung", "ANATOMY", 131, 135], ["pulmonary", "ANATOMY", 176, 185], ["lung", "ANATOMY", 207, 211], ["NO2", "CHEMICAL", 80, 83], ["pulmonary insufficiency", "DISEASE", 176, 199], ["NO2", "CHEMICAL", 80, 83], ["NO2", "SIMPLE_CHEMICAL", 80, 83], ["lung", "ORGAN", 131, 135], ["pulmonary", "ORGAN", 176, 185], ["lung", "ORGAN", 207, 211], ["ambient NO2 exposure", "PROBLEM", 72, 92], ["longitudinal effects on growth in lung function", "PROBLEM", 97, 144], ["pulmonary insufficiency", "PROBLEM", 176, 199], ["lung volume", "TEST", 207, 218], ["expiratory flow", "TEST", 220, 235], ["lung", "ANATOMY", 131, 135], ["pulmonary", "ANATOMY", 176, 185], ["insufficiency", "OBSERVATION", 186, 199], ["lung", "ANATOMY", 207, 211], ["volume", "OBSERVATION_MODIFIER", 212, 218], ["expiratory flow", "OBSERVATION", 220, 235]]], ["In addition, previous studies have suggested that ambient NO2 exposure may play a role in the phenotypes of respiratory diseases including but not limited to influenza (Huang et al., 2016), asthma (Weinmayr et al., 2010), and severe acute respiratory syndrome (Kan et al., 2005).", [["respiratory", "ANATOMY", 108, 119], ["NO2", "CHEMICAL", 58, 61], ["respiratory diseases", "DISEASE", 108, 128], ["influenza", "DISEASE", 158, 167], ["asthma", "DISEASE", 190, 196], ["acute respiratory syndrome", "DISEASE", 233, 259], ["NO2", "CHEMICAL", 58, 61], ["NO2", "SIMPLE_CHEMICAL", 58, 61], ["previous studies", "TEST", 13, 29], ["ambient NO2 exposure", "PROBLEM", 50, 70], ["respiratory diseases", "PROBLEM", 108, 128], ["influenza", "PROBLEM", 158, 167], ["asthma", "PROBLEM", 190, 196], ["severe acute respiratory syndrome", "PROBLEM", 226, 259], ["respiratory diseases", "OBSERVATION", 108, 128], ["severe", "OBSERVATION_MODIFIER", 226, 232], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["respiratory syndrome", "OBSERVATION", 239, 259]]], ["For example, NO2 might increase adults\u2019 susceptibility to viral infections (Goings et al., 1989).", [["NO2", "CHEMICAL", 13, 16], ["viral infections", "DISEASE", 58, 74], ["NO2", "CHEMICAL", 13, 16], ["NO2", "SIMPLE_CHEMICAL", 13, 16], ["NO2", "PROBLEM", 13, 16], ["viral infections", "PROBLEM", 58, 74], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["infections", "OBSERVATION", 64, 74]]], ["Exposure to high levels of NO2 before the start of a respiratory viral infection is associated with the severity of asthma exacerbation (Chauhan et al., 2003).IntroductionRecently, a European study found that 78% of COVID-19 fatalities were located in five regions that showed the highest concentrations of NO2 (Ogen, 2020).", [["NO2", "CHEMICAL", 27, 30], ["respiratory viral infection", "DISEASE", 53, 80], ["asthma", "DISEASE", 116, 122], ["fatalities", "DISEASE", 225, 235], ["NO2", "CHEMICAL", 307, 310], ["NO2", "CHEMICAL", 27, 30], ["NO2", "CHEMICAL", 307, 310], ["NO2", "SIMPLE_CHEMICAL", 27, 30], ["NO2", "SIMPLE_CHEMICAL", 307, 310], ["NO2", "TREATMENT", 27, 30], ["a respiratory viral infection", "PROBLEM", 51, 80], ["asthma exacerbation", "PROBLEM", 116, 135], ["a European study", "TEST", 181, 197], ["COVID", "TEST", 216, 221], ["high levels", "OBSERVATION_MODIFIER", 12, 23], ["respiratory", "ANATOMY", 53, 64], ["viral infection", "OBSERVATION", 65, 80], ["asthma", "OBSERVATION", 116, 122], ["highest", "OBSERVATION_MODIFIER", 281, 288], ["concentrations", "OBSERVATION_MODIFIER", 289, 303]]], ["This finding indicates that long-term NO2 exposure may be an important risk factor for COVID-19 fatality.", [["NO2", "CHEMICAL", 38, 41], ["NO2", "CHEMICAL", 38, 41], ["NO2", "SIMPLE_CHEMICAL", 38, 41], ["long-term NO2 exposure", "PROBLEM", 28, 50], ["COVID", "TEST", 87, 92], ["long-term", "OBSERVATION_MODIFIER", 28, 37]]], ["However, Contini et al. (Contini and Costabile, 2020) discussed the relationships between atmospheric parameters and COVID-19 prevalence or fatality are influenced by several confounding factors, which made difficult to interpret correlations that are not indicating necessarily a cause-effect relationship in the description study.", [["atmospheric parameters", "TEST", 90, 112], ["COVID", "TEST", 117, 122], ["the description study", "TEST", 310, 331]]], ["Although it\u2019s an inevitable limitation in our description study, our study aims to thoroughly explore the influence of NO2 on COVID-19 transmission and to try to acquire more solid results with potential confounders adjusted.Theory/calculationIn this study, we aim to assess the associations between ambient NO2 levels and the spread ability of COVID-19 across 63 Chinese cities, and we provide information to facilitate the further prevention and control of COVID-19.Data collection ::: MethodsWe collected COVID-19 confirmed case information reported by the National Health Commission of the People\u2019s Republic of China (WHO, 2020) and Health Commission of Hubei Province (http://wjw.hubei.gov.cn/bmdt/ztzl/fkxxgzbdgrfyyq/).", [["NO2", "CHEMICAL", 119, 122], ["NO2", "CHEMICAL", 308, 311], ["NO2", "CHEMICAL", 119, 122], ["NO2", "CHEMICAL", 308, 311], ["COVID-19", "CHEMICAL", 459, 467], ["NO2", "SIMPLE_CHEMICAL", 119, 122], ["NO2", "SIMPLE_CHEMICAL", 308, 311], ["COVID-19", "SPECIES", 345, 353], ["our description study", "TEST", 42, 63], ["our study", "TEST", 65, 74], ["COVID-19 transmission", "TREATMENT", 126, 147], ["this study", "TEST", 246, 256], ["ambient NO2 levels", "TEST", 300, 318], ["COVID", "TEST", 345, 350], ["COVID", "TEST", 459, 464], ["inevitable", "OBSERVATION_MODIFIER", 17, 27], ["limitation", "OBSERVATION_MODIFIER", 28, 38]]], ["Guidelines on the diagnosis and treatment of patients were defined according to the fourth version of the guidelines (issued on January 27, 2020).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["treatment", "TREATMENT", 32, 41]]], ["The clinical criteria for diagnosis were to meet any two of the three remaining clinical criteria (i.e., fever, radiographic findings of pneumonia, and normal or reduced white blood cell count or reduced lymphocyte count in the early stage of illness).", [["white blood cell", "ANATOMY", 170, 186], ["lymphocyte", "ANATOMY", 204, 214], ["fever", "DISEASE", 105, 110], ["pneumonia", "DISEASE", 137, 146], ["blood cell", "CELL", 176, 186], ["lymphocyte", "CELL", 204, 214], ["fever", "PROBLEM", 105, 110], ["pneumonia", "PROBLEM", 137, 146], ["reduced white blood cell count", "PROBLEM", 162, 192], ["reduced lymphocyte count", "PROBLEM", 196, 220], ["pneumonia", "OBSERVATION", 137, 146], ["lymphocyte count", "OBSERVATION", 204, 220], ["early stage", "OBSERVATION_MODIFIER", 228, 239]]], ["The population movement in cities outside Hubei from the same period was obtained from Baidu Qianxi data (https://qianxi.baidu.com/2020/), and we used migration index and travel intensity to describe the movement.", [["migration index", "TREATMENT", 151, 166], ["population", "OBSERVATION_MODIFIER", 4, 14], ["movement", "OBSERVATION_MODIFIER", 15, 23]]], ["We obtained hourly concentrations of various air pollutants, including sulfur dioxide (SO2), NO2, carbon monoxide (CO), ozone (O3), fine particulate matter (PM2.5), and inhalable particulate matter (PM10).", [["sulfur dioxide", "CHEMICAL", 71, 85], ["SO2", "CHEMICAL", 87, 90], ["NO2", "CHEMICAL", 93, 96], ["carbon monoxide", "CHEMICAL", 98, 113], ["CO", "CHEMICAL", 115, 117], ["ozone", "CHEMICAL", 120, 125], ["O3", "CHEMICAL", 127, 129], ["PM2.5", "CHEMICAL", 157, 162], ["PM10", "CHEMICAL", 199, 203], ["sulfur dioxide", "CHEMICAL", 71, 85], ["SO2", "CHEMICAL", 87, 90], ["NO2", "CHEMICAL", 93, 96], ["carbon monoxide", "CHEMICAL", 98, 113], ["CO", "CHEMICAL", 115, 117], ["ozone", "CHEMICAL", 120, 125], ["O3", "CHEMICAL", 127, 129], ["sulfur dioxide", "SIMPLE_CHEMICAL", 71, 85], ["SO2", "SIMPLE_CHEMICAL", 87, 90], ["NO2", "SIMPLE_CHEMICAL", 93, 96], ["carbon monoxide", "SIMPLE_CHEMICAL", 98, 113], ["CO", "SIMPLE_CHEMICAL", 115, 117], ["ozone", "SIMPLE_CHEMICAL", 120, 125], ["O3", "SIMPLE_CHEMICAL", 127, 129], ["PM2.5", "SIMPLE_CHEMICAL", 157, 162], ["inhalable particulate matter", "SIMPLE_CHEMICAL", 169, 197], ["various air pollutants", "TREATMENT", 37, 59], ["sulfur dioxide (SO2", "TREATMENT", 71, 90], ["NO2", "TREATMENT", 93, 96], ["carbon monoxide (CO)", "TREATMENT", 98, 118], ["ozone (O3)", "TREATMENT", 120, 130], ["air pollutants", "OBSERVATION", 45, 59]]], ["These data came from 63 cities (cities in China with more than 50 confirmed COVID-19 cases as of February 10, 2020) and ranged from January 1, 2020 to February 8, 2020.", [["These data", "TEST", 0, 10]]], ["The data were acquired from the National Urban Air Quality Publishing Platform (http://106.37.208.233:20035/), which is administered by China\u2019s Ministry of Environmental Protection.", [["The data", "TEST", 0, 8], ["Environmental Protection", "TREATMENT", 156, 180]]], ["Daily concentrations of these air pollutants were calculated as the average of at least 18 (75%) hourly concentrations for all state-controlled stations, and then the values for each city were calculated as the average among all valid stations within the city limits.", [["these air pollutants", "TREATMENT", 24, 44], ["air pollutants", "OBSERVATION", 30, 44]]], ["We calculated the average daily concentrations of these air pollutants in all 63 Chinese cities.", [["these air pollutants", "TREATMENT", 50, 70], ["air pollutants", "OBSERVATION", 56, 70]]], ["In addition, the average of the annual NO2 concentrations from 2016\u20132019 was obtained to estimate the long-term exposure level.", [["NO2", "CHEMICAL", 39, 42], ["NO2", "CHEMICAL", 39, 42], ["NO2", "SIMPLE_CHEMICAL", 39, 42], ["the annual NO2 concentrations", "TEST", 28, 57], ["long-term", "OBSERVATION_MODIFIER", 102, 111]]], ["Other meteorological data including daily mean temperature and relative humidity were collected from the China Meteorological Data Sharing Service System.Basic reproductive number ::: MethodsThe reproductive number (R0), the average number of individuals infected by an initial infectious individual in a completely susceptible population, is fundamental to understanding disease transmission.", [["Other meteorological data", "TEST", 0, 25], ["daily mean temperature", "TEST", 36, 58], ["Methods", "TREATMENT", 184, 191], ["reproductive", "OBSERVATION_MODIFIER", 195, 207], ["number", "OBSERVATION_MODIFIER", 208, 214], ["average", "OBSERVATION_MODIFIER", 225, 232], ["number", "OBSERVATION_MODIFIER", 233, 239], ["infected", "OBSERVATION_MODIFIER", 255, 263], ["infectious", "OBSERVATION_MODIFIER", 278, 288], ["susceptible", "OBSERVATION_MODIFIER", 316, 327], ["population", "OBSERVATION", 328, 338]]], ["We calculated R0 for 63 Chinese cities with more than 50 cases as of February 10, 2020 (the COVID-19 peak period in China), including 12 and 51 cities inside and outside Hubei, respectively.", [["the COVID", "TEST", 88, 97]]], ["We used the method introduced by Aaron et al. to estimate R0 (Aaron A. King et al., 2017).", [["the method", "TREATMENT", 8, 18]]], ["First, we constructed a linear regression model to estimate the relevant coefficient.", [["a linear regression model", "TREATMENT", 22, 47]]], ["Second, we obtained R0 by combining the coefficients obtained from the previous step with the average incubation and confirmation periods.", [["the average incubation", "TREATMENT", 90, 112]]], ["We assigned the average values of the incubation period and the mean course from case infection to confirmation as 7 and 3.8 days, respectively.", [["infection", "DISEASE", 86, 95], ["case infection", "PROBLEM", 81, 95]]], ["These values were obtained in previous mathematical research (Pan et al., 2020).", [["These values", "TEST", 0, 12]]], ["All calculations were completed in R software version 3.6.1 (R Foundation for Statistical Computing).Testing for mediation ::: MethodsMediation is a hypothesized causal chain in which one variable affects a second variable that, in turn, affects a third variable (Lederer et al., 2019).", [["All calculations", "TEST", 0, 16], ["R software version", "TEST", 35, 53]]], ["The relationship between NO2 concentration and R0 of COVID-19 may be mediated by population density or other air pollutants, such as city population and city area.", [["NO2", "CHEMICAL", 25, 28], ["COVID-19", "CHEMICAL", 53, 61], ["NO2", "CHEMICAL", 25, 28], ["COVID-19", "CHEMICAL", 53, 61], ["NO2", "SIMPLE_CHEMICAL", 25, 28], ["NO2 concentration", "TREATMENT", 25, 42], ["R0 of COVID", "TREATMENT", 47, 58], ["other air pollutants", "PROBLEM", 103, 123], ["density", "OBSERVATION", 92, 99], ["air pollutants", "OBSERVATION", 109, 123]]], ["Those mediators may indirectly affect the R0 value of COVID-19 by modulating the NO2 concentration, thus affecting the spread of COVID-19.", [["NO2", "CHEMICAL", 81, 84], ["COVID-19", "CHEMICAL", 54, 62], ["NO2", "CHEMICAL", 81, 84], ["COVID-19", "CHEMICAL", 129, 137], ["NO2", "SIMPLE_CHEMICAL", 81, 84], ["the R0 value", "TEST", 38, 50], ["COVID", "TEST", 54, 59], ["the NO2 concentration", "TEST", 77, 98], ["COVID", "TEST", 129, 134], ["NO2 concentration", "OBSERVATION", 81, 98]]], ["In this study, we used mediation analysis to explore whether these factors were mediators of the relationship between NO2 and R0 of COVID-19, and we used bootstrapping to estimate standard error while testing the significance of these mediating effects.Statistical analysis ::: MethodsWe conducted a cross-sectional analysis to examine the associations of NO2 with R0 of COVID-19.", [["NO2", "CHEMICAL", 118, 121], ["NO2", "CHEMICAL", 356, 359], ["NO2", "CHEMICAL", 118, 121], ["COVID-19", "CHEMICAL", 132, 140], ["NO2", "CHEMICAL", 356, 359], ["COVID-19", "CHEMICAL", 371, 379], ["NO2", "SIMPLE_CHEMICAL", 118, 121], ["NO2", "SIMPLE_CHEMICAL", 356, 359], ["this study", "TEST", 3, 13], ["mediation analysis", "TEST", 23, 41], ["NO2", "TREATMENT", 118, 121], ["COVID", "TEST", 132, 137], ["bootstrapping", "TREATMENT", 154, 167], ["a cross-sectional analysis", "TEST", 298, 324], ["COVID", "TEST", 371, 376]]], ["We also conducted a longitudinal analysis to examine the temporal associations (with daily data points) of NO2 with R0 in cities inside Hubei Province since the date when they had enough confirmed cases to acquire stable daily R0 values.", [["NO2", "CHEMICAL", 107, 110], ["NO2", "CHEMICAL", 107, 110], ["NO2", "SIMPLE_CHEMICAL", 107, 110], ["a longitudinal analysis", "TEST", 18, 41]]], ["When examining the correlation between NO2 and R0 of COVID-19, we estimated the associations of NO2 concentration with R0 both inside and outside Hubei province (r & p) in the same period by using multiple linear regression models after controlling for temperature and relative humidity (as covariates in the regression model) separately.", [["NO2", "CHEMICAL", 39, 42], ["NO2", "CHEMICAL", 96, 99], ["NO2", "CHEMICAL", 39, 42], ["COVID-19", "CHEMICAL", 53, 61], ["NO2", "CHEMICAL", 96, 99], ["NO2", "SIMPLE_CHEMICAL", 39, 42], ["NO2", "SIMPLE_CHEMICAL", 96, 99], ["NO2", "TEST", 39, 42], ["COVID", "TEST", 53, 58], ["NO2 concentration", "TREATMENT", 96, 113], ["R0", "TREATMENT", 119, 121], ["multiple linear regression models", "TREATMENT", 197, 230]]], ["Then, we used meta-analysis to pool the estimates of the specific associations of NO2 concentration with R0 (meta \u03c72 & p).", [["NO2", "CHEMICAL", 82, 85], ["NO2", "CHEMICAL", 82, 85], ["NO2", "SIMPLE_CHEMICAL", 82, 85], ["meta-analysis", "TREATMENT", 14, 27], ["NO2 concentration", "TREATMENT", 82, 99], ["R0 (meta \u03c7", "TREATMENT", 105, 115]]], ["We also examined the corresponding temporal associations between NO2 and R0 of COVID-19 across the different cities inside and outside Hubei Province using multiple linear regression models after controlling for temperature and relative humidity separately.", [["NO2", "CHEMICAL", 65, 68], ["NO2", "CHEMICAL", 65, 68], ["NO2", "SIMPLE_CHEMICAL", 65, 68], ["COVID", "TEST", 79, 84], ["multiple linear regression models", "TREATMENT", 156, 189], ["multiple", "OBSERVATION_MODIFIER", 156, 164], ["linear", "OBSERVATION_MODIFIER", 165, 171]]], ["The change of R0 per 10 \u03bcg/m3 increase in NO2 pollution was calculated.", [["NO2", "CHEMICAL", 42, 45], ["NO2", "CHEMICAL", 42, 45], ["NO2", "SIMPLE_CHEMICAL", 42, 45], ["R0", "TREATMENT", 14, 16], ["NO2 pollution", "TREATMENT", 42, 55], ["NO2 pollution", "OBSERVATION", 42, 55]]], ["Given that associations between NO2 and COVID-19 prevalence are influenced by several confounding factors, we further examined the associations of NO2 with the R0 of COVID-19 with adjustment for density of population, GDP per capita and hospital beds per capita in the main model.", [["NO2", "CHEMICAL", 32, 35], ["NO2", "CHEMICAL", 147, 150], ["GDP", "CHEMICAL", 218, 221], ["NO2", "CHEMICAL", 32, 35], ["COVID-19", "CHEMICAL", 40, 48], ["NO2", "CHEMICAL", 147, 150], ["NO2", "SIMPLE_CHEMICAL", 32, 35], ["COVID-19", "GENE_OR_GENE_PRODUCT", 40, 48], ["NO2", "SIMPLE_CHEMICAL", 147, 150], ["GDP", "SIMPLE_CHEMICAL", 218, 221], ["NO2", "TEST", 32, 35], ["COVID", "TEST", 40, 45], ["NO2", "TEST", 147, 150], ["COVID", "TEST", 166, 171], ["main model", "ANATOMY", 269, 279]]], ["Additionally, residual analysis was conducted to test the reliability of correlation.", [["residual analysis", "TEST", 14, 31]]], ["And principal component analysis was used to explore the relevance of various factors.", [["principal component analysis", "TEST", 4, 32], ["various factors", "PROBLEM", 70, 85]]], ["The \u03c72 values and corresponding p values were obtained by combining the correlations together using the meta-analysis method.", [["The \u03c72 values", "TEST", 0, 13], ["the meta-analysis method", "TEST", 100, 124]]], ["This part of the statistical analysis was conducted with MATLAB R2019a.", [["the statistical analysis", "TEST", 13, 37]]], ["A p value of less than 0.05 was considered to indicate statistical significance.Temporal and spatial distributions of NO2 ::: ResultsAmong the 63 investigated cities, the mean\u00b1standard deviation and range of NO2 concentration and R0 were (27.9\u00b18.3 ug/m3, 10.7\u201353.0 ug/m3) and (1.4\u00b10.3, 0.6\u20132.5), respectively.", [["NO2", "CHEMICAL", 118, 121], ["NO2", "CHEMICAL", 208, 211], ["NO2", "CHEMICAL", 118, 121], ["NO2", "CHEMICAL", 208, 211], ["NO2", "SIMPLE_CHEMICAL", 118, 121], ["NO2", "SIMPLE_CHEMICAL", 208, 211], ["A p value", "TEST", 0, 9], ["the mean\u00b1standard deviation", "TEST", 167, 194], ["NO2 concentration", "TEST", 208, 225], ["R0", "TEST", 230, 232], ["spatial distributions", "OBSERVATION", 93, 114]]], ["The similarity of the spatial distributions between R0 and NO2 suggests a relationship between R0 and NO2 concentration (Fig. 1).", [["NO2", "CHEMICAL", 59, 62], ["NO2", "CHEMICAL", 102, 105], ["NO2", "CHEMICAL", 59, 62], ["NO2", "CHEMICAL", 102, 105], ["NO2", "SIMPLE_CHEMICAL", 59, 62], ["NO2", "SIMPLE_CHEMICAL", 102, 105], ["R0 and NO2 concentration", "TREATMENT", 95, 119], ["spatial", "OBSERVATION_MODIFIER", 22, 29], ["distributions", "OBSERVATION_MODIFIER", 30, 43]]], ["No matter Hubei Province or outside of Hubei Province, the daily concentration trend of NO2 from January to march in 2016-2019 is almost the same, but it is obvious that the daily concentration of NO2 in 2020 is lower than that in other years, especially after January 23, 2020 (Fig. 2), which may be due to the closure of Wuhan city in Hubei.Correlation analysis of spatial distribution ::: ResultsThe scatter diagram of R0 and NO2 distributions (Fig. 3) shows that R0 tends to increase with NO2 concentration, suggesting a positive correlation between R0 and NO2 concentration.", [["NO2", "CHEMICAL", 88, 91], ["NO2", "CHEMICAL", 197, 200], ["NO2", "CHEMICAL", 429, 432], ["NO2", "CHEMICAL", 493, 496], ["NO2", "CHEMICAL", 561, 564], ["NO2", "CHEMICAL", 88, 91], ["NO2", "CHEMICAL", 197, 200], ["NO2", "CHEMICAL", 429, 432], ["NO2", "CHEMICAL", 493, 496], ["NO2", "CHEMICAL", 561, 564], ["NO2", "SIMPLE_CHEMICAL", 88, 91], ["NO2", "SIMPLE_CHEMICAL", 197, 200], ["NO2", "SIMPLE_CHEMICAL", 493, 496], ["NO2", "SIMPLE_CHEMICAL", 561, 564], ["R0 and NO2 concentration", "TREATMENT", 554, 578], ["closure", "OBSERVATION", 312, 319], ["NO2 distributions", "OBSERVATION", 429, 446]]], ["The cross-sectional analysis indicates that, after adjustment for temperature and relative humidity, R0 was positively associated with NO2 concentration at city level (meta \u03c72=10.18, p=0.037) (Fig. 3).", [["NO2", "CHEMICAL", 135, 138], ["NO2", "CHEMICAL", 135, 138], ["NO2", "SIMPLE_CHEMICAL", 135, 138], ["The cross-sectional analysis", "TEST", 0, 28], ["temperature", "TEST", 66, 77], ["NO2 concentration", "TEST", 135, 152], ["meta \u03c7", "TEST", 168, 174]]], ["Additionally, we further examined the associations of NO2 with the R0 of COVID-19 adjusted for density of population, GDP per capita, hospital beds per capita separately in the main model, and we found that none of the three covariate would affect the significant positive association between NO2 with R0.", [["NO2", "CHEMICAL", 54, 57], ["GDP", "CHEMICAL", 118, 121], ["NO2", "CHEMICAL", 293, 296], ["NO2", "CHEMICAL", 54, 57], ["NO2", "CHEMICAL", 293, 296], ["NO2", "SIMPLE_CHEMICAL", 54, 57], ["GDP", "SIMPLE_CHEMICAL", 118, 121], ["NO2", "SIMPLE_CHEMICAL", 293, 296], ["NO2", "TEST", 54, 57], ["COVID", "TEST", 73, 78], ["R0", "TREATMENT", 302, 304], ["main model", "ANATOMY", 177, 187], ["significant", "OBSERVATION_MODIFIER", 252, 263], ["positive", "OBSERVATION", 264, 272]]], ["In the following stratified analysis, a significant association was confirmed in cities outside Hubei (r=0.29, p=0.046), whereas the trend observed in cities inside Hubei was not significant (r=0.51, p=0.130) (Fig. 3).", [["stratified analysis", "TEST", 17, 36], ["not", "UNCERTAINTY", 175, 178], ["significant", "OBSERVATION_MODIFIER", 179, 190]]], ["For every 10 \u03bcg/m3 increase in NO2, R0 increased by 0.12 (0.01\u20130.23) and 0.52 (\u22120.20 to 1.25), respectively.", [["NO2", "CHEMICAL", 31, 34], ["NO2", "CHEMICAL", 31, 34], ["NO2", "SIMPLE_CHEMICAL", 31, 34]]], ["We did not find significant associations of temperature or relative humidity with R0 of COVID-19 (meta \u03c72=4.62, p=0.370 and meta \u03c72=1.63, p=0.800, respectively).Correlation analysis of spatial distribution ::: ResultsIn addition, we found that R0 was positively associated with the average NO2 value from 2016\u20132019 (meta \u03c72=13.74, p=0.008;Fig. 4a) with adjustment for temperature and relative humidity.", [["NO2", "CHEMICAL", 290, 293], ["NO2", "CHEMICAL", 290, 293], ["NO2", "SIMPLE_CHEMICAL", 290, 293], ["COVID", "TEST", 88, 93], ["p", "TEST", 112, 113], ["meta", "TEST", 124, 128], ["p", "TEST", 138, 139], ["meta", "TEST", 316, 320], ["p", "TEST", 331, 332], ["temperature", "TEST", 368, 379], ["relative humidity", "TREATMENT", 384, 401]]], ["Because the average NO2 value from 2016\u20132019 was significantly associated with that in early 2020 (r=0.85, p<0.0001), it is difficult to determine which factor is dominant in COVID-19 transmission.", [["NO2", "CHEMICAL", 20, 23], ["NO2", "CHEMICAL", 20, 23], ["NO2", "SIMPLE_CHEMICAL", 20, 23], ["COVID-19", "SPECIES", 175, 183], ["the average NO2 value", "TEST", 8, 29], ["dominant", "OBSERVATION_MODIFIER", 163, 171]]], ["Moreover, the other investigated air pollutants (SO2, CO, O3, PM2.5, and PM10) had no significant associations with R0 (meta \u03c72<9.09, p>0.06; Fig. 4b\u2013f).", [["SO2", "CHEMICAL", 49, 52], ["O3", "CHEMICAL", 58, 60], ["PM2.5", "CHEMICAL", 62, 67], ["PM10", "CHEMICAL", 73, 77], ["SO2", "CHEMICAL", 49, 52], ["CO", "CHEMICAL", 54, 56], ["O3", "CHEMICAL", 58, 60], ["PM2.5", "CHEMICAL", 62, 67], ["PM10", "CHEMICAL", 73, 77], ["SO2", "SIMPLE_CHEMICAL", 49, 52], ["CO", "SIMPLE_CHEMICAL", 54, 56], ["O3", "SIMPLE_CHEMICAL", 58, 60], ["PM2.5", "SIMPLE_CHEMICAL", 62, 67], ["air pollutants", "PROBLEM", 33, 47], ["SO2", "TEST", 49, 52], ["CO", "TEST", 54, 56], ["p", "TEST", 134, 135], ["air pollutants", "OBSERVATION", 33, 47]]], ["Furthermore, in order to avoid potential population movement effects in our study, which could decrease both NO2 and R0, we collected reduced population movement data from 51 cities outside Hubei in the same period.", [["NO2", "CHEMICAL", 109, 112], ["NO2", "CHEMICAL", 109, 112], ["NO2", "SIMPLE_CHEMICAL", 109, 112], ["potential population movement effects", "PROBLEM", 31, 68], ["our study", "TEST", 72, 81], ["reduced population movement data", "PROBLEM", 134, 166]]], ["We re-calculated NO2-R0 associations including the population movement as a covariate, and we found that the NO2 was still significantly correlated with R0 of COVID-19 outside Hubei (r=0.32, p=0.024)Temporal correlation analysis ::: ResultsWe calculated the daily R0 values of 11 cities in Hubei (except Wuhan) from January 27 to February 26, 2020 (there were few COVID-19 confirmed cases in these cities afterwards) and normalized them based on Wuhan\u2019s daily R0 value to eliminate the effects of other covariates.", [["NO2", "CHEMICAL", 17, 20], ["NO2", "CHEMICAL", 109, 112], ["NO2", "CHEMICAL", 17, 20], ["NO2", "CHEMICAL", 109, 112], ["NO2", "SIMPLE_CHEMICAL", 17, 20], ["NO2", "SIMPLE_CHEMICAL", 109, 112], ["the NO2", "TEST", 105, 112], ["COVID", "TEST", 159, 164], ["Temporal correlation analysis", "TEST", 199, 228], ["the daily R0 values", "TEST", 254, 273], ["R0 value", "TEST", 460, 468]]], ["We found that 11 Hubei cities (except Xianning City) had significantly positive correlations between NO2 concentration (with 12-day time lag) and R0 (r>0.51, p<0.005), suggesting a positive association between daily NO2 concentration and COVID-19 spread ability on the temporal scale (Fig. 5).", [["NO2", "CHEMICAL", 101, 104], ["NO2", "CHEMICAL", 216, 219], ["NO2", "CHEMICAL", 101, 104], ["NO2", "CHEMICAL", 216, 219], ["NO2", "SIMPLE_CHEMICAL", 101, 104], ["NO2", "SIMPLE_CHEMICAL", 216, 219], ["NO2 concentration", "TEST", 101, 118], ["R0", "TEST", 146, 148], ["daily NO2 concentration", "TREATMENT", 210, 233], ["COVID", "TEST", 238, 243], ["positive", "OBSERVATION", 181, 189]]], ["The results of residual analysis and principal component analysis were shown in Figure S1 and Figure S2, respectively.Testing for mediation ::: ResultsTo eliminate the effects of city population and city area on the relationship between NO2 concentration and R0 value, we applied a mediation analysis to verify whether more densely populated cities had both greater R0 and NO2 concentration values.", [["NO2", "CHEMICAL", 237, 240], ["NO2", "CHEMICAL", 373, 376], ["NO2", "CHEMICAL", 237, 240], ["NO2", "CHEMICAL", 373, 376], ["NO2", "SIMPLE_CHEMICAL", 237, 240], ["NO2", "SIMPLE_CHEMICAL", 373, 376], ["residual analysis", "TEST", 15, 32], ["principal component analysis", "TEST", 37, 65], ["NO2 concentration", "TEST", 237, 254], ["R0 value", "TEST", 259, 267], ["a mediation analysis", "TEST", 280, 300], ["NO2 concentration values", "TEST", 373, 397], ["densely", "OBSERVATION_MODIFIER", 324, 331], ["populated", "OBSERVATION", 332, 341]]], ["After adjustment for temperature and relative humidity, the mediation analysis found insignificant direct and indirect effects of city population and city area on R0 (z=\u22121.43, p=0.15 & z=\u22120.24, p=0.800 and z=\u22120.46, p=0.650 & z=1.15, p=0.250, respectively).", [["temperature", "TEST", 21, 32], ["relative humidity", "TREATMENT", 37, 54], ["the mediation analysis", "TEST", 56, 78], ["R0", "TEST", 163, 165], ["z", "TEST", 167, 168], ["p", "TEST", 176, 177], ["z", "TEST", 185, 186], ["p", "TEST", 194, 195], ["z", "TEST", 206, 207], ["p", "TEST", 215, 216], ["z", "TEST", 225, 226], ["p", "TEST", 233, 234]]], ["Thus, there were no apparent mediation effects between city population, city area, NO2, and R0.", [["NO2", "CHEMICAL", 83, 86], ["NO2", "CHEMICAL", 83, 86], ["NO2", "SIMPLE_CHEMICAL", 83, 86], ["apparent mediation effects", "PROBLEM", 20, 46], ["no apparent", "UNCERTAINTY", 17, 28]]], ["City population and city area did not influence the association between NO2 concentration and R0.DiscussionThis study explored the association between environmental factors and COVID-19 transmission.", [["NO2", "CHEMICAL", 72, 75], ["NO2", "CHEMICAL", 72, 75], ["NO2", "SIMPLE_CHEMICAL", 72, 75], ["COVID-19", "GENE_OR_GENE_PRODUCT", 177, 185], ["This study", "TEST", 107, 117], ["COVID", "TEST", 177, 182]]], ["To our knowledge, little research has been done on the relationship between ambient air pollution and COVID-19 transmission.", [["ambient air pollution", "TREATMENT", 76, 97], ["air pollution", "OBSERVATION", 84, 97]]], ["Our results show a significant association between NO2 exposure and R0, suggesting that ambient NO2 may contribute to the spread ability of COVID-19.", [["NO2", "CHEMICAL", 51, 54], ["NO2", "CHEMICAL", 96, 99], ["COVID-19", "CHEMICAL", 140, 148], ["NO2", "CHEMICAL", 51, 54], ["NO2", "CHEMICAL", 96, 99], ["COVID-19", "CHEMICAL", 140, 148], ["NO2", "SIMPLE_CHEMICAL", 51, 54], ["NO2", "SIMPLE_CHEMICAL", 96, 99], ["R0", "TREATMENT", 68, 70], ["ambient NO2", "PROBLEM", 88, 99], ["COVID", "TEST", 140, 145], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["To prevent city population and city area from affecting the relationship between NO2 concentration and R0 level, we applied a mediation analysis to verify whether more densely populated cities have both greater R0 values and higher NO2 concentrations.", [["NO2", "CHEMICAL", 81, 84], ["NO2", "CHEMICAL", 232, 235], ["NO2", "CHEMICAL", 81, 84], ["NO2", "CHEMICAL", 232, 235], ["city area", "MULTI-TISSUE_STRUCTURE", 31, 40], ["NO2", "SIMPLE_CHEMICAL", 81, 84], ["NO2", "SIMPLE_CHEMICAL", 232, 235], ["NO2 concentration", "TEST", 81, 98], ["a mediation analysis", "TEST", 124, 144], ["higher NO2 concentrations", "PROBLEM", 225, 250], ["greater", "OBSERVATION_MODIFIER", 203, 210], ["NO2 concentrations", "OBSERVATION", 232, 250]]], ["The results showed that city population and city area did not influence the association between NO2 concentration and R0 level.DiscussionAlthough the closures of cities throughout Hubei occurred at approximately the same time point: the other cities of Hubei were locked down no longer than 1\u20132 days later than Wuhan City, the effect of the lockdown measure in different cities (e.g. cities with busy traffic vs. small rural cities) was not expected to have the same influence on the association between NO2 and COVID-19 transmission.", [["NO2", "CHEMICAL", 96, 99], ["NO2", "CHEMICAL", 504, 507], ["NO2", "CHEMICAL", 96, 99], ["NO2", "CHEMICAL", 504, 507], ["COVID-19", "CHEMICAL", 512, 520], ["NO2", "SIMPLE_CHEMICAL", 96, 99], ["NO2", "SIMPLE_CHEMICAL", 504, 507], ["COVID-19", "GENE_OR_GENE_PRODUCT", 512, 520], ["small rural cities", "PROBLEM", 413, 431], ["NO2", "TEST", 504, 507], ["COVID", "TEST", 512, 517], ["rural cities", "OBSERVATION", 419, 431]]], ["Multiple impact factors (the population density of the city, the typical road traffic and commercial exchanges, etc.) may still have confounded the association in the current analysis, but we have controlled for as many factors as possible to reduce confounding and solid our results, including the density of population, GDP per capita and hospital beds per capita.", [["GDP", "CHEMICAL", 322, 325], ["GDP", "SIMPLE_CHEMICAL", 322, 325], ["Multiple impact factors", "PROBLEM", 0, 23], ["the current analysis", "TEST", 163, 183]]], ["Previous studies also have suggested that the increased spread ability resulting from NO2 exposure might be caused by the effects of NO2 on host defenses that prevent viral spread (Becker and Soukup, 1999).", [["NO2", "CHEMICAL", 86, 89], ["NO2", "CHEMICAL", 133, 136], ["NO2", "CHEMICAL", 86, 89], ["NO2", "CHEMICAL", 133, 136], ["NO2", "SIMPLE_CHEMICAL", 86, 89], ["NO2", "SIMPLE_CHEMICAL", 133, 136], ["Previous studies", "TEST", 0, 16], ["the increased spread ability", "PROBLEM", 42, 70], ["NO2 exposure", "PROBLEM", 86, 98], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["spread", "OBSERVATION_MODIFIER", 56, 62]]], ["TM Chen et al. (Chen et al., 2007) found that exposure to NO2 may harm to humans\u2019 health by interacting with the immune system; besides, IC Mills et al. (Mills et al., 2015) observed that short-term exposure to NO2 had increased the hospital admission rates for a range of respiratory diseases in different age groups.", [["respiratory", "ANATOMY", 273, 284], ["NO2", "CHEMICAL", 58, 61], ["NO2", "CHEMICAL", 211, 214], ["respiratory diseases", "DISEASE", 273, 293], ["NO2", "CHEMICAL", 58, 61], ["NO2", "CHEMICAL", 211, 214], ["NO2", "SIMPLE_CHEMICAL", 58, 61], ["humans", "ORGANISM", 74, 80], ["NO2", "SIMPLE_CHEMICAL", 211, 214], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 74, 80], ["respiratory diseases", "PROBLEM", 273, 293], ["respiratory diseases", "OBSERVATION", 273, 293]]], ["Therefore, we speculated NO2 have potential ability to contribute in the infection process of COVID-19 directly.DiscussionIn addition, NO2 emissions primarily come from burning fossil fuels (diesel, gasoline, coal), resulting in automobile and smokestack exhaust, the latter of which can be produced by electricity generation.", [["NO2", "CHEMICAL", 25, 28], ["infection", "DISEASE", 73, 82], ["NO2", "CHEMICAL", 135, 138], ["NO2", "CHEMICAL", 25, 28], ["COVID-19", "CHEMICAL", 94, 102], ["NO2", "CHEMICAL", 135, 138], ["coal", "CHEMICAL", 209, 213], ["NO2", "SIMPLE_CHEMICAL", 25, 28], ["COVID-19", "CELL", 94, 102], ["NO2", "SIMPLE_CHEMICAL", 135, 138], ["the infection process", "PROBLEM", 69, 90], ["COVID", "TEST", 94, 99], ["infection", "OBSERVATION", 73, 82], ["smokestack exhaust", "OBSERVATION", 244, 262]]], ["Therefore, changes in NO2 levels can be used to indicate changes in human activity and population movement due to the lockdown of cities.", [["NO2", "CHEMICAL", 22, 25], ["NO2", "CHEMICAL", 22, 25], ["NO2", "SIMPLE_CHEMICAL", 22, 25], ["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["NO2 levels", "TEST", 22, 32], ["changes in human activity", "PROBLEM", 57, 82]]], ["For example, we can see that since January 23, 2020, the daily average concentration of NO2 after the closure of Wuhan is obviously lower than that of the same period in previous years (Fig. 2).", [["NO2", "CHEMICAL", 88, 91], ["NO2", "CHEMICAL", 88, 91], ["NO2", "SIMPLE_CHEMICAL", 88, 91], ["NO2", "TREATMENT", 88, 91], ["the closure", "TREATMENT", 98, 109], ["closure", "OBSERVATION", 102, 109]]], ["Besides, it is well known that the spread of respiratory virus is through contact (direct or indirect via fomites) or through contaminated droplets emitted by cough, sneeze, respiration and speaking of infected individuals, both of which are related with human contact, social distance and population movement.", [["respiratory virus", "DISEASE", 45, 62], ["cough", "DISEASE", 159, 164], ["respiratory virus", "ORGANISM", 45, 62], ["human", "ORGANISM", 255, 260], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 255, 260], ["respiratory virus", "PROBLEM", 45, 62], ["cough", "PROBLEM", 159, 164], ["infected individuals", "PROBLEM", 202, 222], ["respiratory virus", "OBSERVATION", 45, 62]]], ["Plus, NO2 is as an indicator of traffic-related air pollution, the association between NO2 and R0 of COVID-19 may be explained by the relationship between viral spread and population movement.", [["NO2", "CHEMICAL", 6, 9], ["NO2", "CHEMICAL", 87, 90], ["NO2", "CHEMICAL", 6, 9], ["NO2", "CHEMICAL", 87, 90], ["COVID-19", "CHEMICAL", 101, 109], ["NO2", "SIMPLE_CHEMICAL", 6, 9], ["NO2", "SIMPLE_CHEMICAL", 87, 90], ["COVID-19", "GENE_OR_GENE_PRODUCT", 101, 109], ["traffic-related air pollution", "PROBLEM", 32, 61], ["NO2", "TEST", 87, 90], ["COVID", "TEST", 101, 106], ["viral spread", "PROBLEM", 155, 167], ["air pollution", "OBSERVATION", 48, 61], ["viral spread", "OBSERVATION", 155, 167]]], ["Of course, further investigations are warranted to provide additional details and illustrate this mechanism.DiscussionOur study has some limitations: first, the averaging of NO2 concentrations across cities likely resulted in an unknown degree of exposure misclassification, given the spatial variability and traffic-dependence of NO2 and the potential for indoor exposure.", [["NO2", "CHEMICAL", 174, 177], ["NO2", "CHEMICAL", 331, 334], ["NO2", "CHEMICAL", 174, 177], ["NO2", "CHEMICAL", 331, 334], ["NO2", "SIMPLE_CHEMICAL", 174, 177], ["NO2", "SIMPLE_CHEMICAL", 331, 334], ["further investigations", "TEST", 11, 33], ["DiscussionOur study", "TEST", 108, 127], ["exposure misclassification", "PROBLEM", 247, 273], ["the spatial variability", "PROBLEM", 281, 304], ["unknown degree", "OBSERVATION_MODIFIER", 229, 243], ["exposure misclassification", "OBSERVATION", 247, 273]]], ["Second, R0 could be highly variable and is influenced by a variety of factors, including not only the previously mentioned mitigation efforts but also the comprehensiveness of case identification.", [["could be", "UNCERTAINTY", 11, 19], ["highly", "OBSERVATION_MODIFIER", 20, 26], ["variable", "OBSERVATION", 27, 35]]], ["Third, for the lack of corresponding data of NO, we did not explore the association between primary pollutant NO and the transmission ability of COVID-19.", [["NO", "CHEMICAL", 45, 47], ["NO", "CHEMICAL", 110, 112], ["COVID-19", "CHEMICAL", 145, 153], ["NO", "CHEMICAL", 45, 47], ["NO", "CHEMICAL", 110, 112], ["COVID-19", "CHEMICAL", 145, 153], ["NO", "SIMPLE_CHEMICAL", 45, 47], ["NO", "SIMPLE_CHEMICAL", 110, 112], ["COVID", "TEST", 145, 150]]], ["Given the ecological nature of this study, other city-level factors, such as the implementation ability of COVID-19 control policy, urbanization rate, and availability of medical resources, may affect the transmissibility of COVID-19 and confound our findings.", [["this study", "TEST", 31, 41], ["COVID-19 control policy", "TREATMENT", 107, 130], ["urbanization rate", "TEST", 132, 149], ["COVID", "TEST", 225, 230]]], ["Future studies should develop individual-based models with high spatial and temporal resolution to assess the correlations between air pollution and the epidemiologic characteristics of COVID-19.", [["COVID-19", "CHEMICAL", 186, 194], ["Future studies", "TEST", 0, 14], ["individual-based models", "PROBLEM", 30, 53], ["high spatial and temporal resolution", "PROBLEM", 59, 95], ["air pollution", "TEST", 131, 144], ["COVID", "TEST", 186, 191]]], ["The mechanisms between NO2 and the transmission of COVID-19 disease still require further research, besides, the spread of COVID-19 could be affected by many factors.", [["NO2", "CHEMICAL", 23, 26], ["COVID-19", "CHEMICAL", 123, 131], ["NO2", "CHEMICAL", 23, 26], ["COVID-19", "CHEMICAL", 123, 131], ["NO2", "SIMPLE_CHEMICAL", 23, 26], ["COVID-19", "GENE_OR_GENE_PRODUCT", 123, 131], ["COVID-19 disease", "PROBLEM", 51, 67], ["COVID", "TEST", 123, 128]]], ["We also believe that there is likely to have interaction of environmental factors and NPIs, which deserves further analysis.Author contributionsYe Yao: Data curation, Conceptualization, Methodology, SoftwareAuthor contributionsJinhua Pan: Data curation, Writing- Original draft preparationAuthor contributionsZhixi Liu: Data curation, Writing- Original draft preparationAuthor contributionsXia Meng: Writing- Original draft preparationAuthor contributionsWeidong Wang: Data curation, ResourcesAuthor contributionsHaidong Kan: Supervision and Writing- Reviewing and EditingAuthor contributionsWeibing Wang: Supervision and Writing- Reviewing and EditingRole of the funding sourceThe funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing the report.", [["NPIs", "GENE_OR_GENE_PRODUCT", 86, 90], ["environmental factors", "PROTEIN", 60, 81], ["NPIs", "PROTEIN", 86, 90], ["NPIs", "TREATMENT", 86, 90], ["further analysis", "TEST", 107, 123], ["the study", "TEST", 693, 702], ["data collection", "TEST", 732, 747], ["data analysis", "TEST", 749, 762], ["data interpretation", "TEST", 764, 783]]], ["The corresponding author had full access to all of the study\u2019s data and takes final responsibility for the decision to submit for publication.FundingThis work was supported by the Bill & Melinda Gates Foundation, Seattle, WA [Grant No.", [["the study", "TEST", 51, 60]]], ["OPP1216424] and the Fudan University Research Project on COVID-19 Emergency [Grant No.", [["OPP1216424", "CHEMICAL", 0, 10], ["COVID", "TEST", 57, 62]]], ["IDF201007].CRediT authorship contribution statement", [["IDF201007", "CHEMICAL", 0, 9], ["IDF201007", "CHEMICAL", 0, 9]]]], "ec8893bdc8ea478b98a13497c8aa38ca9f8b27a4": [["J o u r n a l P r e -p r o o fTHE NOVEL CORONAVIRUS COVID-19Classified as a pandemic by the World Health Organization on March 11, 2020, a marketplace in Wuhan, China has been identified as a hotspot for the early spread, and perhaps origin, of the novel coronavirus COVID-19 [1] .", [["coronavirus", "SPECIES", 255, 266], ["a l P r e -p r o o fTHE", "TEST", 10, 33], ["NOVEL CORONAVIRUS COVID", "TEST", 34, 57]]], ["Since the outbreak began in December 2019, the virus has spread to more than 200 countries with the global fatalities presently exceeding 367,000 as of 31 May 2020 [2] .", [["the virus", "PROBLEM", 43, 52]]], ["Extreme forecasts predicted that >2.7 million people could die of COVID-19 in the USA and UK alone [3] .", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["Extreme forecasts", "PROBLEM", 0, 17], ["COVID", "TEST", 66, 71]]], ["The restrictive measures implemented to limit disease spread have involved evacuated schools and university campuses, cancelled sporting events and public gatherings, broad-scale travel bans, and stay-at-home ordinances.", [["The restrictive measures", "TREATMENT", 0, 24], ["restrictive", "OBSERVATION", 4, 15]]], ["Byproducts of these measures include widespread unemployment, closure of many small and independent businesses, geopolitical discourse about globalization, and an economic recession sweeping the world almost as swiftly as the disease itself.", [["closure", "TREATMENT", 62, 69], ["an economic recession", "PROBLEM", 160, 181], ["the disease itself", "PROBLEM", 222, 240], ["widespread", "OBSERVATION_MODIFIER", 37, 47], ["unemployment", "OBSERVATION", 48, 60], ["many", "OBSERVATION_MODIFIER", 73, 77], ["small", "OBSERVATION_MODIFIER", 78, 83], ["economic", "OBSERVATION_MODIFIER", 163, 171], ["recession", "OBSERVATION", 172, 181], ["disease", "OBSERVATION", 226, 233]]], ["Such answers are urgent not only for human health but also for conservation.THE ZOONOTIC ORIGINS OF MANY PANDEMICSJ o u r n a l P r e -p r o o fCREATING A MORE SUSTAINABLE FUTURE FOR PEOPLE AND ANIMALSWe recommend that the most immediate and fair priority is critical scrutiny of wildlife trade.", [["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42]]], ["Governments, regulators, and wildlife authorities should not tolerate blind-eyes, loopholes, or the negligence of legislation that is now vividly exposed not only to conserve wildlife, but also to save human lives.", [["eyes", "ANATOMY", 76, 80], ["eyes", "ORGAN", 76, 80], ["human", "ORGANISM", 202, 207], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 202, 207], ["eyes", "ANATOMY", 76, 80]]], ["Furthermore, the contours of illegality should be extended.", [["contours", "OBSERVATION_MODIFIER", 17, 25]]], ["Currently, wildlife can be legally traded for a variety of consumptive and consumerist purposes at costs, sometimes devastatingly measurable to human health, all too often to animal welfare and conservation, and which COVID-19 reveals now to be extraordinarily high.", [["human", "ORGANISM", 144, 149], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149], ["COVID", "TEST", 218, 223], ["high", "OBSERVATION", 261, 265]]], ["The use of animals (e.g., consumptive, medicament, pets, or ceremony) however, are so diverse around the world that they defy simple arguments orBox 1: The Interconnectedness of the WorldThe COVID-19 pandemic has illustrated the extent to which human communities are linked.", [["human", "ORGANISM", 245, 250], ["human", "SPECIES", 245, 250], ["human", "SPECIES", 245, 250], ["medicament", "TREATMENT", 39, 49]]], ["Diseases emanating from a single marketplace can spread around the globe in months.", [["Diseases", "PROBLEM", 0, 8], ["globe", "ANATOMY", 67, 72]]], ["Such calls are understandable, both as humane reactions to the gravity of the COVID-19 pandemic and as tactical efforts to rapidly promote changes that might otherwise take decades to enact.", [["the COVID", "TEST", 74, 83]]], ["But in the desire to make the post-COVID-19 world a better one, both for humans and animals, the details matter [14] .", [["humans", "ORGANISM", 73, 79], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 73, 79]]], ["We note here that millions of people around the world depend on meat, often wild-caught, traded in markets and rural communities for subsistence [15] .", [["meat", "ANATOMY", 64, 68], ["people", "ORGANISM", 30, 36], ["meat", "ORGANISM_SUBDIVISION", 64, 68], ["people", "SPECIES", 30, 36]]], ["Sometimes, unacceptably, people illegally kill threatened species, but more often they harvest wildlife that can be taken both legally and sustainably, where sanctioned harvest systems exist [15] .", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31]]], ["There are a variety of very good reasons to reduce human dependence on illegally-harvested wildlife for subsistence.", [["human", "ORGANISM", 51, 56], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["variety", "OBSERVATION_MODIFIER", 12, 19]]], ["Importantly however, these are long-term goals requiring fierce attention to the multi-faceted and highly variable details inherent to the diverse coupled human and natural systems around the world and feasible only beyond the time-scale affordable for COVID-19 disease control and human health improvement.", [["human", "ORGANISM", 155, 160], ["human", "ORGANISM", 282, 287], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 282, 287], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 282, 287], ["COVID-19 disease control", "TREATMENT", 253, 277], ["long-term", "OBSERVATION_MODIFIER", 31, 40]]], ["J o u r n a l P r e -p r o o f preserve the rapidly-dwindling biodiversity that remains.", [["dwindling", "OBSERVATION_MODIFIER", 52, 61], ["biodiversity", "OBSERVATION", 62, 74]]], ["Therefore, without taking our eyes off the long game (e.g. carbon neutrality, strategic agriculture, reduced meat dependence, greater appreciation of conservation value), there is an obvious need, and opportunity, for immediate change.", [["eyes", "ANATOMY", 30, 34], ["meat", "ANATOMY", 109, 113], ["carbon", "CHEMICAL", 59, 65], ["eyes", "ORGAN", 30, 34], ["meat", "ORGANISM_SUBDIVISION", 109, 113], ["strategic agriculture", "TREATMENT", 78, 99], ["reduced meat dependence", "PROBLEM", 101, 124]]]], "PMC7127740": [["IntroductionThe template-dependent polynucleotide polymerases (TDPPs) that replicate cellular and viral genomes are central to life.", [["cellular", "ANATOMY", 85, 93], ["polynucleotide", "CHEMICAL", 35, 49], ["polynucleotide polymerases", "GENE_OR_GENE_PRODUCT", 35, 61], ["TDPPs", "GENE_OR_GENE_PRODUCT", 63, 68], ["cellular", "CELL", 85, 93], ["template-dependent polynucleotide polymerases", "PROTEIN", 16, 61], ["TDPPs", "PROTEIN", 63, 68], ["cellular and viral genomes", "DNA", 85, 111], ["The template-dependent polynucleotide polymerases (TDPPs", "TREATMENT", 12, 68], ["cellular and viral genomes", "PROBLEM", 85, 111], ["polynucleotide polymerases", "OBSERVATION", 35, 61], ["viral genomes", "OBSERVATION", 98, 111]]], ["The DNA genomes of cellular organisms and the majority of DNA viruses are replicated by DNA-dependent DNA polymerases (DdDp).", [["cellular organisms", "ANATOMY", 19, 37], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["cellular", "CELL", 19, 27], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["DNA genomes", "DNA", 4, 15], ["DNA-dependent DNA polymerases", "PROTEIN", 88, 117], ["DdDp", "PROTEIN", 119, 123], ["cellular organisms", "PROBLEM", 19, 37], ["DNA viruses", "PROBLEM", 58, 69], ["dependent DNA polymerases", "PROBLEM", 92, 117], ["cellular organisms", "OBSERVATION", 19, 37], ["DNA viruses", "OBSERVATION", 58, 69]]], ["RNA genomes, currently found only in viruses, comprise four types: positive and negative-sense single-stranded RNA (ssRNA+ and ssRNA\u2212, respectively) viruses, double-stranded RNA (dsRNA) viruses, and RNA viruses that use reverse transcriptase for genome replication.", [["ssRNA\u2212", "GENE_OR_GENE_PRODUCT", 127, 133], ["reverse transcriptase", "PROTEIN", 220, 241], ["RNA genomes", "PROBLEM", 0, 11], ["viruses", "PROBLEM", 37, 44], ["ssRNA", "TEST", 116, 121], ["ssRNA\u2212", "TEST", 127, 133], ["viruses", "PROBLEM", 149, 156], ["double-stranded RNA (dsRNA) viruses", "PROBLEM", 158, 193], ["RNA viruses", "PROBLEM", 199, 210], ["reverse transcriptase", "TREATMENT", 220, 241], ["genome replication", "TREATMENT", 246, 264], ["viruses", "OBSERVATION", 37, 44], ["RNA viruses", "OBSERVATION", 199, 210]]], ["RNA-dependent polymerase is the only enzyme universally conserved in all of the thousands of known non-satellite RNA viruses.", [["non-satellite", "GENE_OR_GENE_PRODUCT", 99, 112], ["RNA-dependent polymerase", "PROTEIN", 0, 24], ["RNA-dependent polymerase", "TEST", 0, 24], ["known non-satellite RNA viruses", "PROBLEM", 93, 124], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["polymerase", "OBSERVATION", 14, 24], ["non-satellite RNA viruses", "OBSERVATION", 99, 124]]], ["RNA-dependent RNA polymerase (RdRp) is used to replicate the genomes of viruses with no DNA stage, and RNA-dependent DNA polymerase (RdDp; reverse transcriptase) is used by viruses with a DNA stage in the life cycle.1", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 0, 28], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["RNA-dependent", "GENE_OR_GENE_PRODUCT", 103, 116], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["RdDp; reverse transcriptase", "GENE_OR_GENE_PRODUCT", 133, 160], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["RNA-dependent RNA polymerase", "PROTEIN", 0, 28], ["RdRp", "PROTEIN", 30, 34], ["RNA-dependent DNA polymerase", "PROTEIN", 103, 131], ["RdDp", "PROTEIN", 133, 137], ["reverse transcriptase", "PROTEIN", 139, 160], ["RNA", "TEST", 0, 3], ["dependent RNA polymerase (RdRp", "PROBLEM", 4, 34], ["DNA stage", "PROBLEM", 88, 97], ["RNA", "TEST", 103, 106], ["dependent DNA polymerase", "PROBLEM", 107, 131], ["reverse transcriptase", "TREATMENT", 139, 160], ["a DNA stage in the life cycle", "PROBLEM", 186, 215], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["RNA polymerase", "OBSERVATION", 14, 28], ["viruses", "OBSERVATION", 72, 79]]]], "PMC7198202": [["Steps to community participation in the COVID-19 responseCommunity participation is essential in the collective response to coronavirus disease 2019 (COVID-19), from compliance with lockdown, to the steps that need to be taken as countries ease restrictions, to community support through volunteering.", [["coronavirus disease", "DISEASE", 124, 143], ["coronavirus", "ORGANISM", 124, 135], ["coronavirus disease", "PROBLEM", 124, 143], ["COVID", "TEST", 150, 155]]], ["Communities clearly want to help: in the UK, about 1 million people volunteered to help the pandemic response1 and highly localised mutual aid groups have sprung up all over the world with citizens helping one another with simple tasks such as checking on wellbeing during lockdowns.2", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67]]]], "a646998f5f64914364c4772a21eeaed7420f2e1d": [["Treatment of purified bovine coronavirus (Mebus strain) with pronase destroyed the integrity of virion surface glycoproteins gp140, gp120, gp100, reduced the amount of gp26 and destroyed the hemagglutinating activity of the virus.", [["surface", "ANATOMY", 103, 110], ["bovine coronavirus", "ORGANISM", 22, 40], ["Mebus strain", "ORGANISM", 42, 54], ["pronase", "SIMPLE_CHEMICAL", 61, 68], ["gp140", "GENE_OR_GENE_PRODUCT", 125, 130], ["gp120", "GENE_OR_GENE_PRODUCT", 132, 137], ["gp100", "GENE_OR_GENE_PRODUCT", 139, 144], ["gp26", "GENE_OR_GENE_PRODUCT", 168, 172], ["virion surface glycoproteins", "PROTEIN", 96, 124], ["gp140", "PROTEIN", 125, 130], ["gp120", "PROTEIN", 132, 137], ["gp100", "PROTEIN", 139, 144], ["gp26", "PROTEIN", 168, 172], ["bovine", "SPECIES", 22, 28], ["coronavirus", "SPECIES", 29, 40], ["bovine coronavirus", "SPECIES", 22, 40], ["Treatment", "TREATMENT", 0, 9], ["purified bovine coronavirus (Mebus strain", "TREATMENT", 13, 54], ["pronase", "TREATMENT", 61, 68], ["virion surface glycoproteins", "TREATMENT", 96, 124], ["the virus", "PROBLEM", 220, 229], ["bovine coronavirus", "OBSERVATION", 22, 40], ["hemagglutinating activity", "OBSERVATION", 191, 216]]], ["Bromelain, on the other hand, destroyed the integrity of gp120, gplO0 and gp26 but failed to remove gp140 and failed to destroy viral hemagglutinating activity.", [["Bromelain", "CHEMICAL", 0, 9], ["Bromelain", "CHEMICAL", 0, 9], ["Bromelain", "SIMPLE_CHEMICAL", 0, 9], ["gp120", "GENE_OR_GENE_PRODUCT", 57, 62], ["gplO0", "GENE_OR_GENE_PRODUCT", 64, 69], ["gp26", "GENE_OR_GENE_PRODUCT", 74, 78], ["gp140", "GENE_OR_GENE_PRODUCT", 100, 105], ["gp120", "PROTEIN", 57, 62], ["gplO0", "PROTEIN", 64, 69], ["gp26", "PROTEIN", 74, 78], ["gp140", "PROTEIN", 100, 105], ["Bromelain", "TREATMENT", 0, 9], ["gp140", "TREATMENT", 100, 105], ["viral hemagglutinating activity", "PROBLEM", 128, 159], ["hemagglutinating activity", "OBSERVATION", 134, 159]]], ["These experiments suggest that gp140 is the virion hema.", [["gp140", "GENE_OR_GENE_PRODUCT", 31, 36], ["gp140", "PROTEIN", 31, 36], ["the virion hema", "PROBLEM", 40, 55], ["virion hema", "OBSERVATION", 44, 55]]]], "539380756ffc5190e2f7000fae05711d26758dbf": [["IntroductionNovel coronavirus disease 2019 provoked by SARS-CoV-2 is a spreading threat and its clinical and epidemiological characteristics are still being documented.", [["coronavirus disease", "DISEASE", 18, 37], ["SARS", "DISEASE", 55, 59], ["SARS-CoV-2", "ORGANISM", 55, 65], ["SARS-CoV", "SPECIES", 55, 63], ["Novel coronavirus disease", "PROBLEM", 12, 37], ["SARS", "PROBLEM", 55, 59], ["a spreading threat", "PROBLEM", 69, 87], ["coronavirus disease", "OBSERVATION", 18, 37]]], ["[1, 2] The current COVID-19 pandemic puts extreme stress on healthcare organisation.", [["The current COVID", "TEST", 7, 24]]], ["In several countries including China, Italy, Brazil, Spain and certain parts of the United-States, the demand for emergency and intensive care exceeded the available resources.IntroductionAlmost all countries are struggling to tackle this pandemic in different ways including different strategies for primary care.", [["primary care", "TREATMENT", 301, 313]]], ["[3] in the UK roughly 75% of patients is seen remotely, in the USA primary care offices are capable of managing patient flows across home, clinic, hospital, and post-acute care [4] , Columbia uses a very similar approach with primary care as a gate keeper [5] and finally, Australia has decided to unprecedented level of support for the primary care system.", [["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 112, 119], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 112, 119]]], ["[6] On 2020/04/20 Belgian health authorities reported a total number of 39 983 infections, 13362 hospitalisations and 5 828 deaths (including 3028 suspected case in homes for the aged).", [["infections", "DISEASE", 79, 89], ["deaths", "DISEASE", 124, 130]]], ["The peak of the current outbreak was situated at the beginning of April, a partial lockdown was initiated on march 13.", [["a partial lockdown", "TREATMENT", 73, 91], ["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["[7] All patients presenting with symptoms of acute respiratory infection were considered as suspected cases as tests were not available in primary care services.", [["respiratory", "ANATOMY", 51, 62], ["acute respiratory infection", "DISEASE", 45, 72], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["symptoms", "PROBLEM", 33, 41], ["acute respiratory infection", "PROBLEM", 45, 72], ["tests", "TEST", 111, 116], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["respiratory", "ANATOMY", 51, 62], ["infection", "OBSERVATION", 63, 72]]], ["These patients needed to stay at home in self-isolation during at least seven days.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["[8] The government's recommendation to always call a doctor before going to a practice or ED was omnipresent in the media.IntroductionAll chronic care both inside and outside hospitals had been suspended and emergency plans had been activated in order to increase the number of beds available in intensive and emergency care.", [["All chronic care", "TREATMENT", 134, 150], ["chronic", "OBSERVATION_MODIFIER", 138, 145]]], ["This might have led to delayed access to hospital care and consequently increased morbidity and mortality unrelated to COVID-19.", [["COVID-19", "CHEMICAL", 119, 127], ["hospital care", "TREATMENT", 41, 54], ["consequently increased morbidity", "PROBLEM", 59, 91], ["COVID", "TEST", 119, 124], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["morbidity", "OBSERVATION", 82, 91]]], ["Patients pay 18% of their healthcare expenditures themselves.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["As a bottom-up response these GPCs have adapted to the COVID-19 pandemic.", [["GPCs", "CANCER", 30, 34], ["these GPCs", "TEST", 24, 34], ["the COVID", "TEST", 51, 60], ["pandemic", "PROBLEM", 64, 72]]], ["[13] In order to prevent infection of patients and healthcare professionals, a shift from in-person to remote consulting by telephone or video is occurring.", [["infection", "DISEASE", 25, 34], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["infection", "PROBLEM", 25, 34], ["infection", "OBSERVATION", 25, 34]]], ["Employees in Belgium unable to work due to medical problems need a medical certificate and for this reason have to see a medical doctor.", [["medical problems", "PROBLEM", 43, 59]]], ["During the COVID-19 pandemic, doctors are allowed to deliver it after a telephone consultation.IntroductionDuring office hours, the organisation of GP-practices in Belgium is very diverse making rapid research difficult.", [["a telephone consultation", "TEST", 70, 94]]], ["During weekends, the organisation of care is much more uniform due to the existence of GPCs.", [["GPCs", "ANATOMY", 87, 91], ["GPCs", "DISEASE", 87, 91], ["GPCs", "CANCER", 87, 91], ["GPCs", "PROTEIN", 87, 91], ["GPCs", "PROBLEM", 87, 91], ["GPCs", "OBSERVATION", 87, 91]]], ["Using the iCAREdata database containing routine data in out-ofhours care in Belgium, quick analysis of all contacts at selected GPCs is possible.", [["GPCs", "CANCER", 128, 132], ["routine data", "TEST", 40, 52], ["quick analysis", "TEST", 85, 99], ["all contacts at selected GPCs", "PROBLEM", 103, 132]]], ["Sharing this database would potentially harm the privacy of the included patients as one might get information about their identity by combining data from several columns (variables).", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["A part of the iCAREdata database is disclosed to the public on a website (https://icare.uantwerpen.be) this includes the data presented in this article but with less detail.", [["iCAREdata database", "DNA", 14, 32], ["the iCAREdata database", "TEST", 10, 32]]], ["We compare these characteristics to a reference period in 2019 and describe the organisational changes the GPCs made.MethodsThis study was approved by the Ethics Committee of the Antwerp University Hospital (reference 20/14/170).", [["GPCs", "CANCER", 107, 111], ["the organisational changes the GPCs", "PROBLEM", 76, 111]]], ["The boards of all participating GPCs gave consent; individual patient consent was waived because we only used pseudonymised data.MethodsWe included 9 GPCs out of the 13 GPCs connected to iCAREdata.", [["GPCs", "CANCER", 32, 36], ["patient", "ORGANISM", 62, 69], ["GPCs", "CANCER", 169, 173], ["iCAREdata", "DNA", 187, 196], ["patient", "SPECIES", 62, 69], ["MethodsWe", "TEST", 129, 138], ["9 GPCs", "TEST", 148, 154]]], ["One GPC was excluded because it is located within an ED which is not the focus of this study; three GPCs were excluded because the quality of data was insufficient.", [["GPCs", "CANCER", 100, 104], ["One GPC", "PROBLEM", 0, 7], ["this study", "TEST", 82, 92], ["three GPCs", "PROBLEM", 94, 104], ["GPC", "OBSERVATION", 4, 7]]], ["The included GPCs cover an average population of 168 169 citizens each (range 85 870-251 000) and have an average of 192 member GPs (range 100-380).", [["GPCs", "CANCER", 13, 17], ["GPCs", "TEST", 13, 17], ["average", "OBSERVATION_MODIFIER", 27, 34]]], ["All GPs having a practice in a community covered by a GPC are obliged to work approximately one shift a month in that GPC.", [["a GPC", "PROBLEM", 52, 57], ["GPC", "OBSERVATION", 118, 121]]], ["The studied GPCs are all located in the Dutch speaking part of Belgium (Flanders) and cover 23% of the Flemish population.", [["GPCs", "ANATOMY", 12, 16], ["GPCs", "CANCER", 12, 16], ["The studied GPCs", "TEST", 0, 16], ["GPCs", "OBSERVATION", 12, 16]]], ["For the historical reference period in 2019, four additional GPCs were excluded because they did not yet deliver reliable data.MethodsAll included GPCs filled in an e-mail questionnaire about their organisation in order to understand the data collected.", [["GPCs", "CANCER", 61, 65], ["four additional GPCs", "TEST", 45, 65], ["GPCs", "TEST", 147, 151]]], ["This questionnaire covered the following subjects: location of possible COVID-19 consultations, number of citizens covered by the GPC, number of active GPs covered by the GPC, starting date of specific COVID-19 care, profile and tasks of call takers, availability of consultations without appointment, organisation of telephone consultations and collaboration with surrounding EDs.", [["the GPC", "TEST", 126, 133], ["active GPs", "PROBLEM", 145, 155], ["the GPC", "TEST", 167, 174]]], ["The first author called the manager or a board member of all GPCs to verify the collected information.MethodsClinical data registered during home visits, telephone-and physical consultations were collected during five weekends (Friday 7 pm to Monday 8 am) and one bank holiday (Easter Monday) in 2020 and 2019.MethodsDuring a telephone consultation, the software allows the GP to electronically prescribe drugs, deliver medical certificates and refer to an ED or the patient's own GP.", [["GPCs", "CANCER", 61, 65], ["patient", "ORGANISM", 467, 474], ["patient", "SPECIES", 467, 474], ["all GPCs", "TEST", 57, 65], ["drugs", "TREATMENT", 405, 410]]], ["This list was extended with four labels related to COVID-19 based on SNOMED-CT concepts: confirmed case, suspected case, case with close contact to confirmed case and fear of COVID-19 without clinical suspicion.", [["COVID-19", "DNA", 51, 59], ["COVID", "TEST", 51, 56], ["COVID", "TEST", 175, 180]]], ["Because not all GPs were aware of the existence of these labels some have used other diagnostic labels or just a symptom as a diagnosis instead.", [["a symptom", "PROBLEM", 111, 120]]], ["The authors SM and VV independently rated all labels used in this study as at risk for COVID-19 or not.", [["COVID-19", "CHEMICAL", 87, 95], ["this study", "TEST", 61, 71], ["COVID", "TEST", 87, 92]]], ["All labels concerning a diagnosis of respiratory tract infections or a symptom in a list of the most common COVID-19 symptoms (fever, cough, myalgia, fatigue, expectorations, conjunctival congestion, diarrhoea, loss of smell and taste and dyspnoea) were rated as at risk.", [["respiratory tract", "ANATOMY", 37, 54], ["conjunctival", "ANATOMY", 175, 187], ["respiratory tract infections", "DISEASE", 37, 65], ["fever", "DISEASE", 127, 132], ["cough", "DISEASE", 134, 139], ["myalgia", "DISEASE", 141, 148], ["fatigue", "DISEASE", 150, 157], ["expectorations", "DISEASE", 159, 173], ["conjunctival congestion", "DISEASE", 175, 198], ["diarrhoea", "DISEASE", 200, 209], ["loss of smell and taste and dyspnoea", "DISEASE", 211, 247], ["respiratory tract", "ORGANISM_SUBDIVISION", 37, 54], ["conjunctival", "ORGANISM_SUBDIVISION", 175, 187], ["respiratory tract infections", "PROBLEM", 37, 65], ["a symptom", "PROBLEM", 69, 78], ["the most common COVID-19 symptoms", "PROBLEM", 92, 125], ["fever", "PROBLEM", 127, 132], ["cough", "PROBLEM", 134, 139], ["myalgia", "PROBLEM", 141, 148], ["fatigue", "PROBLEM", 150, 157], ["expectorations", "PROBLEM", 159, 173], ["conjunctival congestion", "PROBLEM", 175, 198], ["diarrhoea", "PROBLEM", 200, 209], ["loss of smell and taste", "PROBLEM", 211, 234], ["dyspnoea", "PROBLEM", 239, 247], ["respiratory tract", "ANATOMY", 37, 54], ["conjunctival", "ANATOMY", 175, 187], ["congestion", "OBSERVATION", 188, 198]]], ["[17] [18] [19] All data were automatically available in iCAREdata: a research database on out-of-hours primary care. iCAREdata uses the pseudonymised Belgian national number as a unique identifier making it possible to link several consultations (even at different GPCs) to one patient but automatically excluding patients without such a number.", [["[17] [18] [19", "SIMPLE_CHEMICAL", 0, 13], ["patient", "ORGANISM", 278, 285], ["patients", "ORGANISM", 314, 322], ["patient", "SPECIES", 278, 285], ["patients", "SPECIES", 314, 322]]], ["[15] It contains most of the data fields from the software used in the GPCs.MethodsData was analysed using JMP 141.", [["JMP 141", "CHEMICAL", 107, 114], ["GPCs", "CANCER", 71, 75], ["GPCs", "CELL_TYPE", 71, 75], ["the software", "TEST", 46, 58], ["the GPCs", "TEST", 67, 75], ["MethodsData", "TEST", 76, 87], ["JMP", "TEST", 107, 110], ["GPCs", "OBSERVATION", 71, 75]]], ["Pearson chi-square testing was used for all comparisons in categorical variables.", [["Pearson chi-square testing", "TEST", 0, 26]]], ["A two sample student's t-test was used to compare the means of age between the consultation types and the historical reference group.PLOS ONEConsultations in out-of-hours primary care during a COVID-19 outbreak lock-down; the other two made this switch one week later at the start of this study.", [["A two sample student's t-test", "TEST", 0, 29], ["this study", "TEST", 284, 294]]], ["They all provide staff with personal protective equipment and clean rooms for physical examination of patients at risk for COVID-19 called Corona Units, located outside of the sites for regular care.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["personal protective equipment", "TREATMENT", 28, 57], ["physical examination", "TEST", 78, 98], ["COVID", "TEST", 123, 128], ["Corona Units", "TREATMENT", 139, 151]]], ["Due to the structure of the iCAREdata database it was not yet possible to make a distinction between the consultations by site.PLOS ONEPatients have to call prior to presentation at the GPC, including those presenting themselves spontaneously at the GPC.", [["the GPC", "TEST", 182, 189], ["the GPC", "TEST", 246, 253]]], ["In two GPCs, the call takers refer selected patients directly to the ED (using a local triage protocol [20] ) while all other GPCs do not perform any kind of triage.", [["GPCs", "ANATOMY", 7, 11], ["GPCs", "CANCER", 7, 11], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["a local triage protocol", "TREATMENT", 79, 102], ["all other GPCs", "TEST", 116, 130], ["GPCs", "OBSERVATION_MODIFIER", 7, 11]]], ["In five GPCS, call takers differentiate the patients between an infectious patient flow (suspected COVID-19) and a regular patient flow (no suspicion of COVID-19)) by checking the most common COVID-19 symptoms (fever, dyspnoea, coughing, sneezing, running nose, throat ache and feeling unwell).", [["GPCS", "ANATOMY", 8, 12], ["throat", "ANATOMY", 262, 268], ["fever", "DISEASE", 211, 216], ["dyspnoea", "DISEASE", 218, 226], ["coughing", "DISEASE", 228, 236], ["sneezing", "DISEASE", 238, 246], ["throat ache", "DISEASE", 262, 273], ["patients", "ORGANISM", 44, 52], ["patient", "ORGANISM", 75, 82], ["patient", "ORGANISM", 123, 130], ["nose", "ORGANISM_SUBDIVISION", 256, 260], ["throat", "ORGANISM_SUBDIVISION", 262, 268], ["ache", "ORGANISM_SUBDIVISION", 269, 273], ["patients", "SPECIES", 44, 52], ["patient", "SPECIES", 75, 82], ["patient", "SPECIES", 123, 130], ["COVID", "TEST", 99, 104], ["COVID", "TEST", 153, 158], ["symptoms", "PROBLEM", 201, 209], ["fever", "PROBLEM", 211, 216], ["dyspnoea", "PROBLEM", 218, 226], ["coughing", "PROBLEM", 228, 236], ["sneezing", "PROBLEM", 238, 246], ["running nose", "PROBLEM", 248, 260], ["throat ache", "PROBLEM", 262, 273], ["feeling unwell", "PROBLEM", 278, 292], ["infectious", "OBSERVATION", 64, 74], ["throat ache", "ANATOMY", 262, 273]]], ["In the other four GPCs, the GP makes this differentiation based upon personal opinion.", [["GPCs", "ANATOMY", 18, 22], ["GPCs", "CANCER", 18, 22]]], ["Within the infectious patient flow, all GPCs perform a thorough telephone consultation, when needed the GP will refer patients to a home visit with PPE, a physical consultation at the corona unit or referral to the ED.", [["patient", "ORGANISM", 22, 29], ["patients", "ORGANISM", 118, 126], ["patient", "SPECIES", 22, 29], ["patients", "SPECIES", 118, 126], ["all GPCs", "TEST", 36, 44], ["infectious", "OBSERVATION_MODIFIER", 11, 21]]], ["Within the regular patient flow, four GPCs perform a telephone consultation on all patients after which the GP decides upon the following care.", [["patient", "ORGANISM", 19, 26], ["patients", "ORGANISM", 83, 91], ["patient", "SPECIES", 19, 26], ["patients", "SPECIES", 83, 91]]], ["In the other five GPCs, the call taker gives an appointment for home visit or physical consultation at a regular care site.Characteristics of GP consultationsWe included 15655 consultations by 12096 unique patients during five weekends in 2020, 8942 (57%) of these were telephone consultations of which 6293 (70%) could be handled by telephone alone.", [["GPCs", "CANCER", 18, 22], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["GP consultations", "TEST", 142, 158]]], ["In 2020, for 6692 (43%) consultations a diagnosis at risk of COVID-19 was registered.", [["COVID", "TEST", 61, 66]]], ["This rate declined from 2055 (58%) in the first weekend to 533 (27%) in the final weekend.", [["This rate", "TEST", 0, 9]]], ["The most common diagnoses at risk of COVID-19 were: suspected case of COVID-19 (N = 3131, 47%), unspecified viral infection (N = 618, 9%), fever (N = 602, 9%), acute upper respiratory tract infection (N = 546, 8%) and coughing (N = 417, 6%).", [["viral infection", "DISEASE", 108, 123], ["fever", "DISEASE", 139, 144], ["upper respiratory tract infection", "DISEASE", 166, 199], ["coughing", "DISEASE", 218, 226], ["tract", "ORGANISM_SUBDIVISION", 184, 189], ["COVID", "TEST", 37, 42], ["COVID", "TEST", 70, 75], ["unspecified viral infection", "PROBLEM", 96, 123], ["fever", "PROBLEM", 139, 144], ["acute upper respiratory tract infection", "PROBLEM", 160, 199], ["coughing", "PROBLEM", 218, 226], ["viral infection", "OBSERVATION", 108, 123], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["upper", "ANATOMY_MODIFIER", 166, 171], ["respiratory tract", "ANATOMY", 172, 189], ["infection", "OBSERVATION", 190, 199]]], ["This proportion was higher in the first weekend (N = 422, 12%) and lower in the final weekend (N = 153, 8%, p<0,001).", [["higher", "OBSERVATION_MODIFIER", 20, 26]]], ["The GPs referred 868 patients (6%) to the ED.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["For patients with a diagnosis at risk of COVID-19, the referral rate to the ED for telephone consultations was lower (N = 96, 2%) whereas it was higher during physical consultations (N = 141, 10%, p<0,001) and home visits (N = 51, 15%, p<0,001).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["COVID", "TEST", 41, 46]]], ["For 969 (6%) of the patients follow-up by the own GP was recommended.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["The first two weekends had a similar workload but the third and fifth had a lower workload due to a decrease in the number of all types of consultations (see Table 2 ).", [["decrease", "OBSERVATION_MODIFIER", 100, 108]]], ["Because it contains Eastern Monday, the small increase in the fourth weekend does not relate to an increased workload.", [["an increased workload", "PROBLEM", 96, 117], ["Eastern", "OBSERVATION_MODIFIER", 20, 27], ["small", "OBSERVATION_MODIFIER", 40, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["workload", "OBSERVATION", 109, 117]]], ["The amount of physical consultations decreased by 45% and even more in the final weekend.Characteristics of GP consultationsAmong the patients who underwent a physical consultation, 2226 (42%) had a prior telephone consultation by a GP.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["GP consultations", "TEST", 108, 124], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["Among the patients with a diagnose at risk for COVID-19 this was significantly more: 1027 (70%, p<0,001) had a prior telephone consultation.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["COVID", "TEST", 47, 52]]], ["However,433 (30%) patients only spoke with a call taker.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Before a home visit, 423 (30%) had a prior telephone consultation, again significantly more (N = 209, 62%, p<0,001) in case of a diagnosis suspected of COVID-19.Changes in the demand for careSee Table 3 for an overview of the changes in the rate of physical consultations by diagnosis (ICPC chapter).", [["COVID", "TEST", 152, 157]]], ["There was a small increase of consultations for psychological (including fear of COVID-19) and cardiovascular diagnoses whereas there was a marked decrease in the amount of physical consultations for respiratory, ophthalmological, digestive and ear-related diagnoses.DiscussionThis study proves it is possible to rapidly collect reliable data about the characteristics of primary out-of-hours care.", [["cardiovascular", "ANATOMY", 95, 109], ["respiratory", "ANATOMY", 200, 211], ["digestive", "ANATOMY", 231, 240], ["cardiovascular", "ANATOMICAL_SYSTEM", 95, 109], ["COVID", "TEST", 81, 86], ["a marked decrease", "PROBLEM", 138, 155], ["This study", "TEST", 277, 287], ["small", "OBSERVATION_MODIFIER", 12, 17], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["marked", "OBSERVATION_MODIFIER", 140, 146], ["decrease", "OBSERVATION_MODIFIER", 147, 155]]], ["GPCs changed their way of working rapidly and profoundly almost immediately after the start of the Belgian lock-down.", [["GPCs", "ANATOMY", 0, 4], ["GPCs", "CELL_TYPE", 0, 4], ["GPCs", "PROBLEM", 0, 4], ["the Belgian lock", "TREATMENT", 95, 111]]], ["This organisational change is very similar to the yet unstudied response in other countries worldwide.", [["This organisational change", "PROBLEM", 0, 26]]], ["[4] [5] [6] At the start of the study half of the primary out-of-hours care was COVID-19 related.", [["the study", "TEST", 28, 37], ["COVID", "TEST", 80, 85]]], ["The GPs handled the vast majority of the patients themselves with a combination of telephone and physical consultations while referring 6% to secondary care.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["The demand for work certificates caused an additional increase in consultations.DiscussionOf the patients who had a diagnosis at risk for COVID-19 after a physical consultation, 30% did not have a prior telephone consultation (they only had a brief contact with a call taker).", [["COVID", "DISEASE", 138, 143], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["COVID", "TEST", 138, 143], ["a physical consultation", "TEST", 153, 176], ["increase", "OBSERVATION_MODIFIER", 54, 62]]], ["Given the fact that all GPCs state that within the infectious patient flow all patients get a GP telephone consultation first, most likely the majority of them have been seen within the regular flow.", [["GPCs", "CANCER", 24, 28], ["patient", "ORGANISM", 62, 69], ["patients", "ORGANISM", 79, 87], ["patient", "SPECIES", 62, 69], ["patients", "SPECIES", 79, 87], ["all GPCs", "PROBLEM", 20, 28], ["GPCs", "OBSERVATION", 24, 28], ["infectious", "OBSERVATION_MODIFIER", 51, 61], ["most likely", "UNCERTAINTY", 127, 138], ["regular flow", "OBSERVATION", 186, 198]]], ["Possibly, a minority of these patients did get another type of COVID-19 risk assessment not registered in the software: prior consultation outside of the GPC (patient's own GP working in the weekend or specialist).", [["patients", "ORGANISM", 30, 38], ["patient", "ORGANISM", 159, 166], ["patients", "SPECIES", 30, 38], ["patient", "SPECIES", 159, 166], ["COVID", "TEST", 63, 68], ["risk assessment", "TEST", 72, 87], ["the GPC", "TEST", 150, 157]]], ["This proportion of patients suspected of COVID-19 physically seen without prior telephone consultation is high and indicates a risk for the GPs working in the regular patient flow, as they do not wear personal protective equipment.", [["patients", "ORGANISM", 19, 27], ["patient", "ORGANISM", 167, 174], ["patients", "SPECIES", 19, 27], ["patient", "SPECIES", 167, 174], ["COVID", "TEST", 41, 46]]], ["Awaiting validated triage guidelines we recommend to give a telephone consultation to all patients and not to rely on call takers to differentiate between infectious and regular care.DiscussionDuring the study, the total workload decreased drastically: from a workload much higher as in 2019, entirely due to telephone consultations, to a total workload much lower than in 2019.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["the study", "TEST", 200, 209], ["infectious", "OBSERVATION", 155, 165]]], ["Finally it might be related to the outbreak itself as the number of hospitalisations followed a similar decline with a one week delay.", [["might be related to", "UNCERTAINTY", 11, 30]]], ["An indirect effect might be due to the lockdown: a decline in infections and accidents can be expected.", [["infections", "DISEASE", 62, 72], ["accidents", "DISEASE", 77, 86], ["a decline in infections", "PROBLEM", 49, 72], ["might be due to", "UNCERTAINTY", 19, 34], ["infections", "OBSERVATION", 62, 72]]], ["The more pronounced decline of ophthalmological and digestive diagnoses might be due to the reduced amount of other infections caused by the lock-down.DiscussionAnother indirect effect is the fear of patients to consult a medical service as described in Italy.", [["digestive", "ANATOMY", 52, 61], ["infections", "DISEASE", 116, 126], ["digestive", "ORGAN", 52, 61], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["other infections", "PROBLEM", 110, 126], ["more", "OBSERVATION_MODIFIER", 4, 8], ["pronounced", "OBSERVATION_MODIFIER", 9, 19], ["decline", "OBSERVATION_MODIFIER", 20, 27], ["reduced", "OBSERVATION_MODIFIER", 92, 99], ["amount", "OBSERVATION_MODIFIER", 100, 106], ["infections", "OBSERVATION", 116, 126]]], ["[10] The decline in physical consultations is most pronounced for respiratory, ophthalmological, digestive and ear-related diagnoses probably also due to a combination of decreased infections and fear of consulting.", [["respiratory", "ANATOMY", 66, 77], ["digestive", "ANATOMY", 97, 106], ["infections", "DISEASE", 181, 191], ["digestive", "ORGAN", 97, 106], ["decreased infections", "PROBLEM", 171, 191], ["decreased", "OBSERVATION_MODIFIER", 171, 180], ["infections", "OBSERVATION", 181, 191]]], ["The decline in respiratory diagnosis can be explained by the trend to handle these patients by telephone.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["The decline", "PROBLEM", 0, 11], ["decline", "OBSERVATION_MODIFIER", 4, 11], ["respiratory diagnosis", "OBSERVATION", 15, 36]]], ["This reduction in care unrelated to COVID-19 is an important finding because it might be correlated to increased morbidity and mortality.DiscussionThe strength of this study lies in the large number of included consultations and the speed of reporting.", [["COVID-19", "CHEMICAL", 36, 44], ["COVID-19", "CHEMICAL", 36, 44], ["This reduction in care", "TREATMENT", 0, 22], ["COVID", "TEST", 36, 41], ["increased morbidity", "PROBLEM", 103, 122], ["this study", "TEST", 163, 173], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["morbidity", "OBSERVATION", 113, 122], ["large", "OBSERVATION_MODIFIER", 186, 191]]], ["This study has got several limitations: it only describes what happens but does not allow for any conclusions about the outcomes, efficacy or safety of these consultations.", [["This study", "TEST", 0, 10]]], ["For telephone consultations, safety was already an issue before the COVID-19 pandemic.", [["the COVID", "TEST", 64, 73], ["pandemic", "PROBLEM", 77, 85]]], ["[21] During the study period, ambulatory testing patients for SARS-CoV-2 in primary care was not allowed in Belgium so the proportion of truly infected patients remains unknown.", [["SARS", "DISEASE", 62, 66], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 152, 160], ["SARS-CoV", "SPECIES", 62, 70], ["the study", "TEST", 12, 21], ["ambulatory testing", "TEST", 30, 48], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["infected", "OBSERVATION", 143, 151]]], ["Rapid changes in the organisation of the GPCs reduced data quality: some consultations might not have been registered correctly and there might be small differences in organisation among the participating GPCs.", [["GPCs", "ANATOMY", 205, 209], ["GPCs", "CANCER", 205, 209], ["GPCs", "CELL_TYPE", 205, 209], ["Rapid changes", "PROBLEM", 0, 13], ["small differences in organisation", "PROBLEM", 147, 180], ["small", "OBSERVATION_MODIFIER", 147, 152], ["differences", "OBSERVATION_MODIFIER", 153, 164]]], ["We were unable to see which patients were in the infectious or the regular patient flow.", [["patients", "ORGANISM", 28, 36], ["patient", "ORGANISM", 75, 82], ["patients", "SPECIES", 28, 36], ["patient", "SPECIES", 75, 82], ["infectious", "OBSERVATION", 49, 59]]], ["This paper does not allow to make any predictions based upon this data.", [["this data", "TEST", 61, 70]]], ["Because COVID-19 patients typically deteriorate one week after the first symptoms [22] , the stress on the primary care system might be a predictor for overcrowding in the hospitals in the near future.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["COVID", "TEST", 8, 13], ["the first symptoms", "PROBLEM", 63, 81]]], ["Further study into the significance of the decline in regular care is needed as this might indicate a safety problem.", [["Further study", "TEST", 0, 13], ["the decline", "PROBLEM", 39, 50], ["a safety problem", "PROBLEM", 100, 116]]], ["When implementing new strategies to limit COVID-19, close attention should be given to its side effects on regular care.DiscussionThe successful implementation of telephone consultations opens new possibilities for the post COVID-19 era but should be studied more profoundly, especially regarding patient's safety.", [["patient", "ORGANISM", 297, 304], ["patient", "SPECIES", 297, 304], ["COVID", "TEST", 42, 47], ["the post COVID-19 era", "TREATMENT", 215, 236]]], ["The current study provides some arguments in favour of a primary care first model with remote consultations but more aspects such as financial consequences, total work burden, proportion of truly infected patients, morbidity and mortality should be studied.ConclusionsBelgian GPs have been able to rapidly re-organise care in order to handle a COVID-19 outbreak and provide a safe working environment.", [["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["The current study", "TEST", 0, 17], ["total work burden", "PROBLEM", 157, 174], ["morbidity", "PROBLEM", 215, 224], ["rapidly re-organise care", "TREATMENT", 298, 322], ["infected", "OBSERVATION", 196, 204]]], ["Initially half of the GP's consultations during out-of-hours care were related to COVID-19 leading to an increased work load followed by a workload below the normal average after five weeks.", [["COVID", "TEST", 82, 87], ["an increased work load", "PROBLEM", 102, 124]]], ["This provokes questions about patient's safety for care unrelated to COVID-19.", [["COVID-19", "CHEMICAL", 69, 77], ["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["COVID", "TEST", 69, 74]]], ["Among the patients with a diagnosis at risk of COVID-19, 30% had a physical consultation without a prior telephone consultation to detect this risk.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["COVID", "TEST", 47, 52]]], ["This implies a risk for unprotected staff providing care for possibly infected patients.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]]], "ca42cf967bbaf76e8e3fa9e9ad3c6b909ff13be3": [["(Page numbers not final at time of first release) 2 to purified human ribosomal subunits ( Fig. 1B and fig. S1A ).", [["ribosomal", "ANATOMY", 70, 79], ["human", "ORGANISM", 64, 69], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 91, 98], ["S1A", "GENE_OR_GENE_PRODUCT", 108, 111], ["purified human ribosomal subunits", "PROTEIN", 55, 88], ["Fig. 1B", "PROTEIN", 91, 98], ["S1A", "PROTEIN", 108, 111], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["purified human ribosomal subunits", "TREATMENT", 55, 88]]], ["Nsp1 from both CoVs associated strongly with 40S subunits but not with 60S subunits, whereas both Nsp1-mt constructs showed no binding (Fig. 1B) .", [["Nsp1", "GENE_OR_GENE_PRODUCT", 0, 4], ["CoVs", "GENE_OR_GENE_PRODUCT", 15, 19], ["40S subunits", "GENE_OR_GENE_PRODUCT", 45, 57], ["60S subunits", "GENE_OR_GENE_PRODUCT", 71, 83], ["Nsp1", "GENE_OR_GENE_PRODUCT", 98, 102], ["Nsp1", "PROTEIN", 0, 4], ["CoVs", "PROTEIN", 15, 19], ["40S subunits", "PROTEIN", 45, 57], ["60S subunits", "PROTEIN", 71, 83], ["Nsp1", "PROTEIN", 98, 102], ["mt constructs", "DNA", 103, 116], ["Nsp1", "PROBLEM", 0, 4], ["both CoVs", "PROBLEM", 10, 19], ["40S subunits", "PROBLEM", 45, 57], ["60S subunits", "TREATMENT", 71, 83], ["Nsp1-mt constructs", "TEST", 98, 116], ["both CoVs", "OBSERVATION", 10, 19], ["no", "UNCERTAINTY", 124, 126]]], ["Thus, ribosome binding to the 40S subunit is preserved and residues K164 and H165 of Nsp1 from both SARS-CoVs are important for this ribosome interaction.", [["ribosome", "ANATOMY", 6, 14], ["ribosome", "ANATOMY", 133, 141], ["ribosome", "CELLULAR_COMPONENT", 6, 14], ["40S", "CELLULAR_COMPONENT", 30, 33], ["K164", "GENE_OR_GENE_PRODUCT", 68, 72], ["Nsp1", "GENE_OR_GENE_PRODUCT", 85, 89], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 100, 109], ["40S subunit", "PROTEIN", 30, 41], ["Nsp1", "PROTEIN", 85, 89], ["ribosome binding", "PROBLEM", 6, 22], ["Nsp1", "PROBLEM", 85, 89], ["ribosome binding", "OBSERVATION", 6, 22], ["preserved", "OBSERVATION", 45, 54]]], ["To further verify this, we expressed wildtype or mutant Nsp1 constructs in human HEK293T cells and analyzed ribosome association by sucrose-gradient centrifugation.", [["HEK293T cells", "ANATOMY", 81, 94], ["ribosome", "ANATOMY", 108, 116], ["sucrose", "CHEMICAL", 132, 139], ["sucrose", "CHEMICAL", 132, 139], ["Nsp1", "GENE_OR_GENE_PRODUCT", 56, 60], ["human", "ORGANISM", 75, 80], ["HEK293T cells", "CELL", 81, 94], ["sucrose", "SIMPLE_CHEMICAL", 132, 139], ["mutant Nsp1 constructs", "DNA", 49, 71], ["human HEK293T cells", "CELL_LINE", 75, 94], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["mutant Nsp1 constructs in human HEK293T cells", "TREATMENT", 49, 94], ["sucrose-gradient centrifugation", "TREATMENT", 132, 163], ["Nsp1 constructs", "OBSERVATION", 56, 71], ["gradient centrifugation", "OBSERVATION", 140, 163]]], ["Consistent with the behavior in vitro, Nsp1 of CoV and CoV-2 co-migrated with 40S ribosomal subunits and 80S ribosomes, but not with actively translating polyribosomes.", [["polyribosomes", "ANATOMY", 154, 167], ["Nsp1", "GENE_OR_GENE_PRODUCT", 39, 43], ["CoV", "GENE_OR_GENE_PRODUCT", 47, 50], ["CoV-2", "GENE_OR_GENE_PRODUCT", 55, 60], ["40S ribosomal subunits", "GENE_OR_GENE_PRODUCT", 78, 100], ["80S", "CELLULAR_COMPONENT", 105, 108], ["polyribosomes", "CELLULAR_COMPONENT", 154, 167], ["Nsp1", "PROTEIN", 39, 43], ["CoV", "PROTEIN", 47, 50], ["CoV", "PROTEIN", 55, 58], ["40S ribosomal subunits", "PROTEIN", 78, 100], ["80S ribosomes", "RNA", 105, 118], ["CoV", "TEST", 47, 50], ["CoV", "TEST", 55, 58], ["40S ribosomal subunits", "TREATMENT", 78, 100], ["80S ribosomes", "TREATMENT", 105, 118], ["80S ribosomes", "OBSERVATION", 105, 118], ["not with", "UNCERTAINTY", 124, 132], ["polyribosomes", "OBSERVATION", 154, 167]]], ["In contrast, the mutant constructs barely penetrated the gradient, indicative of their loss of affinity for ribosomes (Fig. 1C) .", [["ribosomes", "CELLULAR_COMPONENT", 108, 117], ["mutant constructs", "DNA", 17, 34], ["ribosomes", "PROTEIN", 108, 117], ["their loss of affinity", "PROBLEM", 81, 103], ["ribosomes (Fig", "TREATMENT", 108, 122], ["gradient", "OBSERVATION_MODIFIER", 57, 65]]]], "6b881730788724e674806854f0c20fec32ee9d96": [["IntroductionIn the last decade, at least seven separate viral outbreaks have caused tens of thousands of human deaths (Woolhouse, Rambaut, and Kellam, 2015) , and the ever-increasing density of livestock, rate of habitat destruction, and extent of human global travel provides a fertile environment for new pandemics to emerge from host switching events (Delwart 2007; Fancello, Raoult, and Desnues 2012) , as was the case for SARS, Ebola, Middle East Respiratory Syndrome (MERS), and influenza-A (H1N1) (Castillo-Chavez et al. 2015) .", [["deaths", "DISEASE", 111, 117], ["SARS", "DISEASE", 427, 431], ["Ebola", "DISEASE", 433, 438], ["Middle East Respiratory Syndrome", "DISEASE", 440, 472], ["MERS", "DISEASE", 474, 478], ["influenza-A", "DISEASE", 485, 496], ["human", "ORGANISM", 105, 110], ["human", "ORGANISM", 248, 253], ["Ebola", "ORGANISM", 433, 438], ["Middle East Respiratory", "ORGANISM", 440, 463], ["influenza-A (H1N1", "ORGANISM", 485, 502], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 248, 253], ["influenza-", "SPECIES", 485, 495], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 248, 253], ["Middle East Respiratory Syndrome (MERS", "SPECIES", 440, 478], ["influenza-A (H1N1)", "SPECIES", 485, 503], ["human deaths", "PROBLEM", 105, 117], ["habitat destruction", "PROBLEM", 213, 232], ["new pandemics", "PROBLEM", 303, 316], ["SARS", "PROBLEM", 427, 431], ["Ebola", "PROBLEM", 433, 438], ["Middle East Respiratory Syndrome", "PROBLEM", 440, 472], ["influenza", "PROBLEM", 485, 494], ["increasing", "OBSERVATION_MODIFIER", 172, 182], ["density", "OBSERVATION", 183, 190], ["habitat destruction", "OBSERVATION", 213, 232], ["Middle", "ANATOMY_MODIFIER", 440, 446], ["Respiratory Syndrome", "OBSERVATION", 452, 472]]], ["At present we have a limited grasp of the extent of viral diversity present in the environment: the 2014 database release from the International Committee for the Taxonomy of Viruses classified just 7 orders, 104 families, 505 genera, and 3286 species (http://www.ictvon line.org/virustaxonomy.asp); yet, one study estimated that there are at least 320,000 virus species infecting mammals alone (Anthony et al. 2013 ).IntroductionV C The Author 2016.", [["Viruses", "PROBLEM", 175, 182], ["genera", "TEST", 227, 233], ["one study", "TEST", 305, 314], ["viral diversity", "OBSERVATION", 52, 67]]], ["For commercial re-use, please contact journals.permissions@oup.com High throughput (or so-called 'next generation') sequencing of viruses during the most recent outbreaks of MERS in South Arabia (Gire et al. 2014; Carroll et al. 2015; Park et al. 2015) and Ebola in West Africa (Quick, J et al. 2016 ) has facilitated rapid identification of transmission chains, rates of viral evolution, and evidence of the zoonotic origin of these outbreaks.", [["MERS", "DISEASE", 174, 178], ["Ebola", "DISEASE", 257, 262], ["Ebola", "ORGANISM", 257, 262], ["viruses", "PROBLEM", 130, 137], ["transmission chains", "PROBLEM", 342, 361], ["viral evolution", "PROBLEM", 372, 387], ["viruses", "OBSERVATION", 130, 137], ["viral evolution", "OBSERVATION", 372, 387], ["zoonotic", "OBSERVATION_MODIFIER", 409, 417]]], ["Access to such information during initial stages of an outbreak would offer invaluable insight into when, where, and how an epidemic might emerge, informing intervention and mitigation measures or even stopping it altogether.", [["intervention", "TREATMENT", 157, 169], ["mitigation measures", "TREATMENT", 174, 193]]], ["A major step towards this goal is therefore to identify existing zoonotic and environmental pathogens with pandemic potential.", [["zoonotic and environmental pathogens", "DISEASE", 65, 101]]], ["This is a significant undertaking, demanding considerable investment and close collaboration between government, NGOs and academia, for example, the USAID program PREDICT http://www.vetmed.ucdavis.edu/ohi/predict/index.cfm, as well as on the ground surveillance by local authorities and scientists in areas of the world most at risk.IntroductionThe characterization of unknown viral entities in the environment is now possible with modern sequencing; however, current tooling for exploiting these data represents a practical and methodological bottleneck for effective data analysis.", [["modern sequencing", "TEST", 432, 449], ["effective data analysis", "TEST", 559, 582], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["viral entities", "OBSERVATION", 377, 391]]], ["Practically, most available software tools are inaccessible to the majority of potential users, demanding expertise and computing resources often lacked by the researchers from diverse backgrounds involved in sample collection, sequencing, and analysis.", [["sample", "ANATOMY", 209, 215], ["sample collection", "TEST", 209, 226], ["sequencing", "TEST", 228, 238], ["analysis", "TEST", 244, 252]]], ["There is a need for robust and intuitive analytical tools without requirements for fast internet connectivity, which may be unavailable in remote or developing regions.", [["may be", "UNCERTAINTY", 117, 123]]], ["More fundamentally, the intended scope of published analytical tools and workflows is often less than clear, and given the diverse applications of viral sequencing, it can be difficult to gauge the relevance of newly published tools without first testing them.", [["viral sequencing", "TREATMENT", 147, 163], ["newly published tools", "PROBLEM", 211, 232]]], ["For example, a fast sequence classifier might fail entirely to detect a novel strain of a well-characterized virus, and equally might perform well with Illumina sequences yet deliver poor results for data generated with the Ion Torrent platform.", [["Illumina sequences", "DNA", 152, 170], ["a fast sequence classifier", "TEST", 13, 39], ["a novel strain", "PROBLEM", 70, 84], ["a well-characterized virus", "PROBLEM", 88, 114], ["Illumina sequences", "TEST", 152, 170], ["the Ion Torrent platform", "TREATMENT", 220, 244], ["virus", "OBSERVATION", 109, 114]]], ["Furthermore, results arising from these analyses should be replicable, intelligible, and useful to the end user, with provision for quality control and error management.", [["these analyses", "TEST", 34, 48], ["quality control", "TREATMENT", 132, 147], ["error management", "TREATMENT", 152, 168]]], ["Software tools that target expert users should be tested, documented and robustly distributed as packages or containers so as to streamline the processes of installation and generating results.IntroductionMethodologically, most genomic sequence analysis software is not well suited for viral genomes.", [["viral genomes", "DNA", 286, 299], ["most genomic sequence analysis software", "TEST", 223, 262], ["viral genomes", "PROBLEM", 286, 299]]], ["Choosing between approaches is made difficult due to an abundance of disparate yet functionally equivalent methodologies and in general a lack of rigorous benchmarks for viral datasets.", [["viral datasets", "PROBLEM", 170, 184]]], ["While there is much ongoing research in this area, both the sensitive detection of previously characterized viruses and viral discovery remain key challenges open for innovation.", [["previously characterized viruses", "PROBLEM", 83, 115], ["viral discovery", "PROBLEM", 120, 135], ["viruses", "OBSERVATION", 108, 115]]], ["Here we survey the landscape of available approaches for analyzing both known and unknown viruses within genomic and metagenomic samples, with focus on their practical and methodological suitability for use by a broad spectrum of researchers seeking to characterize viral metagenomes.Viral sequence enrichment: physical and in silico approachesWithin metagenomes the proportion of viral nucleic acids is typically far lower than that of host or other microbes, limiting the amount of signal available for analysis after sequencing.", [["samples", "ANATOMY", 129, 136], ["nucleic acids", "CHEMICAL", 387, 400], ["unknown viruses", "PROBLEM", 82, 97], ["viral metagenomes", "PROBLEM", 266, 283], ["viral nucleic acids", "PROBLEM", 381, 400], ["analysis", "TEST", 505, 513], ["sequencing", "TEST", 520, 530], ["viral metagenomes", "OBSERVATION", 266, 283], ["viral nucleic acids", "OBSERVATION", 381, 400], ["microbes", "OBSERVATION", 451, 459]]], ["Alternatively, PCR amplification may be used to generate an abundance of specific viral sequences present in a sample, a widely used strategy, which was employed in the identification and analysis of MERS coronavirus (Zaki et al. 2012; Cotten et al. 2013 Cotten et al. , 2014 , although effective primer design can be challenging in the presence of high genomic diversity in the target viral species.", [["sample", "ANATOMY", 111, 117], ["MERS coronavirus", "ORGANISM", 200, 216], ["viral sequences", "DNA", 82, 97], ["MERS coronavirus", "SPECIES", 200, 216], ["PCR amplification", "TEST", 15, 32], ["specific viral sequences", "PROBLEM", 73, 97], ["MERS coronavirus", "PROBLEM", 200, 216], ["high genomic diversity", "PROBLEM", 349, 371], ["the target viral species", "PROBLEM", 375, 399], ["high genomic diversity", "OBSERVATION", 349, 371], ["viral species", "OBSERVATION", 386, 399]]], ["Conversely, an excess of sequencing coverage can lead to the construction of overly complex and unwieldy de novo assembly graphs in the presence of high genomic diversity, reducing assembly quality.", [["sequencing coverage", "TREATMENT", 25, 44], ["high genomic diversity", "PROBLEM", 148, 170], ["high genomic diversity", "OBSERVATION", 148, 170]]], ["Using in silico normalisation (Crusoe et al. 2015) , excess coverage may be reduced by discarding sequences containing redundant information.", [["excess coverage", "TREATMENT", 53, 68]]], ["This approach increases analytical efficiency when dealing with high coverage sequence data, and we have shown that it can benefit de novo assembly of viral consensus sequences.", [["viral consensus sequences", "DNA", 151, 176], ["viral consensus sequences", "TEST", 151, 176]]], ["Another in silico strategy for increasing analytical efficiency by discarding unneeded data is to filter sequences from known abundant organisms through alignment with one or more reference genomes using an aligner or specialist tool (approaches reviewed in Daly et al. 2015) .Choosing a sequencing platformThere are several sequencing technologies in widespread use that are capable of reading hundreds of thousands to billions of DNA sequences per run (Reuter, Spacek, and Snyder 2015) .", [["DNA", "CELLULAR_COMPONENT", 432, 435], ["DNA sequences", "DNA", 432, 445], ["increasing analytical efficiency", "PROBLEM", 31, 63], ["filter sequences", "TEST", 98, 114], ["DNA sequences", "TEST", 432, 445], ["abundant", "OBSERVATION_MODIFIER", 126, 134], ["organisms", "OBSERVATION", 135, 144]]], ["The current market leader, Illumina, manufactures instruments capable of generating billions of 150 base pair (bp) paired end reads (see 'Glossary') per run, with read lengths of up to 300 bp.", [["bp", "TEST", 189, 191]]], ["The Illumina short read platform is widely used for analyses of viral genomes and metagenomes, and, given sufficient sequencing coverage, enables sensitive characterization of lowfrequency variation within viral populations (e.g. HIV resistance mutations as low as 0.1% (Li et al. 2014) ).", [["viral genomes", "DNA", 64, 77], ["HIV", "SPECIES", 230, 233], ["viral genomes", "PROBLEM", 64, 77], ["lowfrequency variation", "PROBLEM", 176, 198], ["viral populations", "PROBLEM", 206, 223], ["HIV resistance mutations", "PROBLEM", 230, 254], ["viral genomes", "OBSERVATION", 64, 77], ["viral populations", "OBSERVATION", 206, 223]]], ["Ion Torrent (ThermoFisher) is capable of generating longer reads than Illumina at the expense of reduced throughput and a higher rate of insertion and deletion (indel) error (Eid et al. 2009 ).", [["Ion Torrent (ThermoFisher)", "TREATMENT", 0, 26], ["reduced throughput", "PROBLEM", 97, 115], ["a higher rate of insertion", "TREATMENT", 120, 146], ["deletion (indel) error", "PROBLEM", 151, 173], ["reduced", "OBSERVATION_MODIFIER", 97, 104]]], ["Single molecule real-time sequencing commercialized by Pacific Biosciences (PacBio) produces much longer (>10 kbp) reads from a single molecule without clonal amplification, which eliminates the errors introduced in this step.", [["clonal amplification", "TREATMENT", 152, 172], ["the errors", "PROBLEM", 191, 201]]], ["However, this platform has a high (10%) intrinsic error rate, and remains much more expensive than Illumina sequencing for equivalent throughput.", [["this platform", "TEST", 9, 22], ["intrinsic error rate", "TEST", 40, 60], ["Illumina sequencing", "TEST", 99, 118], ["high", "OBSERVATION_MODIFIER", 29, 33]]], ["The Nanopore platform from Oxford Nanopore Technologies, which includes the pocket sized MinION sequencer, also implements long read single molecule sequencing, and permits truly real-time analysis of individual sequences as they are generated.", [["Oxford Nanopore Technologies", "TEST", 27, 55], ["single molecule sequencing", "TEST", 133, 159], ["individual sequences", "TEST", 201, 221]]], ["Although more affordable than PacBio single molecule sequencing, the Nanopore platform also suffers from high error rates in comparison with Illumina (Reuter, Spacek, and Snyder 2015) .", [["high error", "OBSERVATION", 105, 115]]], ["However, the technology is maturing rapidly and has already demonstrated potential to revolutionize pathogen surveillance and discovery in the field, as well as enabling contiguous assembly of entire bacterial genomes at relatively low cost (Feng et al. 2015; Quick et al. 2015; Hoenen et al. 2016 ).", [["pathogen surveillance", "TEST", 100, 121], ["entire bacterial genomes", "PROBLEM", 193, 217], ["bacterial genomes", "OBSERVATION", 200, 217]]], ["Hybrid sequencing strategies using both long and short reads leverage the ability of long reads to resolve repetitive DNA regions while benefitting from the high accuracy of short reads, at the expense of additional sequencing, library preparation and data analysis (Madoui et al. 2015) .Assembling genomes: de novo and reference-based assemblyThe reconstruction of sequencing reads into full length genes and genomes can be performed by means of either referencebased alignment or de novo assembly, a decision dependent on experimental objectives, read length, quality and data complexity.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["repetitive DNA regions", "DNA", 107, 129], ["Hybrid sequencing strategies", "TREATMENT", 0, 28], ["repetitive DNA regions", "PROBLEM", 107, 129], ["library preparation", "TEST", 228, 247], ["data analysis", "TEST", 252, 265], ["The reconstruction of sequencing", "TREATMENT", 344, 376]]], ["In reference-based approaches, reads are mapped to similar regions of a supplied template genome, a well-studied and computationally efficient process implemented with a suffix array index of the reference genome.", [["supplied template genome", "DNA", 72, 96], ["reference genome", "DNA", 196, 212], ["a supplied template genome", "PROBLEM", 70, 96], ["template genome", "OBSERVATION", 81, 96]]], ["In contrast, de novo assembly is computationally exhaustive but important in cases where either a target genome is poorly characterized or reconstruction of genomes of a priori unknown entities in metagenomes is sought, such as in surveillance studies.", [["target genome", "DNA", 98, 111], ["surveillance studies", "TEST", 231, 251], ["poorly characterized", "OBSERVATION_MODIFIER", 115, 135]]], ["For short read data, the increased sequence length afforded by assembly can be necessary to distinguish members of highly conserved gene families from one another.", [["the increased sequence length", "PROBLEM", 21, 50]]], ["Assembly is also widely used for generating whole genome consensus sequences to facilitate analyses of viral variation, and is a typical starting point for analyses of diverse populations of well-characterized viruses.", [["whole genome consensus sequences", "DNA", 44, 76], ["viral variation", "PROBLEM", 103, 118], ["viral variation", "OBSERVATION", 103, 118], ["viruses", "OBSERVATION", 210, 217]]], ["Even where Glossary Contigs: Contiguous nucleotide sequences assembled from multiple overlapping reads.Assembling genomes: de novo and reference-based assemblyCoverage: The number of times a genome (or part thereof) has been sequenced. de Bruijn graph: A network of nodes and edges, where each edge represents a k-mer found in the collection of reads, and each node represents either the prefix or suffix of the k-mer.", [["nodes", "ANATOMY", 266, 271], ["node", "ANATOMY", 361, 365], ["nucleotide", "CHEMICAL", 40, 50], ["nucleotide", "CHEMICAL", 40, 50], ["nodes", "MULTI-TISSUE_STRUCTURE", 266, 271], ["Glossary Contigs", "DNA", 11, 27], ["Contiguous nucleotide sequences", "DNA", 29, 60], ["Contiguous nucleotide sequences", "TEST", 29, 60], ["A network of nodes and edges", "PROBLEM", 253, 281], ["a k-mer", "PROBLEM", 310, 317], ["each node", "PROBLEM", 356, 365], ["the prefix", "TREATMENT", 384, 394], ["suffix of the k-mer", "TREATMENT", 398, 417], ["nodes", "OBSERVATION", 266, 271], ["edges", "OBSERVATION_MODIFIER", 276, 281], ["edge", "OBSERVATION_MODIFIER", 294, 298], ["k-mer", "OBSERVATION", 312, 317], ["node", "OBSERVATION", 361, 365]]], ["De novo assembly: Reconstruction of short sequences into longer sequences (or contigs), without use of a reference sequence Digital signal processing data transformation: Analytical techniques for transforming sequential data into a domain representative of data features.", [["short sequences", "DNA", 36, 51], ["reference sequence", "DNA", 105, 123], ["a reference sequence", "TEST", 103, 123], ["transforming sequential data", "TEST", 197, 225]]], ["Discrete Fourier transform: A spectral analysis technique for identifying sine and cosine frequency components in numerical signal data.", [["A spectral analysis technique", "TEST", 28, 57], ["numerical signal data", "TEST", 114, 135]]], ["Discrete wavelet transform: A spectral analysis technique for decomposing data to its frequency and spatial components. k-mer: A subsequence of length k.", [["A spectral analysis technique", "TEST", 28, 57], ["decomposing data", "TEST", 62, 78]]], ["Many genomic analyses involve decomposition of sequences into all possible subsequences of a specified length k.", [["Many genomic analyses", "PROBLEM", 0, 21]]], ["Numerical sequence representation: Numerical mapping of nucleotide sequences, permitting the application of signal processing transformation approaches.Assembling genomes: de novo and reference-based assemblyPaired-end reads: Reads generated from both 5 and 3 ends of the same DNA molecule.", [["nucleotide", "CHEMICAL", 56, 66], ["nucleotide", "CHEMICAL", 56, 66], ["DNA", "CELLULAR_COMPONENT", 277, 280], ["nucleotide sequences", "DNA", 56, 76], ["5 and 3 ends", "DNA", 252, 264], ["nucleotide sequences", "TEST", 56, 76], ["DNA molecule", "OBSERVATION", 277, 289]]], ["Depending on the length of the molecule and that of the reads, these pairs may or may not overlap in the middle.", [["middle", "ANATOMY_MODIFIER", 105, 111]]], ["Read overlap graphs: A network of nodes and edges, where each edge represents a read and each vertex represents an overlap between two nodes.", [["nodes", "ANATOMY", 34, 39], ["nodes", "MULTI-TISSUE_STRUCTURE", 34, 39], ["nodes and edges", "PROBLEM", 34, 49], ["an overlap between two nodes", "PROBLEM", 112, 140], ["nodes", "OBSERVATION", 34, 39], ["edges", "OBSERVATION_MODIFIER", 44, 49], ["vertex", "ANATOMY_MODIFIER", 94, 100], ["overlap", "OBSERVATION", 115, 122], ["two", "OBSERVATION_MODIFIER", 131, 134], ["nodes", "OBSERVATION", 135, 140]]], ["Scaffolds: DNA sequences comprising contigs with gaps between them, often generated using read pairing information.", [["DNA", "CELLULAR_COMPONENT", 11, 14], ["DNA sequences", "DNA", 11, 24], ["DNA sequences", "PROBLEM", 11, 24]]], ["Suffix array: A sorted array of all suffixes of a string, such as a DNA sequence, enabling efficient sequence comparison.Assembling genomes: de novo and reference-based assemblylong reads are available, assembly plays an important role in mitigating the high error rates associated with single molecule sequencing technologies, yielding accurate consensus sequences from inaccurate individual reads.De novo assembly methodologiesModern de novo assemblers generally leverage either de Bruijn graphs or read overlap graphs as part of the approach known as overlap layout consensus (OLC).", [["DNA", "CELLULAR_COMPONENT", 68, 71], ["DNA sequence", "DNA", 68, 80], ["assemblylong reads", "DNA", 169, 187], ["consensus sequences", "DNA", 346, 365], ["a DNA sequence", "TEST", 66, 80], ["single molecule sequencing technologies", "PROBLEM", 287, 326]]], ["OLC assemblers use the similarity of whole reads in order to construct a graph wherein each read is represented by a node, and subsequently merge overlapping reads into consensus contigs (Deng et al. 2015) .", [["node", "ANATOMY", 117, 121], ["consensus contigs", "DNA", 169, 186], ["node", "OBSERVATION", 117, 121]]], ["OLC is relatively time and memory intensive, scaling poorly to millions of reads and beyond.", [["relatively time", "OBSERVATION_MODIFIER", 7, 22]]], ["However, the fewer, longer reads generated by emerging single molecule sequencing technologies tend to be well suited to OLC assembly, which can be easily implemented to tolerate long and noisy sequences (Compeau, Pevzner, and Tesler 2011) .", [["single molecule sequencing technologies", "TREATMENT", 55, 94]]], ["There also exist a number of OLC assemblers intended for use with viral sequences: VICUNA was designed for short, nonrepetitive and highly variable reads from a single population (Yang et al. 2012) , and PRICE (Ruby, Bellare, and Derisi, 2013) iteratively assembles low to moderate complexity metagenomes (e.g. Runckel et al. 2011; Grard et al. 2012 ;) using a similar algorithm to the actively developed consensus assembler IVA (Hunt et al. 2015) , which like VICUNA is designed for single virus populations rather than metagenomes (see Table 1 for additional details on programs).", [["viral sequences", "DNA", 66, 81], ["VICUNA", "DNA", 83, 89], ["VICUNA", "PROTEIN", 461, 467], ["viral sequences", "TEST", 66, 81], ["moderate complexity metagenomes", "PROBLEM", 273, 304], ["single virus populations", "PROBLEM", 484, 508]]], ["A de Bruijn or k-mer graph represents a set of reads in terms of its k-mer composition, where k-mers are subsequences of a length k, specified by the user.", [["Bruijn", "DNA", 5, 11], ["A de Bruijn or k-mer graph", "PROBLEM", 0, 26]]], ["Each k-mer is assigned to an edge in a graph, where the nodes are k-1 prefixes and suffixes of the k-mer.", [["nodes", "ANATOMY", 56, 61], ["a graph", "TEST", 37, 44], ["the nodes", "TEST", 52, 61], ["k", "TEST", 66, 67], ["nodes", "OBSERVATION", 56, 61]]], ["De Bruijn graphs are much more efficient to construct than overlap graphs and are suited to large numbers of short reads, and where coverage is high, since redundant k-mers occupy negligible random access memory (RAM).", [["De Bruijn graphs", "TEST", 0, 16], ["overlap graphs", "TEST", 59, 73]]], ["However, with this efficiency comes a lack of error tolerance in identifying overlaps, less tolerance of repeated sequences in comparison to overlap graphs, and a loss of read coherence, meaning that k-mers originating from different reads may be co-assembled.", [["this efficiency", "PROBLEM", 14, 29], ["error tolerance", "PROBLEM", 46, 61], ["repeated sequences", "TEST", 105, 123], ["overlap graphs", "TEST", 141, 155], ["a loss of read coherence", "PROBLEM", 161, 185]]], ["In OLC, a pairwise comparison of all reads is performed, identifying reads with overlapping regions.", [["OLC", "CANCER", 3, 6], ["OLC", "CELL_LINE", 3, 6]]], ["These overlaps are used to construct a read graph.", [["a read graph", "TEST", 37, 49]]], ["Next, overlapping reads are bundled into aligned contigs in what is referred to as the layout step, before finally the most likely nucleotide at position is determined through consensus.", [["nucleotide", "CHEMICAL", 131, 141], ["nucleotide", "CHEMICAL", 131, 141], ["most likely", "UNCERTAINTY", 119, 130]]], ["This figure is simplified to demonstrate the theory for the assembly of single genomes; note that the process has additional complexities for the reconstruction of metagenomes.", [["the reconstruction of metagenomes", "TREATMENT", 142, 175]]], ["(Butler et al. 2008) , SPAdes (Bankevich et al. 2012) , and ABySS (Simpson et al. 2009 ).De novo assembly for metagenomesTypical de novo assemblers are designed to reconstruct genomes with uniform sequencing coverage across their length.", [["uniform sequencing coverage", "TREATMENT", 189, 216]]], ["This is problematic for metagenomes (including viromes) where coverage typically varies considerably both among different genomes and within individual genomes.", [["metagenomes", "PROBLEM", 24, 35], ["different genomes", "OBSERVATION", 112, 129]]], ["To address this problem, dedicated metagenome assemblers have been developed.", [["this problem", "PROBLEM", 11, 23]]], ["Omega (Haider et al. 2014 ) is an OLC-based method that uses a minimum cost flow analysis of the OLC graph to generate initial contigs, merging these to create longer contigs and scaffolds using mate-pair information.", [["OLC graph", "DNA", 97, 106], ["a minimum cost flow analysis", "TREATMENT", 61, 89], ["the OLC graph", "TREATMENT", 93, 106], ["longer contigs and scaffolds", "TREATMENT", 160, 188]]], ["Genovo (Laserson, Jojic, and Koller 2011) is another OLCbased method that generates a probabilistic model for the dataset and subsequently uses an iterative approach to reconstruct the most likely genome contigs.", [["genome contigs", "DNA", 197, 211], ["an iterative approach", "TREATMENT", 144, 165]]], ["MetaSPAdes (Nurk et al. 2016 ) is a metagenome-specific release of the SPAdes pipeline with refinements to its graph simplification and repeat resolution algorithms, counterintuitively capable of leveraging rare strain information so as to improve its consensus reconstruction capabilities.", [["the SPAdes pipeline", "TREATMENT", 67, 86], ["repeat resolution algorithms", "TEST", 136, 164]]], ["Other de Bruijn graph metagenome assemblers based on their genomic counterparts include Ray-Meta (Boisvert et al. 2012) , MetAMOS (Treangen et al. 2013) , MetaVelvet (Namiki et al. 2012; Afiahayati, Sato, and Sakakibara 2015) , and IDBA-UD (Peng et al. 2012) .De novo assembly for metagenomesFor example, unlike the genome assembler Velvet, MetaVelvet's de Bruijn graph is decomposed into many subgraphs (using coverage difference and graph connectivity), and scaffolds are built independently for each subgraph.", [["genome assembler Velvet", "DNA", 316, 339], ["MetaVelvet's de Bruijn graph", "DNA", 341, 369], ["scaffolds", "TREATMENT", 460, 469]]], ["MetaVelvet-SL addresses limitations with MetaVelvet, using supervised learning to detect and classify chimeric nodes within the de Bruijn graph.", [["MetaVelvet", "TREATMENT", 41, 51], ["chimeric nodes", "PROBLEM", 102, 116], ["nodes", "OBSERVATION", 111, 116]]], ["IDBA-UD partitions a de Bruijn graph into isolated components, constructs a multiple alignment, and subsequently identifies variation within these partitions using multiple depth relative thresholds to remove erroneous k-mers.", [["IDBA", "PROTEIN", 0, 4], ["UD", "DNA", 5, 7], ["multiple depth relative thresholds", "TREATMENT", 164, 198], ["erroneous k-mers", "TREATMENT", 209, 225], ["multiple", "OBSERVATION_MODIFIER", 76, 84], ["alignment", "OBSERVATION_MODIFIER", 85, 94]]], ["Ray Meta (Boisvert et al. 2012 ) extends the massively distributed assembly model of Ray to variable coverage metagenomes, while MetAMOS (Treangen et al. 2013 ) is both a metagenomic extension and successor to the AMOS genome assembler.De novo assembly for metagenomesWe recently proposed a method based on numerical sequence representations and digital signal processing data transformation (SPDT) approaches to reduce the size of working datasets, permitting fast and sensitive read alignment and de novo assembly of diverse viral populations (Tapinos et al. 2015) .", [["AMOS genome assembler", "DNA", 214, 235], ["a metagenomic extension", "PROBLEM", 169, 192], ["a method", "TREATMENT", 289, 297], ["numerical sequence representations", "TREATMENT", 307, 341], ["digital signal processing data transformation", "PROBLEM", 346, 391], ["diverse viral populations", "PROBLEM", 519, 544], ["size", "OBSERVATION_MODIFIER", 424, 428], ["diverse", "OBSERVATION_MODIFIER", 519, 526], ["viral populations", "OBSERVATION", 527, 544]]], ["SPDT methods, such as the discrete Fourier transform (DFT) (Agrawal, Faloutsos, and Swami 1993) , and discrete wavelet transform (DWT) (Percival and Walden 2006) (Fig. 2) , are used to reduce sequences into lower dimensional space, preserving only prominent data characteristics.", [["SPDT methods", "TEST", 0, 12], ["lower", "ANATOMY_MODIFIER", 207, 212], ["prominent", "OBSERVATION_MODIFIER", 248, 257]]], ["Analysis is subsequently performed with these lower dimensionality transformations, enabling faster data comparison.", [["Analysis", "TEST", 0, 8], ["these lower dimensionality transformations", "PROBLEM", 40, 82]]], ["Since SPDT methodologies such as the Fourier and wavelet transforms are applicable only to numerical sequences, nucleotide sequences must first be numerically transformed with one of several techniques including real number representations (Chakravarthy et al. 2004 ), complex number representations (Anastassiou 2001) , the DNA walk (Lobry 1996) , and the Voss method (Voss 1992) .De novo assembly for metagenomesAlthough metagenome assemblers generally outperform single genome assemblers in reconstructing different genomes simultaneously, the complexity of this task stipulates their tendency to collapse variation at or beneath strain level into consensus sequences.", [["nucleotide", "CHEMICAL", 112, 122], ["nucleotide", "CHEMICAL", 112, 122], ["DNA", "CELLULAR_COMPONENT", 325, 328], ["nucleotide sequences", "DNA", 112, 132], ["consensus sequences", "DNA", 651, 670], ["numerical sequences", "TEST", 91, 110], ["nucleotide sequences", "TEST", 112, 132], ["the DNA walk", "TEST", 321, 333], ["this task", "TEST", 561, 570], ["collapse variation", "PROBLEM", 600, 618], ["collapse", "OBSERVATION", 600, 608]]], ["Even to this end, their effectiveness may be limited as a consequence of extreme variation within specific RNA virus populations due to mutation and recombination, and low and/or uneven sequencing coverage across a particular genome.", [["extreme variation", "PROBLEM", 73, 90], ["specific RNA virus populations", "PROBLEM", 98, 128], ["mutation", "PROBLEM", 136, 144], ["uneven sequencing coverage", "TREATMENT", 179, 205]]], ["Furthermore, it should be noted that de novo assembly is particularly sensitive to the quality of input sequences, meaning that problems during sample extraction, enrichment and library preparation can be highly detrimental to downstream analyses.", [["sample", "ANATOMY", 144, 150], ["input sequences", "TEST", 98, 113], ["sample extraction", "TREATMENT", 144, 161], ["enrichment and library preparation", "TREATMENT", 163, 197]]], ["Of key importance therefore are quality control methods for detecting, and where appropriate correcting, problems associated with contamination (Darling et al. 2014; Orton et al. 2015) , primer read-through and low quality reads (reviewed in Leggett et al. 2013 ).Haplotype reconstruction in specific viral populationsViral genomes and metagenomes comprising high intraspecific variation can be challenging targets for assembly, giving rise to complex assembly graphs and fragmented assemblies.", [["Viral genomes", "DNA", 318, 331], ["contamination", "PROBLEM", 130, 143], ["Haplotype reconstruction", "TREATMENT", 264, 288], ["Viral genomes", "PROBLEM", 318, 331], ["metagenomes", "PROBLEM", 336, 347], ["high intraspecific variation", "PROBLEM", 359, 387], ["viral populations", "OBSERVATION", 301, 318], ["fragmented", "OBSERVATION_MODIFIER", 472, 482]]], ["This is often the case for clinical samples from HIV and Hepatitis C patients, in which high rates of mutation and long durations of infection can contribute to extreme population divergence, but can also be observed in environmental samples.", [["samples", "ANATOMY", 36, 43], ["samples", "ANATOMY", 234, 241], ["HIV and Hepatitis C", "DISEASE", 49, 68], ["infection", "DISEASE", 133, 142], ["HIV", "ORGANISM", 49, 52], ["Hepatitis C patients", "ORGANISM", 57, 77], ["HIV", "SPECIES", 49, 52], ["patients", "SPECIES", 69, 77], ["HIV", "SPECIES", 49, 52], ["clinical samples", "TEST", 27, 43], ["HIV", "PROBLEM", 49, 52], ["Hepatitis C patients", "PROBLEM", 57, 77], ["mutation", "PROBLEM", 102, 110], ["infection", "PROBLEM", 133, 142], ["extreme population divergence", "PROBLEM", 161, 190], ["long durations", "OBSERVATION_MODIFIER", 115, 129], ["infection", "OBSERVATION", 133, 142]]], ["Where such diversity exists, alignment based probabilistic population reconstruction approaches can be effective, permitting the reconstruction of individual viral variants into 'haplotypes' exceeding read length.", [["alignment based probabilistic population reconstruction approaches", "TREATMENT", 29, 95], ["the reconstruction", "TREATMENT", 125, 143]]], ["This problem has been well studied, and tools such as ShoRAH, QuRE, and PredictHaplo (Giallonardo et al. 2014 ) are designed for haplotyping viral populations.", [["haplotyping viral populations", "PROBLEM", 129, 158], ["well studied", "OBSERVATION_MODIFIER", 22, 34]]], ["ShoRAH (Zagordi et al. 2011 ) extracts local alignments of a specified window length, reconstructs haplotypes for each 'cluster' in that window, and removes mutations from sequences in the cluster not matching the reconstructed haplotype using a model-based probabilistic clustering algorithm.", [["reconstructs haplotypes", "TREATMENT", 86, 109], ["mutations from sequences", "PROBLEM", 157, 181]]], ["QuRe (Prosperi and Salemi 2012; Prosperi et al. 2013 ) removes nucleotide substitutions and indels with a Poisson model and reconstructs haplotypes using a heuristic algorithm based on a multinomial distribution.", [["nucleotide", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 63, 73], ["nucleotide substitutions", "TREATMENT", 63, 87], ["a Poisson model and reconstructs haplotypes", "TREATMENT", 104, 147], ["a heuristic algorithm", "TREATMENT", 154, 175]]], ["Both approaches have the advantage of reporting probabilities for the reconstructed haplotypes.", [["the reconstructed haplotypes", "TREATMENT", 66, 94]]], ["A limitation of all of these approaches; however, is their reliance upon a single reference sequence with which to perform the initial alignment, a process which assumes a degree of sequence similarity which may not always be observed in diverse regions, such as regions encoding envelope proteins, of RNA virus genomes.", [["envelope proteins", "PROTEIN", 280, 297], ["RNA virus genomes", "DNA", 302, 319], ["RNA virus genomes", "PROBLEM", 302, 319], ["may not always be", "UNCERTAINTY", 208, 225], ["RNA virus genomes", "OBSERVATION", 302, 319]]], ["This can be mitigated through construction of a data-specific template through iterative reference mapping and consensus refinement strategies (Archer et al. 2010; B rinda, Boeva, and Kucherov 2016) .", [["a data", "TEST", 46, 52], ["iterative reference mapping", "TEST", 79, 106]]], ["Other possibilities for broader utility of these approaches include the use of multiple viral reference sequences, either through consideration of multiple linear sequences or by direct alignment of sequences to a variation graph [https://github.com/vgteam/ vg], an emerging approach for modeling genomic variation.Sequence classificationSequence classification is one of the most studied problems in computational biology, and taxonomic assignment is a key objective of metagenome analysis.", [["viral reference sequences", "DNA", 88, 113], ["multiple linear sequences", "DNA", 147, 172], ["multiple viral reference sequences", "TEST", 79, 113], ["multiple linear sequences", "TEST", 147, 172], ["a variation graph", "TEST", 212, 229], ["an emerging approach", "TREATMENT", 263, 283], ["modeling genomic variation", "PROBLEM", 288, 314], ["Sequence classification", "TEST", 315, 338], ["Sequence classification", "TEST", 338, 361], ["metagenome analysis", "TEST", 471, 490]]], ["All classification methods, to some extent, depend upon detecting similarity between a query sequence and a collection of annotated sequences.", [["All classification methods", "TEST", 0, 26], ["a query sequence", "TEST", 85, 101], ["a collection of annotated sequences", "TEST", 106, 141]]], ["The computational requirements of available approaches vary dramatically according to their ability to detect homology in divergent sequences; for example, exact k-mer matching approaches permit rapid sequence classification, yet typically struggle to identify divergent sequences of viral origin, while high-sensitivity protein alignment searches may be prohibitively slow, especially in application to entire sequencing datasets.", [["rapid sequence classification", "TEST", 195, 224], ["viral origin", "PROBLEM", 284, 296], ["high-sensitivity protein alignment searches", "PROBLEM", 304, 347], ["viral origin", "OBSERVATION_MODIFIER", 284, 296]]], ["Some of the more contemporary and speed-optimized taxonomic assignment approaches also have high RAM requirements, limiting scope for their use with readily available computer hardware.", [["high RAM requirements", "PROBLEM", 92, 113], ["computer hardware", "TREATMENT", 167, 184], ["high RAM", "OBSERVATION", 92, 100], ["hardware", "OBSERVATION", 176, 184]]], ["Retroactive taxonomic assignment using these results is non-trivial, requiring additional database lookups, for example, for determination of a conservative 'lowest common ancestor' (LCA) taxon shared by all matches for each query sequence.", [["additional database lookups", "TEST", 79, 106], ["a conservative 'lowest common ancestor' (LCA) taxon", "TREATMENT", 142, 193], ["each query sequence", "TEST", 220, 239]]], ["This kind of complexity necessitates the need for the integration of different tools within application-specific 'pipelines'.Sequence similarity searchesViral identification approaches typically depend on similarity searches against a database using an aligner such as BLAST (Altschul et al. 1990 ).", [["Sequence similarity searches", "TEST", 125, 153]]], ["Comprehensive databases (e.g. GenBank) or smaller custom databases containing for example, only viral sequences of interest may be used, although the latter can generate misleading results.", [["viral sequences", "DNA", 96, 111], ["smaller custom databases", "PROBLEM", 42, 66]]], ["ProViDE (Ghosh et al. 2011 ) uses virusspecific alignment parameters and thresholds to assign viruses at different taxonomic levels from BLAST matches to a protein database.", [["virusspecific alignment parameters", "TEST", 34, 68], ["viruses", "PROBLEM", 94, 101], ["taxonomic levels", "TEST", 115, 131], ["a protein database", "TEST", 154, 172]]], ["MEGAN (Huson et al. 2011 ) is a generally applicable metagenomic classifier, which uses BLAST results to infer the LCA for a given sequence and provides functional analyses through a graphical interface.", [["LCA", "ANATOMY", 115, 118]]], ["Automatic pipelines which combine various homology search strategies to identify a final set of viral reads include VirusHunter (Zhao et al. 2013) , a Perl script that automates viral identification using BLAST prior to assembly; MetaVir (Roux et al. 2011) , a web application that compares users' datasets to published viral sequences; and VirSorter (Roux et al. 2015) , which identifies prophages and viruses by comparison with custom datasets.", [["viral sequences", "DNA", 320, 335], ["Automatic pipelines", "TREATMENT", 0, 19], ["a web application", "TREATMENT", 259, 276]]], ["With the exception of web applications, however, these are not intuitive tools for the majority of users, requiring manual configuration and installation of software dependencies.", [["web applications", "TREATMENT", 22, 38], ["manual configuration", "TREATMENT", 116, 136], ["software dependencies", "PROBLEM", 157, 178], ["web", "OBSERVATION", 22, 25], ["software dependencies", "OBSERVATION", 157, 178]]], ["To address this problem, tools have emerged leveraging optimized search algorithms and prebuilt databases so as to increase the tractability of classifying millions of reads.", [["this problem", "PROBLEM", 11, 23], ["search algorithms", "TEST", 65, 82]]], ["For example, Kraken (Wood and Salzberg 2014) and Clark (Ounit et al. 2015) are fast exact k-mer matching approaches that use prebuilt databases of viruses, bacteria, human, and fungi, although custom databases may also be built.", [["human", "ORGANISM", 166, 171], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["viruses", "PROBLEM", 147, 154], ["bacteria", "PROBLEM", 156, 164], ["fungi", "PROBLEM", 177, 182], ["custom databases", "TEST", 193, 209], ["viruses", "OBSERVATION", 147, 154]]], ["One Codex is a proprietary web-based metagenome analysis platform with an integrated fast k-mer matching engine (similar to that of Kraken) which is both fast, very easy to use, and free for academic use (Minot, Krumm, and Greenfield) .", [["an integrated fast k-mer matching engine", "TREATMENT", 71, 111]]], ["Lambda (Hauswedell, Singer, and Reinert 2014) and Diamond (Buchfink, Xie, and Huson 2015) are sensitive and heavily optimized BLAST-like aligners which leverage alphabet reduction to permit protein searches three to five orders of magnitude faster than BLAST, offering prebuilt database indexes for common applications.Alternatives to similarity searchesAlthough exhaustive BLAST-like methods can detect homology in divergent sequences, these methods are in general limited by the relatively few validated viral sequences deposited in public databases, the high diversity within viral families which can obscure relatedness, and the lack of a defined set of core genes common to all viruses that can be used to distinguish species (e.g. the 16S gene for bacteria) (Fancello, Raoult, and Desnues 2012) .", [["viral sequences", "DNA", 506, 521], ["core genes", "DNA", 658, 668], ["16S gene", "DNA", 741, 749], ["leverage alphabet reduction", "TREATMENT", 152, 179], ["protein searches", "TEST", 190, 206], ["exhaustive BLAST-like methods", "PROBLEM", 363, 392], ["the relatively few validated viral sequences", "PROBLEM", 477, 521], ["all viruses", "PROBLEM", 679, 690], ["bacteria", "PROBLEM", 754, 762], ["high diversity", "OBSERVATION_MODIFIER", 557, 571]]], ["Comparison methods that do not rely on sequence similarity include PhyloPythia (McHardy et al. 2007 ), which uses nucleotide frequencies to classify reads, and PHYMM (Brady and Salzberg 2009) , which uses interpolated Markov models to find variable length oligonucleotides that characterize species in the NCBI RefSeq database.Alternatives to similarity searchesAlthough these approaches are less accurate than BLAST searches, PHYMMBL (Brady and Salzberg 2011) combines PHYMM and BLAST and outperforms either one on its own.", [["nucleotide", "CHEMICAL", 114, 124], ["PHYMM", "DNA", 470, 475], ["Comparison methods", "TEST", 0, 18], ["PhyloPythia", "PROBLEM", 67, 78], ["Brady", "TEST", 167, 172], ["interpolated Markov models", "TREATMENT", 205, 231], ["variable length oligonucleotides", "PROBLEM", 240, 272], ["BLAST searches", "TEST", 411, 425], ["PHYMMBL", "TEST", 427, 434], ["Brady", "TEST", 436, 441]]], ["Alignment-free comparison approaches, for example, based on dinucleotide frequencies, codon usage patterns, or small but conserved regions of family wide ubiquitous genes, may be more robust to the limitations of the database than sequence similarity searches.", [["dinucleotide", "CHEMICAL", 60, 72], ["dinucleotide", "CHEMICAL", 60, 72], ["ubiquitous genes", "DNA", 154, 170], ["dinucleotide frequencies", "TEST", 60, 84], ["codon usage patterns", "TEST", 86, 106], ["small", "OBSERVATION_MODIFIER", 111, 116]]], ["These features may also reduce the computation required and highlight evolutionary relationships otherwise obscured by high sequence variability.Alternatives to similarity searchesA fundamental challenge in the classification of viral sequences with any of these methods remains their limited representation within curated sequence databases.", [["viral sequences", "DNA", 229, 244], ["high sequence variability", "PROBLEM", 119, 144], ["A fundamental challenge", "TEST", 180, 203], ["viral sequences", "TEST", 229, 244], ["these methods", "TEST", 257, 270]]], ["While the rate at which new viruses are being added to NCBI's RefSeq collection has increased considerably, from a year average 0.34 species/ day in 2010 to 2.5 species/day in 2015 (Fig. 3) , our documented understanding of the extent of viral diversity remains superficial (Anthony et al. 2013) .", [["NCBI's RefSeq", "DNA", 55, 68], ["the rate", "TEST", 6, 14], ["new viruses", "PROBLEM", 24, 35], ["NCBI's RefSeq collection", "PROBLEM", 55, 79], ["viral diversity", "PROBLEM", 238, 253], ["new", "OBSERVATION_MODIFIER", 24, 27], ["viruses", "OBSERVATION", 28, 35], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["considerably", "OBSERVATION_MODIFIER", 94, 106], ["viral diversity", "OBSERVATION", 238, 253]]], ["Reads of true viral origin are therefore liable to be missed in many cases.", [["viral origin", "OBSERVATION", 14, 26]]], ["The rate of database growth also highlights the need to maintain frequently updated search indexes for sequence classification, construction of which often demands specialist servers equipped with hundreds of gigabytes of RAM.", [["sequence classification", "TEST", 103, 126]]], ["Consequently, complete outsourcing of sequence classification to remote web services is a compelling prospect for those with adequate internet connections but without powerful computing hardware, increasing scope for conducting analyses with portable computers.ConclusionWe see several barriers to realizing the goal of active, on-theground surveillance and early detection of viruses with epidemic potential.Conclusion1.", [["powerful computing hardware", "TREATMENT", 167, 194], ["conducting analyses", "TEST", 217, 236], ["portable computers", "TEST", 242, 260], ["theground surveillance", "TEST", 331, 353], ["viruses", "PROBLEM", 377, 384], ["hardware", "OBSERVATION", 186, 194], ["viruses", "OBSERVATION", 377, 384]]], ["The emergence of virus-specific assembly and metagenomic tools is a relatively recent phenomenon, with many of the methodologies in use today repurposing one or more existing algorithms.", [["virus", "PROBLEM", 17, 22], ["metagenomic tools", "PROBLEM", 45, 62], ["a relatively recent phenomenon", "PROBLEM", 66, 96], ["virus", "OBSERVATION", 17, 22]]], ["These tools mostly target a small audience of expert users and, as with most research software, decay after initial release due to a lack of ongoing funding, poor software development practices and/or authors' change of circumstances (Duck et al. 2016 ).", [["small", "OBSERVATION_MODIFIER", 28, 33]]], ["Researchers and granting agencies should consider the importance of this step and allocate resources accordingly.", [["this step", "TREATMENT", 68, 77]]], ["Maintaining up to date indexes of large sequence databases is a problem all classification tools must address, stipulating access either to powerful computers for index construction or the ability to download the prebuilt indexes over a fast connection.", [["large sequence databases", "PROBLEM", 34, 58], ["index construction", "TREATMENT", 163, 181]]], ["Furthermore, classification of viral sequences is critically dependent upon the quality of curated viral databases such as RefSeq, to which submitting newly discovered sequences can be prohibitively time consuming.", [["viral sequences", "DNA", 31, 46], ["viral sequences", "TEST", 31, 46], ["critically dependent", "PROBLEM", 50, 70], ["viral", "OBSERVATION", 31, 36], ["critically dependent", "OBSERVATION_MODIFIER", 50, 70]]], ["A solution might involve the creation of a central database containing for any given sequencing project both raw reads as well as filtered, assembled and/or annotated reads, and analysed using a single central pipeline.", [["A solution", "TREATMENT", 0, 10], ["a central database", "TREATMENT", 41, 59], ["a single central pipeline", "TREATMENT", 193, 218]]], ["On a regular basis, the database could report sequences and corresponding metadata for unclassified 'dark matter', which is often discarded and yet is likely to contain sequences belonging to novel pathogens.", [["unclassified 'dark matter'", "PROBLEM", 87, 113], ["novel pathogens", "PROBLEM", 192, 207], ["dark matter", "OBSERVATION_MODIFIER", 101, 112]]], ["By combining the dark matter from multiple studies, trends within these unclassified reads may be identified that could lead to greater power to identify new biological entities.", [["the dark matter", "PROBLEM", 13, 28], ["multiple studies", "TEST", 34, 50], ["dark matter", "OBSERVATION", 17, 28]]], ["Benchmarking of software also remains an open problem within the field, which lacks standardized test datasets that are used across multiple studies.", [["standardized test datasets", "TEST", 84, 110], ["multiple studies", "TEST", 132, 148], ["open", "OBSERVATION", 41, 45]]], ["Often benchmarking datasets are chosen to highlight the advantages of the method under study, and therefore may be quite specific for a given application.", [["the method under study", "TEST", 70, 92]]], ["Thus the field needs to agree upon a set of standard, well-characterized reference datasets for virusfocused studies.ConclusionThe future of the field is promising, with emerging technologies showing potential to eliminate certain challenges.", [["virusfocused studies", "TEST", 96, 116]]], ["Single molecule sequencing, for example, permits the sequencing of whole viral genomes as single reads, with forthcoming portable and smartphone operated sequencers promising potentially revolutionary analyses in the field.", [["whole viral genomes", "DNA", 67, 86], ["Single molecule sequencing", "TEST", 0, 26], ["forthcoming portable", "TEST", 109, 129]]], ["Broader communication among developers and end users is essential, and in conjunction with well-funded international initiatives directed at this goal, intelligent viral surveillance could soon be realized.", [["intelligent viral surveillance", "TREATMENT", 152, 182]]]], "b00221d46789d370622aab20d4fcb6a92017a4e7": [["Despite the heterogeneity in potential etiology, a thorough history and physical examination can often focus the approach and narrow the differential diagnosis.", [["physical examination", "TEST", 72, 92], ["heterogeneity", "OBSERVATION_MODIFIER", 12, 25]]], ["The American Gastroenterological Association (AGA) recommends a pragmatic 3-step approach to the management of the patient with nausea and vomiting.", [["nausea and vomiting", "DISEASE", 128, 147], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["a pragmatic 3-step approach", "TREATMENT", 62, 89], ["the management", "TREATMENT", 93, 107], ["nausea", "PROBLEM", 128, 134], ["vomiting", "PROBLEM", 139, 147]]], ["6 After a complete history and physical examination, the clinician should first correct any complications of vomiting such as hypokalemia, metabolic alkalosis, hypovolemia, ketosis, or vitamin deficiencies.", [["vomiting", "DISEASE", 109, 117], ["hypokalemia", "DISEASE", 126, 137], ["metabolic alkalosis", "DISEASE", 139, 158], ["hypovolemia", "DISEASE", 160, 171], ["ketosis", "DISEASE", 173, 180], ["vitamin deficiencies", "DISEASE", 185, 205], ["vitamin", "SIMPLE_CHEMICAL", 185, 192], ["physical examination", "TEST", 31, 51], ["vomiting", "PROBLEM", 109, 117], ["hypokalemia", "PROBLEM", 126, 137], ["metabolic alkalosis", "PROBLEM", 139, 158], ["hypovolemia", "PROBLEM", 160, 171], ["ketosis", "PROBLEM", 173, 180], ["vitamin deficiencies", "PROBLEM", 185, 205], ["metabolic alkalosis", "OBSERVATION", 139, 158], ["hypovolemia", "OBSERVATION", 160, 171]]], ["Second, the underlying cause should be sought with the intention of initiating targeted therapy.", [["targeted therapy", "TREATMENT", 79, 95]]], ["The third step is the initiation of treatment strategies to suppress the symptoms.", [["treatment strategies", "TREATMENT", 36, 56], ["the symptoms", "PROBLEM", 69, 81]]], ["Although there are no clinical guidelines in the initial workup of the patient with vomiting, pregnancy testing should be considered in women of reproductive age.", [["vomiting", "DISEASE", 84, 92], ["patient", "ORGANISM", 71, 78], ["women", "ORGANISM", 136, 141], ["patient", "SPECIES", 71, 78], ["women", "SPECIES", 136, 141], ["the initial workup", "TEST", 45, 63], ["vomiting", "PROBLEM", 84, 92], ["pregnancy testing", "TEST", 94, 111], ["no", "UNCERTAINTY", 19, 21]]], ["Serum electrolytes, complete blood count, liver function tests, lipase, urinalysis, and electrocardiogram may also be considered depending on the clinical situation.Antiemetics Dopamine receptor antagonistsWhen a specific etiology of vomiting is diagnosed, targeted intervention toward the underlying process is important.", [["Serum", "ANATOMY", 0, 5], ["blood", "ANATOMY", 29, 34], ["liver", "ANATOMY", 42, 47], ["Dopamine", "CHEMICAL", 177, 185], ["vomiting", "DISEASE", 234, 242], ["Dopamine", "CHEMICAL", 177, 185], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["liver", "ORGAN", 42, 47], ["lipase", "GENE_OR_GENE_PRODUCT", 64, 70], ["Dopamine receptor antagonists", "GENE_OR_GENE_PRODUCT", 177, 206], ["lipase", "PROTEIN", 64, 70], ["Serum electrolytes", "TEST", 0, 18], ["complete blood count", "TEST", 20, 40], ["liver function tests", "TEST", 42, 62], ["lipase", "TEST", 64, 70], ["urinalysis", "TEST", 72, 82], ["electrocardiogram", "TEST", 88, 105], ["Antiemetics", "TREATMENT", 165, 176], ["Dopamine receptor antagonists", "TREATMENT", 177, 206], ["vomiting", "PROBLEM", 234, 242], ["targeted intervention", "TREATMENT", 257, 278], ["liver", "ANATOMY", 42, 47]]], ["For the empiric treatment of undifferentiated vomiting, the pharmaceutical armamentarium consists of many different drug classes primarily directed at 5 neurotransmitter receptor sites ( Table 2) .", [["undifferentiated vomiting", "DISEASE", 29, 54], ["the empiric treatment", "TREATMENT", 4, 25], ["undifferentiated vomiting", "PROBLEM", 29, 54], ["the pharmaceutical armamentarium", "TREATMENT", 56, 88], ["many different drug classes", "TREATMENT", 101, 128], ["undifferentiated", "OBSERVATION_MODIFIER", 29, 45], ["vomiting", "OBSERVATION", 46, 54]]], ["Before the recent increase in use of the serotonin 5-hydroxytryptamine-3 (5-HT 3 ) antagonists, the mainstay of therapy had been dopamine receptor antagonists.", [["serotonin", "CHEMICAL", 41, 50], ["5-hydroxytryptamine", "CHEMICAL", 51, 70], ["5-HT", "CHEMICAL", 74, 78], ["dopamine", "CHEMICAL", 129, 137], ["serotonin", "CHEMICAL", 41, 50], ["5-hydroxytryptamine", "CHEMICAL", 51, 70], ["5-HT", "CHEMICAL", 74, 78], ["dopamine", "CHEMICAL", 129, 137], ["serotonin 5-hydroxytryptamine-3", "GENE_OR_GENE_PRODUCT", 41, 72], ["5-HT 3 ) antagonists", "SIMPLE_CHEMICAL", 74, 94], ["dopamine receptor antagonists", "GENE_OR_GENE_PRODUCT", 129, 158], ["the serotonin", "TREATMENT", 37, 50], ["hydroxytryptamine", "TREATMENT", 53, 70], ["antagonists", "TREATMENT", 83, 94], ["therapy", "TREATMENT", 112, 119], ["dopamine receptor antagonists", "TREATMENT", 129, 158], ["increase", "OBSERVATION_MODIFIER", 18, 26]]], ["The literature on this class of Table 1 Differential diagnosis of vomiting medications is vast and at times contradictory.", [["vomiting", "DISEASE", 66, 74], ["vomiting", "PROBLEM", 66, 74], ["medications", "TREATMENT", 75, 86]]], ["One of the most extensively studied drugs is metoclopramide (Reglan).", [["metoclopramide", "CHEMICAL", 45, 59], ["metoclopramide", "CHEMICAL", 45, 59], ["Reglan", "CHEMICAL", 61, 67], ["metoclopramide", "SIMPLE_CHEMICAL", 45, 59], ["Reglan", "SIMPLE_CHEMICAL", 61, 67], ["metoclopramide (Reglan", "TREATMENT", 45, 67]]], ["Metoclopramide has been compared with prochlorperazine (Compazine), with some investigators finding similar efficacy 7, 8 and others finding a modest benefit of one over the other.", [["Metoclopramide", "CHEMICAL", 0, 14], ["prochlorperazine", "CHEMICAL", 38, 54], ["Compazine", "CHEMICAL", 56, 65], ["Metoclopramide", "CHEMICAL", 0, 14], ["prochlorperazine", "CHEMICAL", 38, 54], ["Compazine", "CHEMICAL", 56, 65], ["Metoclopramide", "SIMPLE_CHEMICAL", 0, 14], ["prochlorperazine", "SIMPLE_CHEMICAL", 38, 54], ["Compazine", "SIMPLE_CHEMICAL", 56, 65], ["Metoclopramide", "TREATMENT", 0, 14], ["prochlorperazine (Compazine", "TREATMENT", 38, 65]]], ["[9] [10] [11] Metoclopramide is often recommended for pregnant patients, as it is the only medication in this class with a pregnancy category B rating.Antiemetics Dopamine receptor antagonistsSimilar inconclusive findings have been found when comparing promethazine (Phenergan) and prochlorperazine.", [["[9] [10] [11]", "CHEMICAL", 0, 13], ["Metoclopramide", "CHEMICAL", 14, 28], ["Dopamine", "CHEMICAL", 163, 171], ["promethazine", "CHEMICAL", 253, 265], ["Phenergan", "CHEMICAL", 267, 276], ["prochlorperazine", "CHEMICAL", 282, 298], ["[9] [10] [11] Metoclopramide", "CHEMICAL", 0, 28], ["Dopamine", "CHEMICAL", 163, 171], ["promethazine", "CHEMICAL", 253, 265], ["Phenergan", "CHEMICAL", 267, 276], ["prochlorperazine", "CHEMICAL", 282, 298], ["[9] [10] [11] Metoclopramide", "SIMPLE_CHEMICAL", 0, 28], ["patients", "ORGANISM", 63, 71], ["Dopamine receptor", "GENE_OR_GENE_PRODUCT", 163, 180], ["promethazine", "SIMPLE_CHEMICAL", 253, 265], ["Phenergan", "SIMPLE_CHEMICAL", 267, 276], ["prochlorperazine", "SIMPLE_CHEMICAL", 282, 298], ["patients", "SPECIES", 63, 71], ["Metoclopramide", "TREATMENT", 14, 28], ["Antiemetics", "TREATMENT", 151, 162], ["Dopamine receptor antagonistsSimilar", "TREATMENT", 163, 199], ["promethazine", "TREATMENT", 253, 265], ["Phenergan", "TREATMENT", 267, 276], ["prochlorperazine", "TREATMENT", 282, 298]]], ["Recently, however, one randomized, double-blind Vomiting, Diarrhea, Constipation, Gastroenteritis study of 84 ED patients found subjects who received promethazine had a treatment failure rate of 31% versus just 9.5% in the prochlorperazine group.", [["Vomiting", "DISEASE", 48, 56], ["Diarrhea", "DISEASE", 58, 66], ["Constipation", "DISEASE", 68, 80], ["Gastroenteritis", "DISEASE", 82, 97], ["promethazine", "CHEMICAL", 150, 162], ["prochlorperazine", "CHEMICAL", 223, 239], ["promethazine", "CHEMICAL", 150, 162], ["prochlorperazine", "CHEMICAL", 223, 239], ["patients", "ORGANISM", 113, 121], ["promethazine", "SIMPLE_CHEMICAL", 150, 162], ["prochlorperazine", "SIMPLE_CHEMICAL", 223, 239], ["patients", "SPECIES", 113, 121], ["blind Vomiting", "PROBLEM", 42, 56], ["Diarrhea", "PROBLEM", 58, 66], ["Constipation", "PROBLEM", 68, 80], ["Gastroenteritis study", "TEST", 82, 103], ["promethazine", "TREATMENT", 150, 162], ["a treatment failure rate", "TREATMENT", 167, 191], ["the prochlorperazine group", "TREATMENT", 219, 245]]], ["12 Of interest, both groups had a similar rate of akathisia although the promethazine group experienced increased drowsiness.", [["akathisia", "DISEASE", 50, 59], ["promethazine", "CHEMICAL", 73, 85], ["promethazine", "CHEMICAL", 73, 85], ["promethazine", "SIMPLE_CHEMICAL", 73, 85], ["akathisia", "PROBLEM", 50, 59], ["the promethazine group", "TREATMENT", 69, 91], ["increased drowsiness", "PROBLEM", 104, 124]]], ["Other studies have shown a higher rate of akathisia and dystonia with prochlorperazine compared with other antiemetics.", [["akathisia", "DISEASE", 42, 51], ["dystonia", "DISEASE", 56, 64], ["prochlorperazine", "CHEMICAL", 70, 86], ["prochlorperazine", "CHEMICAL", 70, 86], ["prochlorperazine", "SIMPLE_CHEMICAL", 70, 86], ["Other studies", "TEST", 0, 13], ["akathisia", "PROBLEM", 42, 51], ["dystonia", "PROBLEM", 56, 64], ["prochlorperazine", "TREATMENT", 70, 86], ["other antiemetics", "TREATMENT", 101, 118]]], ["13, 14 In an ED-based study of 229 patients receiving prochlorperazine, 16% developed akathisia and 4% developed acute dystonia.", [["prochlorperazine", "CHEMICAL", 54, 70], ["akathisia", "DISEASE", 86, 95], ["dystonia", "DISEASE", 119, 127], ["prochlorperazine", "CHEMICAL", 54, 70], ["patients", "ORGANISM", 35, 43], ["prochlorperazine", "SIMPLE_CHEMICAL", 54, 70], ["patients", "SPECIES", 35, 43], ["based study", "TEST", 16, 27], ["prochlorperazine", "TREATMENT", 54, 70], ["akathisia", "PROBLEM", 86, 95], ["acute dystonia", "PROBLEM", 113, 127], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["dystonia", "OBSERVATION", 119, 127]]], ["15 Diphenhydramine (Benadryl) is the first-line choice to treat these reactions.", [["Diphenhydramine", "CHEMICAL", 3, 18], ["Benadryl", "CHEMICAL", 20, 28], ["Diphenhydramine", "CHEMICAL", 3, 18], ["Benadryl", "CHEMICAL", 20, 28], ["Diphenhydramine", "SIMPLE_CHEMICAL", 3, 18], ["Benadryl", "SIMPLE_CHEMICAL", 20, 28], ["Diphenhydramine (Benadryl)", "TREATMENT", 3, 29], ["the first-line choice", "TREATMENT", 33, 54], ["these reactions", "PROBLEM", 64, 79]]], ["A study of 82 patients with akathisia found diphenhydramine was effective in reducing akathisia from 9.8 to 1.2 on a scale of 0 to 17.", [["akathisia", "DISEASE", 28, 37], ["diphenhydramine", "CHEMICAL", 44, 59], ["akathisia", "DISEASE", 86, 95], ["diphenhydramine", "CHEMICAL", 44, 59], ["patients", "ORGANISM", 14, 22], ["diphenhydramine", "SIMPLE_CHEMICAL", 44, 59], ["patients", "SPECIES", 14, 22], ["A study", "TEST", 0, 7], ["akathisia", "PROBLEM", 28, 37], ["diphenhydramine", "TREATMENT", 44, 59], ["reducing akathisia", "PROBLEM", 77, 95]]], ["16 These findings have led some clinicians to administer diphenhydramine concurrently with prochlorperazine in an effort to prevent akathisia; however, this practice has not been validated with a randomized, placebo-controlled study.Antiemetics Dopamine receptor antagonistsAs the literature does not consistently support one dopamine receptor antagonist over another, it is not surprising that practice patterns vary.", [["diphenhydramine", "CHEMICAL", 57, 72], ["prochlorperazine", "CHEMICAL", 91, 107], ["akathisia", "DISEASE", 132, 141], ["Dopamine", "CHEMICAL", 245, 253], ["dopamine", "CHEMICAL", 326, 334], ["diphenhydramine", "CHEMICAL", 57, 72], ["prochlorperazine", "CHEMICAL", 91, 107], ["Dopamine", "CHEMICAL", 245, 253], ["dopamine", "CHEMICAL", 326, 334], ["diphenhydramine", "SIMPLE_CHEMICAL", 57, 72], ["prochlorperazine", "SIMPLE_CHEMICAL", 91, 107], ["Dopamine receptor antagonists", "GENE_OR_GENE_PRODUCT", 245, 274], ["dopamine receptor", "GENE_OR_GENE_PRODUCT", 326, 343], ["dopamine receptor", "PROTEIN", 326, 343], ["diphenhydramine", "TREATMENT", 57, 72], ["prochlorperazine", "TREATMENT", 91, 107], ["akathisia", "PROBLEM", 132, 141], ["placebo-controlled study", "TEST", 208, 232], ["Antiemetics", "TREATMENT", 233, 244], ["Dopamine receptor antagonists", "TREATMENT", 245, 274], ["one dopamine receptor antagonist", "TREATMENT", 322, 354]]], ["A 2000 ED-based analysis found antiemetics to be used with the frequencies promethazine (55%), prochlorperazine (25.3%), metoclopramide (5.2%), and ondansetron (Zofran) (1.3%), reflecting the choice of antiemetic remains one of clinician preference.", [["promethazine", "CHEMICAL", 75, 87], ["prochlorperazine", "CHEMICAL", 95, 111], ["metoclopramide", "CHEMICAL", 121, 135], ["ondansetron", "CHEMICAL", 148, 159], ["Zofran", "CHEMICAL", 161, 167], ["promethazine", "CHEMICAL", 75, 87], ["prochlorperazine", "CHEMICAL", 95, 111], ["metoclopramide", "CHEMICAL", 121, 135], ["ondansetron", "CHEMICAL", 148, 159], ["promethazine", "SIMPLE_CHEMICAL", 75, 87], ["prochlorperazine", "SIMPLE_CHEMICAL", 95, 111], ["metoclopramide", "SIMPLE_CHEMICAL", 121, 135], ["ondansetron", "SIMPLE_CHEMICAL", 148, 159], ["Zofran", "SIMPLE_CHEMICAL", 161, 167], ["based analysis", "TEST", 10, 24], ["antiemetics", "TREATMENT", 31, 42], ["the frequencies promethazine", "TREATMENT", 59, 87], ["prochlorperazine", "TREATMENT", 95, 111], ["metoclopramide", "TREATMENT", 121, 135], ["ondansetron (Zofran)", "TREATMENT", 148, 168], ["antiemetic", "TREATMENT", 202, 212]]], ["17Serotonin 5-HT 3 antagonistsOver the past decade, there has been an increase in the use of 5-HT 3 antagonists due to a lower incidence of side effects.", [["17Serotonin 5-HT", "CHEMICAL", 0, 16], ["5-HT", "CHEMICAL", 93, 97], ["5-HT", "CHEMICAL", 12, 16], ["5-HT", "CHEMICAL", 93, 97], ["5-HT 3", "GENE_OR_GENE_PRODUCT", 12, 18], ["5-HT 3 antagonists", "GENE_OR_GENE_PRODUCT", 93, 111], ["17Serotonin", "TREATMENT", 0, 11], ["5-HT 3 antagonists", "TREATMENT", 93, 111], ["side effects", "PROBLEM", 140, 152], ["increase", "OBSERVATION_MODIFIER", 70, 78]]], ["Although controversial, the 2001 black box warning by the Food and Drug Administration (FDA) of droperidol (Inapsine) 18 may also have contributed to shifting practice patterns.", [["droperidol", "CHEMICAL", 96, 106], ["Inapsine", "CHEMICAL", 108, 116], ["droperidol", "CHEMICAL", 96, 106], ["Inapsine) 18", "CHEMICAL", 108, 120], ["droperidol", "SIMPLE_CHEMICAL", 96, 106], ["droperidol (Inapsine)", "TREATMENT", 96, 117]]], ["Of the currently approved drugs in the United States, ondansetron (Zofran), granisetron (Granisol, Kytril), and dolasetron (Anzemet) have all been shown to be equally effective and tolerated.", [["ondansetron", "CHEMICAL", 54, 65], ["Zofran", "CHEMICAL", 67, 73], ["granisetron", "CHEMICAL", 76, 87], ["Granisol", "CHEMICAL", 89, 97], ["Kytril", "CHEMICAL", 99, 105], ["dolasetron", "CHEMICAL", 112, 122], ["Anzemet", "CHEMICAL", 124, 131], ["ondansetron", "CHEMICAL", 54, 65], ["Zofran", "CHEMICAL", 67, 73], ["granisetron", "CHEMICAL", 76, 87], ["Granisol", "CHEMICAL", 89, 97], ["Kytril", "CHEMICAL", 99, 105], ["dolasetron", "CHEMICAL", 112, 122], ["Anzemet", "CHEMICAL", 124, 131], ["ondansetron", "SIMPLE_CHEMICAL", 54, 65], ["Zofran", "SIMPLE_CHEMICAL", 67, 73], ["granisetron", "SIMPLE_CHEMICAL", 76, 87], ["Granisol", "SIMPLE_CHEMICAL", 89, 97], ["Kytril", "SIMPLE_CHEMICAL", 99, 105], ["dolasetron", "SIMPLE_CHEMICAL", 112, 122], ["Anzemet", "SIMPLE_CHEMICAL", 124, 131], ["drugs", "TREATMENT", 26, 31], ["ondansetron (Zofran)", "TREATMENT", 54, 74], ["granisetron (Granisol, Kytril)", "TREATMENT", 76, 106], ["dolasetron (Anzemet", "TREATMENT", 112, 131]]], ["[19] [20] [21] Palonosetron (Aloxi) differs from the others in this class by its longer half-life, and has been shown to reduce delayed chemotherapy-induced vomiting when compared with dolasetron.", [["[19] [20] [21] Palonosetron", "CHEMICAL", 0, 27], ["Aloxi", "CHEMICAL", 29, 34], ["vomiting", "DISEASE", 157, 165], ["dolasetron", "CHEMICAL", 185, 195], ["[19] [20] [21] Palonosetron", "CHEMICAL", 0, 27], ["Aloxi", "CHEMICAL", 29, 34], ["dolasetron", "CHEMICAL", 185, 195], ["[19] [20] [21] Palonosetron", "SIMPLE_CHEMICAL", 0, 27], ["Aloxi", "SIMPLE_CHEMICAL", 29, 34], ["dolasetron", "SIMPLE_CHEMICAL", 185, 195], ["Palonosetron (Aloxi)", "TREATMENT", 15, 35], ["delayed chemotherapy", "TREATMENT", 128, 148], ["vomiting", "PROBLEM", 157, 165], ["dolasetron", "TREATMENT", 185, 195]]], ["22 Although the bulk of the research on this class of drugs comes from the oncology literature for chemotherapy-induced vomiting, 23,24 studies examining undifferentiated ED patients have recently been published.", [["vomiting", "DISEASE", 120, 128], ["ED", "ORGANISM", 171, 173], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["drugs", "TREATMENT", 54, 59], ["chemotherapy", "TREATMENT", 99, 111], ["vomiting", "PROBLEM", 120, 128], ["bulk", "OBSERVATION_MODIFIER", 16, 20]]], ["A randomized, placebocontrolled, double-blind trial found ondansetron was not superior to metoclopramide and promethazine in 163 patients presenting to the ED with undifferentiated nausea.", [["ondansetron", "CHEMICAL", 58, 69], ["metoclopramide", "CHEMICAL", 90, 104], ["promethazine", "CHEMICAL", 109, 121], ["undifferentiated nausea", "DISEASE", 164, 187], ["ondansetron", "CHEMICAL", 58, 69], ["metoclopramide", "CHEMICAL", 90, 104], ["promethazine", "CHEMICAL", 109, 121], ["ondansetron", "SIMPLE_CHEMICAL", 58, 69], ["metoclopramide", "SIMPLE_CHEMICAL", 90, 104], ["promethazine", "SIMPLE_CHEMICAL", 109, 121], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["placebocontrolled", "TREATMENT", 14, 31], ["double-blind trial", "TREATMENT", 33, 51], ["ondansetron", "TREATMENT", 58, 69], ["metoclopramide", "TREATMENT", 90, 104], ["promethazine", "TREATMENT", 109, 121], ["undifferentiated nausea", "PROBLEM", 164, 187], ["undifferentiated", "OBSERVATION_MODIFIER", 164, 180], ["nausea", "OBSERVATION", 181, 187]]], ["25 Furthermore, a 2008 study of 120 ED patients found no difference in the reduction of nausea between ondansetron and promethazine, however, the group that received ondansetron experienced less sedation.", [["nausea", "DISEASE", 88, 94], ["ondansetron", "CHEMICAL", 103, 114], ["promethazine", "CHEMICAL", 119, 131], ["ondansetron", "CHEMICAL", 166, 177], ["ondansetron", "CHEMICAL", 103, 114], ["promethazine", "CHEMICAL", 119, 131], ["ondansetron", "CHEMICAL", 166, 177], ["patients", "ORGANISM", 39, 47], ["ondansetron", "SIMPLE_CHEMICAL", 103, 114], ["promethazine", "SIMPLE_CHEMICAL", 119, 131], ["ondansetron", "SIMPLE_CHEMICAL", 166, 177], ["patients", "SPECIES", 39, 47], ["a 2008 study", "TEST", 16, 28], ["nausea", "PROBLEM", 88, 94], ["ondansetron", "TREATMENT", 103, 114], ["promethazine", "TREATMENT", 119, 131], ["ondansetron", "TREATMENT", 166, 177], ["less sedation", "TREATMENT", 190, 203], ["nausea", "OBSERVATION", 88, 94]]], ["26 A recent review article examined the evidence supporting the use of droperidol, promethazine, prochlorperazine, metoclopramide, and ondansetron for the treatment of nausea or vomiting in the ED.", [["droperidol", "CHEMICAL", 71, 81], ["promethazine", "CHEMICAL", 83, 95], ["prochlorperazine", "CHEMICAL", 97, 113], ["metoclopramide", "CHEMICAL", 115, 129], ["ondansetron", "CHEMICAL", 135, 146], ["nausea", "DISEASE", 168, 174], ["vomiting", "DISEASE", 178, 186], ["droperidol", "CHEMICAL", 71, 81], ["promethazine", "CHEMICAL", 83, 95], ["prochlorperazine", "CHEMICAL", 97, 113], ["metoclopramide", "CHEMICAL", 115, 129], ["ondansetron", "CHEMICAL", 135, 146], ["droperidol", "SIMPLE_CHEMICAL", 71, 81], ["promethazine", "SIMPLE_CHEMICAL", 83, 95], ["prochlorperazine", "SIMPLE_CHEMICAL", 97, 113], ["metoclopramide", "SIMPLE_CHEMICAL", 115, 129], ["ondansetron", "SIMPLE_CHEMICAL", 135, 146], ["droperidol", "TREATMENT", 71, 81], ["promethazine", "TREATMENT", 83, 95], ["prochlorperazine", "TREATMENT", 97, 113], ["metoclopramide", "TREATMENT", 115, 129], ["ondansetron", "TREATMENT", 135, 146], ["nausea", "PROBLEM", 168, 174], ["vomiting", "PROBLEM", 178, 186]]], ["The investigators concluded that \"based on the safety and efficacy of ondansetron, it may be used as a first-line agent for relief of nausea or vomiting for most patient populations in the ED.\" 27Pediatric PatientsVomiting in the pediatric patient is an extremely common complaint in children presenting to the ED.", [["ondansetron", "CHEMICAL", 70, 81], ["nausea", "DISEASE", 134, 140], ["vomiting", "DISEASE", 144, 152], ["Vomiting", "DISEASE", 214, 222], ["ondansetron", "CHEMICAL", 70, 81], ["ondansetron", "SIMPLE_CHEMICAL", 70, 81], ["patient", "ORGANISM", 162, 169], ["Patients", "ORGANISM", 206, 214], ["patient", "ORGANISM", 240, 247], ["children", "ORGANISM", 284, 292], ["patient", "SPECIES", 162, 169], ["Patients", "SPECIES", 206, 214], ["patient", "SPECIES", 240, 247], ["children", "SPECIES", 284, 292], ["ondansetron", "TREATMENT", 70, 81], ["a first-line agent", "TREATMENT", 101, 119], ["nausea", "PROBLEM", 134, 140], ["vomiting", "PROBLEM", 144, 152], ["Vomiting", "PROBLEM", 214, 222]]], ["28 While most patients have a self-limiting disease process, vomiting may also be the presenting symptom for severe life-threatening conditions, and a thorough history and physical examination are therefore required to guide management.", [["vomiting", "DISEASE", 61, 69], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["a self-limiting disease process", "PROBLEM", 28, 59], ["vomiting", "PROBLEM", 61, 69], ["the presenting symptom", "PROBLEM", 82, 104], ["severe life-threatening conditions", "PROBLEM", 109, 143], ["physical examination", "TEST", 172, 192], ["self-limiting", "OBSERVATION_MODIFIER", 30, 43], ["disease", "OBSERVATION", 44, 51]]], ["Clinicians have historically been cautious to prescribe antiemetics for children, a practice reinforced by the American Academy of Pediatrics' (AAP) recommendation to use oral rehydration as first-line therapy for both mildly and moderately dehydrated children with gastroenteritis.", [["oral", "ANATOMY", 171, 175], ["gastroenteritis", "DISEASE", 266, 281], ["children", "ORGANISM", 72, 80], ["oral", "ORGANISM_SUBDIVISION", 171, 175], ["children", "ORGANISM", 252, 260], ["children", "SPECIES", 72, 80], ["children", "SPECIES", 252, 260], ["antiemetics", "TREATMENT", 56, 67], ["oral rehydration", "TREATMENT", 171, 187], ["first-line therapy", "TREATMENT", 191, 209], ["mildly and moderately dehydrated children", "PROBLEM", 219, 260], ["gastroenteritis", "PROBLEM", 266, 281], ["gastroenteritis", "OBSERVATION", 266, 281]]], ["29 In a recent study, 73 children ranging in age from 8 weeks to 3 years with moderate dehydration from viral gastroenteritis were randomized to either oral rehydration therapy (ORT) or intravenous fluids.", [["oral", "ANATOMY", 152, 156], ["intravenous", "ANATOMY", 186, 197], ["dehydration", "DISEASE", 87, 98], ["viral gastroenteritis", "DISEASE", 104, 125], ["children", "ORGANISM", 25, 33], ["oral", "ORGANISM_SUBDIVISION", 152, 156], ["children", "SPECIES", 25, 33], ["a recent study", "TEST", 6, 20], ["moderate dehydration", "PROBLEM", 78, 98], ["viral gastroenteritis", "PROBLEM", 104, 125], ["oral rehydration therapy", "TREATMENT", 152, 176], ["intravenous fluids", "TREATMENT", 186, 204], ["moderate", "OBSERVATION_MODIFIER", 78, 86], ["dehydration", "OBSERVATION", 87, 98], ["viral gastroenteritis", "OBSERVATION", 104, 125]]], ["Based on their findings, the investigators opined that ORT was the preferred treatment option.", [["treatment option", "TREATMENT", 77, 93]]], ["30 Despite these recommendations, a survey found 36% of pediatricians believed vomiting was a contraindication to ORT.", [["vomiting", "DISEASE", 79, 87], ["a survey", "TEST", 34, 42], ["vomiting", "PROBLEM", 79, 87]]], ["31 The FDA's 2006 black box warning on promethazine for pediatric patients younger than 2 years may have contributed to the hesitancy to use antiemetics and subsequently avoid ORT in children.", [["promethazine", "CHEMICAL", 39, 51], ["promethazine", "CHEMICAL", 39, 51], ["promethazine", "SIMPLE_CHEMICAL", 39, 51], ["patients", "ORGANISM", 66, 74], ["children", "ORGANISM", 183, 191], ["patients", "SPECIES", 66, 74], ["children", "SPECIES", 183, 191], ["promethazine", "TREATMENT", 39, 51], ["antiemetics", "TREATMENT", 141, 152]]], ["Nonetheless, the past decade has also seen an increase in 5-HT 3 antagonists in the pediatric population.", [["5-HT", "CHEMICAL", 58, 62], ["5-HT 3 antagonists", "GENE_OR_GENE_PRODUCT", 58, 76], ["5-HT 3 antagonists", "TREATMENT", 58, 76], ["increase", "OBSERVATION_MODIFIER", 46, 54]]], ["A double-blind, placebo-controlled study from 2002 on intravenous ondansetron for gastroenteritis found a reduction in admission rates for pediatric patients presenting with vomiting and an initial serum carbon dioxide level of 15 mEq/L or more.", [["intravenous", "ANATOMY", 54, 65], ["serum", "ANATOMY", 198, 203], ["ondansetron", "CHEMICAL", 66, 77], ["gastroenteritis", "DISEASE", 82, 97], ["vomiting", "DISEASE", 174, 182], ["carbon dioxide", "CHEMICAL", 204, 218], ["ondansetron", "CHEMICAL", 66, 77], ["carbon dioxide", "CHEMICAL", 204, 218], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 65], ["ondansetron", "SIMPLE_CHEMICAL", 66, 77], ["patients", "ORGANISM", 149, 157], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["carbon dioxide", "SIMPLE_CHEMICAL", 204, 218], ["patients", "SPECIES", 149, 157], ["placebo", "TREATMENT", 16, 23], ["intravenous ondansetron", "TREATMENT", 54, 77], ["gastroenteritis", "PROBLEM", 82, 97], ["a reduction", "TREATMENT", 104, 115], ["vomiting", "PROBLEM", 174, 182], ["an initial serum carbon dioxide level", "TEST", 187, 224]]], ["32 Pharmacologic data demonstrating that orally administered ondansetron tablets are equivalent to its intravenous formulation have led to further investigations exploring whether intravenous access could be avoided.", [["intravenous", "ANATOMY", 103, 114], ["intravenous", "ANATOMY", 180, 191], ["ondansetron", "CHEMICAL", 61, 72], ["ondansetron", "CHEMICAL", 61, 72], ["ondansetron", "SIMPLE_CHEMICAL", 61, 72], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 114], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 180, 191], ["Pharmacologic data", "TEST", 3, 21], ["ondansetron tablets", "TREATMENT", 61, 80], ["its intravenous formulation", "TREATMENT", 99, 126], ["further investigations", "TEST", 139, 161], ["intravenous access", "TREATMENT", 180, 198]]], ["In 2006, investigators enrolled 215 children aged 6 months to 10 years treated in the ED for gastroenteritis-related dehydration.", [["gastroenteritis", "DISEASE", 93, 108], ["dehydration", "DISEASE", 117, 128], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["gastroenteritis", "PROBLEM", 93, 108], ["related dehydration", "PROBLEM", 109, 128], ["gastroenteritis", "OBSERVATION", 93, 108], ["dehydration", "OBSERVATION", 117, 128]]], ["Compared with placebo, subjects who received ondansetron orally were less likely to vomit (14% vs 35%), had greater oral intake (239 mL vs 196 mL), and were less likely to require intravenous fluids (14% vs 31%).", [["oral", "ANATOMY", 116, 120], ["intravenous", "ANATOMY", 180, 191], ["ondansetron", "CHEMICAL", 45, 56], ["ondansetron", "CHEMICAL", 45, 56], ["ondansetron", "SIMPLE_CHEMICAL", 45, 56], ["oral", "ORGANISM_SUBDIVISION", 116, 120], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 180, 191], ["ondansetron", "TREATMENT", 45, 56], ["vomit", "PROBLEM", 84, 89], ["intravenous fluids", "TREATMENT", 180, 198]]], ["33 Another pediatric study replicated these results, finding subjects who received oral ondansetron had a decreased need for intravenous fluids than those who received a placebo (21.6% vs 54.5%).", [["oral", "ANATOMY", 83, 87], ["intravenous", "ANATOMY", 125, 136], ["ondansetron", "CHEMICAL", 88, 99], ["ondansetron", "CHEMICAL", 88, 99], ["oral", "ORGANISM_SUBDIVISION", 83, 87], ["ondansetron", "SIMPLE_CHEMICAL", 88, 99], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 136], ["Another pediatric study", "TEST", 3, 26], ["oral ondansetron", "TREATMENT", 83, 99], ["intravenous fluids", "TREATMENT", 125, 143], ["a placebo", "TREATMENT", 168, 177]]], ["34 These results reinforce the practice of using oral ondansetron and ORT to treat pediatric patients with mild to moderate dehydration.DIARRHEADiarrhea is classically thought of as a physical sign of a disease rather than a disease in itself; therefore, much of the pertinent literature focuses on its etiology and the supportive, empiric treatment of diarrhea.", [["oral", "ANATOMY", 49, 53], ["ondansetron", "CHEMICAL", 54, 65], ["dehydration", "DISEASE", 124, 135], ["DIARRHEADiarrhea", "DISEASE", 136, 152], ["diarrhea", "DISEASE", 353, 361], ["ondansetron", "CHEMICAL", 54, 65], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["ondansetron", "SIMPLE_CHEMICAL", 54, 65], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["oral ondansetron", "TREATMENT", 49, 65], ["ORT", "TREATMENT", 70, 73], ["mild to moderate dehydration", "PROBLEM", 107, 135], ["a disease", "PROBLEM", 201, 210], ["a disease in itself", "PROBLEM", 223, 242], ["empiric treatment", "TREATMENT", 332, 349], ["diarrhea", "PROBLEM", 353, 361], ["mild", "OBSERVATION_MODIFIER", 107, 111], ["moderate", "OBSERVATION_MODIFIER", 115, 123], ["dehydration", "OBSERVATION", 124, 135], ["disease", "OBSERVATION", 203, 210], ["disease", "OBSERVATION", 225, 232], ["diarrhea", "OBSERVATION", 353, 361]]], ["Nevertheless, while the majority of cases of diarrhea in the United States are self-limited, diarrhea continues to pose an enormous health challenge worldwide.", [["diarrhea", "DISEASE", 45, 53], ["diarrhea", "DISEASE", 93, 101], ["diarrhea", "PROBLEM", 45, 53], ["diarrhea", "PROBLEM", 93, 101], ["diarrhea", "OBSERVATION", 45, 53]]], ["The World Health Organization (WHO) 35 estimates approximately 4 billion cases of diarrhea worldwide per year, with such episodes responsible for a staggering 2.2 million deaths annually.", [["diarrhea", "DISEASE", 82, 90], ["deaths", "DISEASE", 171, 177], ["diarrhea", "PROBLEM", 82, 90]]], ["Overall, in the United States, there are an estimated 211 million to 375 million cases of acute diarrhea, resulting in 900,000 hospitalizations.", [["diarrhea", "DISEASE", 96, 104], ["acute diarrhea", "PROBLEM", 90, 104], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["diarrhea", "OBSERVATION", 96, 104]]], ["36 Furthermore, diarrhea remains the most common and incapacitating symptom of patients with ulcerative colitis.", [["diarrhea", "DISEASE", 16, 24], ["ulcerative colitis", "DISEASE", 93, 111], ["patients", "ORGANISM", 79, 87], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 93, 111], ["patients", "SPECIES", 79, 87], ["diarrhea", "PROBLEM", 16, 24], ["incapacitating symptom", "PROBLEM", 53, 75], ["ulcerative colitis", "PROBLEM", 93, 111], ["diarrhea", "OBSERVATION", 16, 24], ["most common", "OBSERVATION_MODIFIER", 37, 48], ["ulcerative", "OBSERVATION_MODIFIER", 93, 103], ["colitis", "OBSERVATION", 104, 111]]], ["37 Diarrhea is an ailment that can be particularly severe in children, with the majority of the deaths worldwide caused by diarrheal illness occurring in children younger than 5 years old.", [["Diarrhea", "DISEASE", 3, 11], ["deaths", "DISEASE", 96, 102], ["diarrheal illness", "DISEASE", 123, 140], ["children", "ORGANISM", 61, 69], ["children", "ORGANISM", 154, 162], ["children", "SPECIES", 61, 69], ["children", "SPECIES", 154, 162], ["Diarrhea", "PROBLEM", 3, 11], ["diarrheal illness", "PROBLEM", 123, 140]]], ["A recent study found ED visits for pediatric patients with diarrhea nearly doubled from 1995 to 2004, with 25% of those presentations being due to rotavirus.", [["diarrhea", "DISEASE", 59, 67], ["rotavirus", "DISEASE", 147, 156], ["patients", "ORGANISM", 45, 53], ["rotavirus", "ORGANISM", 147, 156], ["patients", "SPECIES", 45, 53], ["rotavirus", "SPECIES", 147, 156], ["A recent study", "TEST", 0, 14], ["diarrhea", "PROBLEM", 59, 67], ["rotavirus", "PROBLEM", 147, 156]]], ["38, 39 Diarrhea is also common in the military.", [["Diarrhea", "DISEASE", 7, 15], ["Diarrhea", "PROBLEM", 7, 15]]], ["More than three-quarters of troops deployed to Iraq and Afghanistan reported at least one diarrhea episode during their deployments, with 45% noting a decreased work performance for a median of 3 days.", [["diarrhea", "DISEASE", 90, 98], ["one diarrhea episode", "PROBLEM", 86, 106], ["a decreased work performance", "PROBLEM", 149, 177]]], ["40 Although definitions vary, diarrhea is typically characterized as a change in normal bowel movements with the passage of 3 or more stools per day or at least 200 g of stool per day.", [["bowel", "ANATOMY", 88, 93], ["diarrhea", "DISEASE", 30, 38], ["bowel", "ORGAN", 88, 93], ["diarrhea", "PROBLEM", 30, 38], ["a change in normal bowel movements", "PROBLEM", 69, 103], ["diarrhea", "OBSERVATION", 30, 38], ["change", "OBSERVATION_MODIFIER", 71, 77], ["normal", "OBSERVATION", 81, 87], ["bowel movements", "OBSERVATION", 88, 103]]], ["41 Acute diarrhea is defined as episodes lasting 14 days or less; persistent diarrhea lasts more than 14 days; and chronic diarrhea lasts for more than 30 days.", [["diarrhea", "DISEASE", 9, 17], ["diarrhea", "DISEASE", 77, 85], ["diarrhea", "DISEASE", 123, 131], ["Acute diarrhea", "PROBLEM", 3, 17], ["persistent diarrhea", "PROBLEM", 66, 85], ["chronic diarrhea", "PROBLEM", 115, 131], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["diarrhea", "OBSERVATION", 9, 17], ["persistent", "OBSERVATION_MODIFIER", 66, 76], ["diarrhea", "OBSERVATION", 77, 85], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["diarrhea", "OBSERVATION", 123, 131]]], ["Furthermore, diarrhea is broadly categorized as either secretory or osmotic.", [["diarrhea", "DISEASE", 13, 21], ["diarrhea", "PROBLEM", 13, 21], ["diarrhea", "OBSERVATION", 13, 21]]], ["Osmotic diarrhea occurs when a nonabsorbable solute exerts an osmotic pressure effect across the intestinal mucosa, a process that produces excessive water output.Vomiting, Diarrhea, Constipation, GastroenteritisSecretory diarrhea, commonly caused by bacterial toxins or neoplasms that disrupt epithelial crypt cells in the gastrointestinal tract, is extremely difficult to control.Differential DiagnosisThe differential diagnosis for diarrhea is broad, with several causes displaying overlapping signs and symptoms.", [["intestinal mucosa", "ANATOMY", 97, 114], ["neoplasms", "ANATOMY", 271, 280], ["epithelial crypt cells", "ANATOMY", 294, 316], ["gastrointestinal tract", "ANATOMY", 324, 346], ["diarrhea", "DISEASE", 8, 16], ["Vomiting", "DISEASE", 163, 171], ["Diarrhea", "DISEASE", 173, 181], ["Constipation", "DISEASE", 183, 195], ["GastroenteritisSecretory diarrhea", "DISEASE", 197, 230], ["neoplasms", "DISEASE", 271, 280], ["diarrhea", "DISEASE", 435, 443], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 97, 114], ["neoplasms", "CANCER", 271, 280], ["epithelial crypt cells", "CELL", 294, 316], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 324, 346], ["epithelial crypt cells", "CELL_TYPE", 294, 316], ["Osmotic diarrhea", "PROBLEM", 0, 16], ["a nonabsorbable solute", "TREATMENT", 29, 51], ["an osmotic pressure effect", "TREATMENT", 59, 85], ["excessive water output", "PROBLEM", 140, 162], ["Vomiting", "PROBLEM", 163, 171], ["Diarrhea", "PROBLEM", 173, 181], ["Constipation", "PROBLEM", 183, 195], ["GastroenteritisSecretory diarrhea", "PROBLEM", 197, 230], ["bacterial toxins", "PROBLEM", 251, 267], ["neoplasms", "PROBLEM", 271, 280], ["epithelial crypt cells in the gastrointestinal tract", "PROBLEM", 294, 346], ["diarrhea", "PROBLEM", 435, 443], ["overlapping signs and symptoms", "PROBLEM", 485, 515], ["diarrhea", "OBSERVATION", 8, 16], ["osmotic pressure", "OBSERVATION", 62, 78], ["intestinal mucosa", "ANATOMY", 97, 114], ["excessive", "OBSERVATION_MODIFIER", 140, 149], ["water output", "OBSERVATION", 150, 162], ["Diarrhea", "OBSERVATION", 173, 181], ["Constipation", "OBSERVATION", 183, 195], ["GastroenteritisSecretory", "ANATOMY", 197, 221], ["diarrhea", "OBSERVATION", 222, 230], ["bacterial toxins", "OBSERVATION", 251, 267], ["neoplasms", "OBSERVATION", 271, 280], ["epithelial crypt cells", "OBSERVATION", 294, 316], ["gastrointestinal tract", "ANATOMY", 324, 346]]], ["A focused history including the onset, frequency, and character of the diarrhea (eg, presence of blood or mucus) as well as associated symptoms (eg, fever, vomiting), medical history (eg, human immunodeficiency virus [HIV], inflammatory bowel disease), medications, and travel history may aid in narrowing the differential.", [["blood", "ANATOMY", 97, 102], ["mucus", "ANATOMY", 106, 111], ["bowel", "ANATOMY", 237, 242], ["diarrhea", "DISEASE", 71, 79], ["fever", "DISEASE", 149, 154], ["vomiting", "DISEASE", 156, 164], ["human immunodeficiency virus [HIV]", "DISEASE", 188, 222], ["inflammatory bowel disease", "DISEASE", 224, 250], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["mucus", "MULTI-TISSUE_STRUCTURE", 106, 111], ["human immunodeficiency virus", "ORGANISM", 188, 216], ["bowel", "ORGAN", 237, 242], ["human immunodeficiency virus [HIV", "SPECIES", 188, 221], ["human immunodeficiency virus", "SPECIES", 188, 216], ["HIV", "SPECIES", 218, 221], ["the diarrhea (eg", "PROBLEM", 67, 83], ["blood or mucus)", "PROBLEM", 97, 112], ["associated symptoms (eg", "PROBLEM", 124, 147], ["fever", "PROBLEM", 149, 154], ["vomiting", "PROBLEM", 156, 164], ["human immunodeficiency virus", "PROBLEM", 188, 216], ["HIV", "PROBLEM", 218, 221], ["inflammatory bowel disease", "PROBLEM", 224, 250], ["medications", "TREATMENT", 253, 264], ["narrowing the differential", "PROBLEM", 296, 322], ["diarrhea", "OBSERVATION", 71, 79], ["inflammatory", "OBSERVATION_MODIFIER", 224, 236], ["bowel", "ANATOMY", 237, 242], ["disease", "OBSERVATION", 243, 250], ["narrowing", "OBSERVATION", 296, 305]]], ["Nevertheless, there are several clinically noteworthy causes of diarrhea that have exceptional treatment regimens as well as important clinical ramifications to consider.Differential DiagnosisClostridium difficile, which affects approximately 3 million patients yearly in the United States with a mortality rate of 1% to 2.5%, 42 is caused by a disruption of normal intestinal flora, 43 and is responsible for 15% to 20% of antibiotic-related cases of diarrhea.", [["intestinal flora", "ANATOMY", 366, 382], ["diarrhea", "DISEASE", 64, 72], ["DiagnosisClostridium difficile", "DISEASE", 183, 213], ["diarrhea", "DISEASE", 452, 460], ["patients", "ORGANISM", 253, 261], ["intestinal", "ORGAN", 366, 376], ["DiagnosisClostridium difficile", "SPECIES", 183, 213], ["patients", "SPECIES", 253, 261], ["DiagnosisClostridium difficile", "SPECIES", 183, 213], ["diarrhea", "PROBLEM", 64, 72], ["exceptional treatment regimens", "TREATMENT", 83, 113], ["Differential DiagnosisClostridium difficile", "PROBLEM", 170, 213], ["a mortality rate", "TEST", 295, 311], ["a disruption of normal intestinal flora", "PROBLEM", 343, 382], ["antibiotic", "TREATMENT", 424, 434], ["diarrhea", "PROBLEM", 452, 460], ["diarrhea", "OBSERVATION", 64, 72], ["difficile", "OBSERVATION", 204, 213], ["normal", "OBSERVATION", 359, 365], ["intestinal flora", "ANATOMY", 366, 382], ["diarrhea", "OBSERVATION", 452, 460]]], ["44 Severe C difficile infection may result in life-threatening complications such as toxic megacolon, intestinal perforation, sepsis, or death.", [["intestinal", "ANATOMY", 102, 112], ["C difficile infection", "DISEASE", 10, 31], ["toxic megacolon", "DISEASE", 85, 100], ["intestinal perforation", "DISEASE", 102, 124], ["sepsis", "DISEASE", 126, 132], ["death", "DISEASE", 137, 142], ["C difficile", "ORGANISM", 10, 21], ["intestinal", "ORGAN", 102, 112], ["C difficile", "SPECIES", 10, 21], ["C difficile", "SPECIES", 10, 21], ["Severe C difficile infection", "PROBLEM", 3, 31], ["life-threatening complications", "PROBLEM", 46, 76], ["toxic megacolon", "PROBLEM", 85, 100], ["intestinal perforation", "PROBLEM", 102, 124], ["sepsis", "PROBLEM", 126, 132], ["death", "PROBLEM", 137, 142], ["difficile", "OBSERVATION_MODIFIER", 12, 21], ["infection", "OBSERVATION", 22, 31], ["toxic", "OBSERVATION_MODIFIER", 85, 90], ["megacolon", "OBSERVATION", 91, 100], ["intestinal", "ANATOMY", 102, 112], ["perforation", "OBSERVATION", 113, 124], ["sepsis", "OBSERVATION", 126, 132]]], ["Furthermore, diarrhea caused by C difficile may present with severe abdominal pain, high fever, and more than 10 watery stools per day; however, as it is common among elderly patients many or all of these signs and symptoms may be absent.", [["abdominal", "ANATOMY", 68, 77], ["diarrhea", "DISEASE", 13, 21], ["C difficile", "DISEASE", 32, 43], ["abdominal pain", "DISEASE", 68, 82], ["fever", "DISEASE", 89, 94], ["watery stools", "DISEASE", 113, 126], ["C difficile", "ORGANISM", 32, 43], ["abdominal", "ORGANISM_SUBDIVISION", 68, 77], ["patients", "ORGANISM", 175, 183], ["C difficile", "SPECIES", 32, 43], ["patients", "SPECIES", 175, 183], ["C difficile", "SPECIES", 32, 43], ["diarrhea", "PROBLEM", 13, 21], ["C difficile", "PROBLEM", 32, 43], ["severe abdominal pain", "PROBLEM", 61, 82], ["high fever", "PROBLEM", 84, 94], ["10 watery stools", "PROBLEM", 110, 126], ["symptoms", "PROBLEM", 215, 223], ["diarrhea", "OBSERVATION", 13, 21], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["abdominal", "ANATOMY", 68, 77], ["pain", "OBSERVATION", 78, 82], ["high", "OBSERVATION_MODIFIER", 84, 88], ["fever", "OBSERVATION", 89, 94]]], ["One study found 15% of patients with diarrhea hospitalized at an academic center tested positive for C difficile, 45 while during times of outbreak more than 50% of patients in an affected ward may become colonized.", [["diarrhea", "DISEASE", 37, 45], ["C difficile", "DISEASE", 101, 112], ["patients", "ORGANISM", 23, 31], ["C difficile", "ORGANISM", 101, 112], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 23, 31], ["C difficile", "SPECIES", 101, 112], ["patients", "SPECIES", 165, 173], ["C difficile", "SPECIES", 101, 112], ["One study", "TEST", 0, 9], ["diarrhea", "PROBLEM", 37, 45], ["C difficile", "PROBLEM", 101, 112], ["colonized", "OBSERVATION", 205, 214]]], ["46 Of interest, although C difficile historically has not been thought of as a pediatric illness, recent evidence suggests the contrary.", [["C difficile", "ORGANISM", 25, 36], ["C difficile", "SPECIES", 25, 36], ["C difficile", "SPECIES", 25, 36], ["C difficile", "PROBLEM", 25, 36], ["a pediatric illness", "PROBLEM", 77, 96]]], ["A pediatric ED-based study found that of specimens that underwent complete testing, 12.4% tested positive for C difficile toxin, 47 and nearly 3% of children tested positive for C difficile toxin in another similar study from France.", [["specimens", "ANATOMY", 41, 50], ["specimens", "CANCER", 41, 50], ["C difficile toxin", "SIMPLE_CHEMICAL", 110, 127], ["children", "ORGANISM", 149, 157], ["C difficile toxin", "SIMPLE_CHEMICAL", 178, 195], ["C difficile toxin", "PROTEIN", 178, 195], ["C difficile toxin", "SPECIES", 110, 127], ["children", "SPECIES", 149, 157], ["C difficile", "SPECIES", 178, 189], ["C difficile", "SPECIES", 110, 121], ["C difficile", "SPECIES", 178, 189], ["A pediatric ED-based study", "TEST", 0, 26], ["specimens", "TEST", 41, 50], ["complete testing", "TEST", 66, 82], ["C difficile toxin", "PROBLEM", 110, 127], ["C difficile toxin", "PROBLEM", 178, 195]]], ["48 Recently a new disease pattern, community-onset C difficile-associated diarrhea, has emerged, and may occur without exposure to the typical risk factors including antibiotic usage.", [["C difficile", "DISEASE", 51, 62], ["diarrhea", "DISEASE", 74, 82], ["C difficile", "ORGANISM", 51, 62], ["C difficile", "SPECIES", 51, 62], ["C difficile", "SPECIES", 51, 62], ["a new disease pattern", "PROBLEM", 12, 33], ["community-onset C difficile-associated diarrhea", "PROBLEM", 35, 82], ["antibiotic usage", "TREATMENT", 166, 182], ["new", "OBSERVATION_MODIFIER", 14, 17], ["disease", "OBSERVATION", 18, 25], ["difficile", "OBSERVATION_MODIFIER", 53, 62], ["diarrhea", "OBSERVATION", 74, 82]]], ["49 Several agents have been implicated in the increased incidence of C difficile, including usage of antibiotics and proton pump inhibitors (PPIs).", [["C difficile", "DISEASE", 69, 80], ["C difficile", "ORGANISM", 69, 80], ["proton pump inhibitors", "SIMPLE_CHEMICAL", 117, 139], ["C difficile", "SPECIES", 69, 80], ["C difficile", "SPECIES", 69, 80], ["C difficile", "PROBLEM", 69, 80], ["antibiotics", "TREATMENT", 101, 112], ["proton pump inhibitors", "TREATMENT", 117, 139], ["PPIs", "TREATMENT", 141, 145], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["difficile", "OBSERVATION", 71, 80]]], ["In one recent study, C difficile diarrhea among hospital inpatients was associated with the use of PPIs (9.3% of patients receiving PPIs vs 4.4% who did not receive PPIs) and receipt of 3 or more antibiotics.", [["C difficile diarrhea", "DISEASE", 21, 41], ["C difficile", "ORGANISM", 21, 32], ["patients", "ORGANISM", 113, 121], ["C difficile diarrhea", "SPECIES", 21, 41], ["patients", "SPECIES", 113, 121], ["C difficile", "SPECIES", 21, 32], ["one recent study", "TEST", 3, 19], ["C difficile diarrhea", "PROBLEM", 21, 41], ["PPIs", "TREATMENT", 99, 103], ["PPIs", "TREATMENT", 132, 136], ["PPIs", "TREATMENT", 165, 169], ["more antibiotics", "TREATMENT", 191, 207]]], ["50 Removing the inciting antibiotic treats up to 25% of cases of C difficile diarrhea.", [["C difficile diarrhea", "DISEASE", 65, 85], ["C difficile diarrhea", "ORGANISM", 65, 85], ["C difficile diarrhea", "SPECIES", 65, 85], ["C difficile", "SPECIES", 65, 76], ["the inciting antibiotic", "TREATMENT", 12, 35], ["C difficile diarrhea", "PROBLEM", 65, 85], ["difficile", "OBSERVATION_MODIFIER", 67, 76], ["diarrhea", "OBSERVATION", 77, 85]]], ["51 Antibiotic treatment regimens have traditionally used oral metronidazole (Flagyl) or vancomycin (Vancocin) for 14 days; however, for recurrent C difficile infection some experts recommend oral tapered-pulsed vancomycin (125 mg once a day for 1 week, 125 mg 3 times a day for 1 week, 125 mg every day for 1 week, 125 mg every other day for 2 weeks, 125 mg every third day for 2 weeks).", [["oral", "ANATOMY", 57, 61], ["oral", "ANATOMY", 191, 195], ["metronidazole", "CHEMICAL", 62, 75], ["Flagyl", "CHEMICAL", 77, 83], ["vancomycin", "CHEMICAL", 88, 98], ["Vancocin", "CHEMICAL", 100, 108], ["C difficile infection", "DISEASE", 146, 167], ["vancomycin", "CHEMICAL", 211, 221], ["metronidazole", "CHEMICAL", 62, 75], ["Flagyl", "CHEMICAL", 77, 83], ["vancomycin", "CHEMICAL", 88, 98], ["Vancocin", "CHEMICAL", 100, 108], ["vancomycin", "CHEMICAL", 211, 221], ["oral", "ORGANISM_SUBDIVISION", 57, 61], ["metronidazole", "SIMPLE_CHEMICAL", 62, 75], ["Flagyl", "SIMPLE_CHEMICAL", 77, 83], ["vancomycin", "SIMPLE_CHEMICAL", 88, 98], ["Vancocin", "SIMPLE_CHEMICAL", 100, 108], ["C difficile", "ORGANISM", 146, 157], ["oral", "ORGANISM_SUBDIVISION", 191, 195], ["vancomycin", "SIMPLE_CHEMICAL", 211, 221], ["C difficile", "SPECIES", 146, 157], ["C difficile", "SPECIES", 146, 157], ["Antibiotic treatment regimens", "TREATMENT", 3, 32], ["oral metronidazole", "TREATMENT", 57, 75], ["Flagyl", "TREATMENT", 77, 83], ["vancomycin", "TREATMENT", 88, 98], ["Vancocin", "TREATMENT", 100, 108], ["recurrent C difficile infection", "PROBLEM", 136, 167], ["oral tapered-pulsed vancomycin", "TREATMENT", 191, 221], ["difficile", "OBSERVATION_MODIFIER", 148, 157], ["infection", "OBSERVATION", 158, 167]]], ["52 Traveler's diarrhea, which affects 20% to 50% of individuals traveling from developed to developing countries and 4% to 9% of individuals traveling from developing to developed countries, is typically caused by enterotoxigenic Escherichia coli (ETEC) and enteroaggregative E coli, which bind to the intestinal mucosa to cause diarrhea typically without fever.", [["intestinal mucosa", "ANATOMY", 302, 319], ["Traveler's diarrhea", "DISEASE", 3, 22], ["enterotoxigenic Escherichia coli", "DISEASE", 214, 246], ["diarrhea", "DISEASE", 329, 337], ["fever", "DISEASE", 356, 361], ["enterotoxigenic Escherichia coli", "ORGANISM", 214, 246], ["ETEC", "ORGANISM", 248, 252], ["enteroaggregative E coli", "ORGANISM", 258, 282], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 302, 319], ["Escherichia coli", "SPECIES", 230, 246], ["E coli", "SPECIES", 276, 282], ["Escherichia coli", "SPECIES", 230, 246], ["ETEC", "SPECIES", 248, 252], ["E coli", "SPECIES", 276, 282], ["Traveler's diarrhea", "PROBLEM", 3, 22], ["enterotoxigenic Escherichia coli", "PROBLEM", 214, 246], ["ETEC", "PROBLEM", 248, 252], ["enteroaggregative E coli", "PROBLEM", 258, 282], ["diarrhea", "PROBLEM", 329, 337], ["fever", "PROBLEM", 356, 361], ["Escherichia coli", "OBSERVATION", 230, 246], ["enteroaggregative E coli", "OBSERVATION_MODIFIER", 258, 282], ["intestinal mucosa", "ANATOMY", 302, 319]]], ["53 Incubation periods for ETEC last between 10 hours and 3 days followed by 3 to 5 days of illness.", [["illness", "DISEASE", 91, 98], ["ETEC", "PROBLEM", 26, 30], ["illness", "PROBLEM", 91, 98]]], ["54 ETEC produces a noninvasive toxin that causes severe watery diarrhea, abdominal cramps, nausea, and (infrequently) fever.", [["abdominal", "ANATOMY", 73, 82], ["ETEC", "DISEASE", 3, 7], ["watery diarrhea", "DISEASE", 56, 71], ["abdominal cramps", "DISEASE", 73, 89], ["nausea", "DISEASE", 91, 97], ["fever", "DISEASE", 118, 123], ["abdominal", "ORGANISM_SUBDIVISION", 73, 82], ["a noninvasive toxin", "PROBLEM", 17, 36], ["severe watery diarrhea", "PROBLEM", 49, 71], ["abdominal cramps", "PROBLEM", 73, 89], ["nausea", "PROBLEM", 91, 97], ["fever", "PROBLEM", 118, 123], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["watery", "OBSERVATION_MODIFIER", 56, 62], ["diarrhea", "OBSERVATION", 63, 71], ["abdominal", "ANATOMY", 73, 82], ["cramps", "OBSERVATION", 83, 89], ["nausea", "OBSERVATION", 91, 97]]], ["55 Shigella species and Salmonella species are other important bacterial pathogens.", [["Shigella species", "ORGANISM", 3, 19], ["Salmonella species", "ORGANISM", 24, 42], ["Shigella species", "PROBLEM", 3, 19], ["Salmonella species", "PROBLEM", 24, 42], ["bacterial pathogens", "PROBLEM", 63, 82], ["Shigella species", "OBSERVATION", 3, 19], ["Salmonella species", "OBSERVATION", 24, 42], ["bacterial pathogens", "OBSERVATION", 63, 82]]], ["Campylobacter jejuni, a bacteria that poses additional hazards because it has been implicated with acute cases of myocarditis, has emerged as another important cause of traveler's diarrhea.", [["Campylobacter jejuni", "DISEASE", 0, 20], ["myocarditis", "DISEASE", 114, 125], ["diarrhea", "DISEASE", 180, 188], ["Campylobacter jejuni", "ORGANISM", 0, 20], ["Campylobacter jejuni", "SPECIES", 0, 20], ["Campylobacter jejuni", "SPECIES", 0, 20], ["Campylobacter jejuni", "PROBLEM", 0, 20], ["a bacteria", "PROBLEM", 22, 32], ["myocarditis", "PROBLEM", 114, 125], ["traveler's diarrhea", "PROBLEM", 169, 188], ["jejuni", "OBSERVATION", 14, 20], ["implicated with", "UNCERTAINTY", 83, 98], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["myocarditis", "OBSERVATION", 114, 125]]], ["56 Electrolyte disturbances for patients with traveler's diarrhea are rare, and therefore laboratory work is usually unnecessary.", [["diarrhea", "DISEASE", 57, 65], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Electrolyte disturbances", "PROBLEM", 3, 27], ["traveler's diarrhea", "PROBLEM", 46, 65], ["laboratory work", "TEST", 90, 105]]], ["57 Treatment of traveler's diarrhea is centered on antibiotic therapy, such as ciprofloxacin (Cipro), trimethoprim-sulfamethoxazole (Bactrim; resistance common), azithromycin (Zithromax), and rifaximin (Xifaxan).", [["diarrhea", "DISEASE", 27, 35], ["ciprofloxacin", "CHEMICAL", 79, 92], ["Cipro", "CHEMICAL", 94, 99], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 102, 131], ["Bactrim", "CHEMICAL", 133, 140], ["azithromycin", "CHEMICAL", 162, 174], ["Zithromax", "CHEMICAL", 176, 185], ["rifaximin", "CHEMICAL", 192, 201], ["Xifaxan", "CHEMICAL", 203, 210], ["ciprofloxacin", "CHEMICAL", 79, 92], ["Cipro", "CHEMICAL", 94, 99], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 102, 131], ["Bactrim", "CHEMICAL", 133, 140], ["azithromycin", "CHEMICAL", 162, 174], ["Zithromax", "CHEMICAL", 176, 185], ["rifaximin", "CHEMICAL", 192, 201], ["Xifaxan", "CHEMICAL", 203, 210], ["ciprofloxacin", "SIMPLE_CHEMICAL", 79, 92], ["Cipro", "SIMPLE_CHEMICAL", 94, 99], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 102, 131], ["Bactrim", "SIMPLE_CHEMICAL", 133, 140], ["azithromycin", "SIMPLE_CHEMICAL", 162, 174], ["Zithromax", "SIMPLE_CHEMICAL", 176, 185], ["rifaximin", "SIMPLE_CHEMICAL", 192, 201], ["Xifaxan", "SIMPLE_CHEMICAL", 203, 210], ["traveler's diarrhea", "PROBLEM", 16, 35], ["antibiotic therapy", "TREATMENT", 51, 69], ["ciprofloxacin", "TREATMENT", 79, 92], ["Cipro", "TREATMENT", 94, 99], ["trimethoprim", "TREATMENT", 102, 114], ["sulfamethoxazole", "TREATMENT", 115, 131], ["Bactrim", "TREATMENT", 133, 140], ["azithromycin", "TREATMENT", 162, 174], ["Zithromax", "TREATMENT", 176, 185], ["rifaximin", "TREATMENT", 192, 201], ["Xifaxan", "TREATMENT", 203, 210]]], ["58 If the patient with suspected traveler's diarrhea has more than 2 unformed stools per day, bloody stools, or fever (>37.8 C), treatment with antibiotics is advised.", [["bloody stools", "ANATOMY", 94, 107], ["diarrhea", "DISEASE", 44, 52], ["bloody stools", "DISEASE", 94, 107], ["fever", "DISEASE", 112, 117], ["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["traveler's diarrhea", "PROBLEM", 33, 52], ["bloody stools", "PROBLEM", 94, 107], ["fever", "PROBLEM", 112, 117], ["antibiotics", "TREATMENT", 144, 155]]], ["59 A short, single-day course of ciprofloxacin, 500 mg twice a day, is usually successful at stopping the illness within 24 hours, 60 although other sources recommend a 3-day course of ciprofloxacin or rifaximin.", [["ciprofloxacin", "CHEMICAL", 33, 46], ["illness", "DISEASE", 106, 113], ["ciprofloxacin", "CHEMICAL", 185, 198], ["rifaximin", "CHEMICAL", 202, 211], ["ciprofloxacin", "CHEMICAL", 33, 46], ["ciprofloxacin", "CHEMICAL", 185, 198], ["rifaximin", "CHEMICAL", 202, 211], ["ciprofloxacin", "SIMPLE_CHEMICAL", 33, 46], ["ciprofloxacin", "SIMPLE_CHEMICAL", 185, 198], ["rifaximin", "SIMPLE_CHEMICAL", 202, 211], ["ciprofloxacin", "TREATMENT", 33, 46], ["ciprofloxacin", "TREATMENT", 185, 198], ["rifaximin", "TREATMENT", 202, 211]]], ["61 Prophylactic administration of antibiotics for those traveling to developing countries is not typically recommended.", [["antibiotics", "TREATMENT", 34, 45]]], ["However, in one placebo-controlled trial performed on United States travelers in Mexico, subjects who took rifaximin prophylactically had significantly reduced rates of diarrhea (53.70% for those taking placebo vs 14.74% for those taking rifaximin).", [["rifaximin", "CHEMICAL", 107, 116], ["diarrhea", "DISEASE", 169, 177], ["rifaximin", "CHEMICAL", 238, 247], ["rifaximin", "CHEMICAL", 107, 116], ["rifaximin", "CHEMICAL", 238, 247], ["rifaximin", "SIMPLE_CHEMICAL", 107, 116], ["rifaximin", "SIMPLE_CHEMICAL", 238, 247], ["rifaximin", "TREATMENT", 107, 116], ["diarrhea", "PROBLEM", 169, 177], ["rifaximin", "TREATMENT", 238, 247]]], ["62 Nonetheless, C difficile and Helicobacter pylori must also be on the differential among the traveler afflicted with diarrhea.", [["Helicobacter pylori", "DISEASE", 32, 51], ["diarrhea", "DISEASE", 119, 127], ["C difficile", "ORGANISM", 16, 27], ["Helicobacter pylori", "ORGANISM", 32, 51], ["traveler", "ORGANISM", 95, 103], ["C difficile", "SPECIES", 16, 27], ["Helicobacter pylori", "SPECIES", 32, 51], ["C difficile", "SPECIES", 16, 27], ["Helicobacter pylori", "SPECIES", 32, 51], ["C difficile", "PROBLEM", 16, 27], ["Helicobacter pylori", "PROBLEM", 32, 51], ["diarrhea", "PROBLEM", 119, 127], ["difficile", "OBSERVATION", 18, 27], ["Helicobacter pylori", "OBSERVATION", 32, 51]]], ["Noninfectious origins need to be considered if there is no response to antimicrobials or antiparasitics and there is a protracted course.", [["Noninfectious origins", "PROBLEM", 0, 21], ["antimicrobials", "TREATMENT", 71, 85], ["antiparasitics", "TREATMENT", 89, 103], ["no", "UNCERTAINTY", 56, 58], ["protracted", "OBSERVATION_MODIFIER", 119, 129]]], ["Nonbacterial causes include enteric viruses, viral hepatitis, influenza, giardia, Cryptosporidium, Cyclospora, Entamoeba, Strongyloides, and other less common parasites.Differential DiagnosisCryptosporidiosis, which typically affects immunocompromised individuals (particularly HIV-infected persons) and may also affect immunocompetent persons (usually children younger than 5 years), causes diarrhea lasting 1 to 2 weeks, and may develop into life-threatening illnesses.", [["enteric viruses", "DISEASE", 28, 43], ["viral hepatitis", "DISEASE", 45, 60], ["influenza, giardia, Cryptosporidium, Cyclospora, Entamoeba, Strongyloides, and other less common parasites", "DISEASE", 62, 168], ["DiagnosisCryptosporidiosis", "DISEASE", 182, 208], ["HIV-infected", "DISEASE", 278, 290], ["diarrhea", "DISEASE", 392, 400], ["enteric viruses", "ORGANISM", 28, 43], ["persons", "ORGANISM", 291, 298], ["persons", "ORGANISM", 336, 343], ["children", "ORGANISM", 353, 361], ["HIV-", "SPECIES", 278, 282], ["persons", "SPECIES", 291, 298], ["persons", "SPECIES", 336, 343], ["children", "SPECIES", 353, 361], ["HIV", "SPECIES", 278, 281], ["Nonbacterial causes", "PROBLEM", 0, 19], ["enteric viruses", "PROBLEM", 28, 43], ["viral hepatitis", "PROBLEM", 45, 60], ["influenza", "PROBLEM", 62, 71], ["giardia", "PROBLEM", 73, 80], ["Cryptosporidium", "PROBLEM", 82, 97], ["Cyclospora", "PROBLEM", 99, 109], ["Entamoeba", "PROBLEM", 111, 120], ["Strongyloides", "PROBLEM", 122, 135], ["other less common parasites", "PROBLEM", 141, 168], ["Differential DiagnosisCryptosporidiosis", "PROBLEM", 169, 208], ["immunocompromised individuals", "PROBLEM", 234, 263], ["diarrhea", "PROBLEM", 392, 400], ["enteric viruses", "OBSERVATION", 28, 43], ["viral hepatitis", "OBSERVATION", 45, 60], ["Strongyloides", "OBSERVATION", 122, 135], ["less common", "OBSERVATION_MODIFIER", 147, 158], ["parasites", "OBSERVATION", 159, 168], ["DiagnosisCryptosporidiosis", "OBSERVATION", 182, 208]]], ["Although it appears that nitazoxanide (Alinia) reduces the load of parasites and may be useful in immunocompetent persons, a recent review found there is no evidence for effective agents in the management of cryptosporidiosis.", [["nitazoxanide", "CHEMICAL", 25, 37], ["Alinia", "CHEMICAL", 39, 45], ["cryptosporidiosis", "DISEASE", 208, 225], ["nitazoxanide", "CHEMICAL", 25, 37], ["Alinia", "CHEMICAL", 39, 45], ["nitazoxanide", "SIMPLE_CHEMICAL", 25, 37], ["Alinia", "SIMPLE_CHEMICAL", 39, 45], ["persons", "ORGANISM", 114, 121], ["persons", "SPECIES", 114, 121], ["nitazoxanide (Alinia", "TREATMENT", 25, 45], ["parasites", "PROBLEM", 67, 76], ["effective agents", "TREATMENT", 170, 186], ["the management", "TREATMENT", 190, 204], ["cryptosporidiosis", "PROBLEM", 208, 225], ["no evidence for", "UNCERTAINTY", 154, 169], ["cryptosporidiosis", "OBSERVATION", 208, 225]]], ["63Pediatric PatientsThe differential diagnosis for the pediatric patient with diarrhea is broad and includes pathogens such as E coli, Campylobacter, Shigella, Salmonella, and viruses.", [["diarrhea", "DISEASE", 78, 86], ["Patients", "ORGANISM", 12, 20], ["patient", "ORGANISM", 65, 72], ["E coli", "ORGANISM", 127, 133], ["Campylobacter, Shigella", "ORGANISM", 135, 158], ["Patients", "SPECIES", 12, 20], ["patient", "SPECIES", 65, 72], ["E coli", "SPECIES", 127, 133], ["E coli", "SPECIES", 127, 133], ["diarrhea", "PROBLEM", 78, 86], ["pathogens", "PROBLEM", 109, 118], ["E coli", "PROBLEM", 127, 133], ["Campylobacter", "PROBLEM", 135, 148], ["Shigella", "PROBLEM", 150, 158], ["Salmonella", "PROBLEM", 160, 170], ["viruses", "PROBLEM", 176, 183]]], ["However, in recent years a newer strain of E coli has emerged in the pediatric population: enteroaggregative E coli.", [["E coli", "ORGANISM", 43, 49], ["enteroaggregative E coli", "CELL", 91, 115], ["E coli", "SPECIES", 43, 49], ["E coli", "SPECIES", 109, 115], ["E coli", "SPECIES", 43, 49], ["E coli", "SPECIES", 109, 115], ["a newer strain of E coli", "PROBLEM", 25, 49], ["enteroaggregative E coli", "PROBLEM", 91, 115], ["enteroaggregative E coli", "OBSERVATION", 91, 115]]], ["In a study of 1327 children younger than 1 year with acute gastroenteritis, enteroaggregative E coli was isolated significantly more often in inpatients (4.7%) and ED patients (10.0%) than from well children (1.4%).", [["gastroenteritis", "DISEASE", 59, 74], ["children", "ORGANISM", 19, 27], ["E coli", "ORGANISM", 94, 100], ["patients", "ORGANISM", 167, 175], ["children", "ORGANISM", 199, 207], ["children", "SPECIES", 19, 27], ["E coli", "SPECIES", 94, 100], ["patients", "SPECIES", 167, 175], ["children", "SPECIES", 199, 207], ["E coli", "SPECIES", 94, 100], ["acute gastroenteritis", "PROBLEM", 53, 74], ["enteroaggregative E coli", "PROBLEM", 76, 100], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["gastroenteritis", "OBSERVATION", 59, 74], ["enteroaggregative", "OBSERVATION_MODIFIER", 76, 93], ["E coli", "OBSERVATION_MODIFIER", 94, 100]]], ["64 Viral gastroenteritis caused by rotaviruses is another concern in the pediatric population.", [["Viral gastroenteritis", "DISEASE", 3, 24], ["rotaviruses", "DISEASE", 35, 46], ["rotaviruses", "ORGANISM", 35, 46], ["Viral gastroenteritis", "PROBLEM", 3, 24], ["rotaviruses", "PROBLEM", 35, 46], ["Viral gastroenteritis", "OBSERVATION", 3, 24], ["rotaviruses", "OBSERVATION", 35, 46]]], ["Among middleand low-income countries, it is estimated rotaviruses are responsible for 600,000 to 870,000 pediatric deaths per year, resulting in up to 6% of all mortality in children younger than 5 years.", [["deaths", "DISEASE", 115, 121], ["rotaviruses", "ORGANISM", 54, 65], ["children", "ORGANISM", 174, 182], ["children", "SPECIES", 174, 182], ["estimated rotaviruses", "PROBLEM", 44, 65], ["rotaviruses", "OBSERVATION", 54, 65]]], ["65 The majority of these deaths were due to dehydration, underscoring the importance of rehydration therapies for children.", [["deaths", "DISEASE", 25, 31], ["dehydration", "DISEASE", 44, 55], ["children", "ORGANISM", 114, 122], ["children", "SPECIES", 114, 122], ["these deaths", "PROBLEM", 19, 31], ["dehydration", "PROBLEM", 44, 55], ["rehydration therapies", "TREATMENT", 88, 109], ["majority", "OBSERVATION_MODIFIER", 7, 15], ["deaths", "OBSERVATION", 25, 31], ["dehydration", "OBSERVATION", 44, 55]]], ["Implementation of the rotavirus vaccine shows promise.", [["rotavirus", "ORGANISM", 22, 31], ["rotavirus", "SPECIES", 22, 31], ["the rotavirus vaccine", "TREATMENT", 18, 39]]], ["A 2004 review of 64 trials conducted on 21,070 children found the vaccine's effectiveness at preventing diarrhea caused by rotavirus ranged from 22% to 89%.", [["diarrhea", "DISEASE", 104, 112], ["rotavirus", "DISEASE", 123, 132], ["children", "ORGANISM", 47, 55], ["rotavirus", "ORGANISM", 123, 132], ["children", "SPECIES", 47, 55], ["rotavirus", "SPECIES", 123, 132], ["the vaccine", "TREATMENT", 62, 73], ["diarrhea", "PROBLEM", 104, 112], ["rotavirus", "PROBLEM", 123, 132]]], ["66 Evaluation of hydration status often dictates the treatment of pediatric patients with diarrhea.", [["diarrhea", "DISEASE", 90, 98], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Evaluation of hydration status", "TEST", 3, 33], ["diarrhea", "PROBLEM", 90, 98]]], ["While acute appendicitis must always remain on the differential diagnosis of the child with diarrhea, digital rectal examinations and nasogastric tubes rarely provide additional actionable information for pediatric patients.", [["rectal", "ANATOMY", 110, 116], ["appendicitis", "DISEASE", 12, 24], ["diarrhea", "DISEASE", 92, 100], ["child", "ORGANISM", 81, 86], ["rectal", "ORGANISM_SUBDIVISION", 110, 116], ["nasogastric tubes", "MULTI-TISSUE_STRUCTURE", 134, 151], ["patients", "ORGANISM", 215, 223], ["child", "SPECIES", 81, 86], ["patients", "SPECIES", 215, 223], ["acute appendicitis", "PROBLEM", 6, 24], ["diarrhea", "PROBLEM", 92, 100], ["digital rectal examinations", "TEST", 102, 129], ["nasogastric tubes", "TREATMENT", 134, 151], ["acute", "OBSERVATION_MODIFIER", 6, 11], ["appendicitis", "OBSERVATION", 12, 24], ["diarrhea", "OBSERVATION", 92, 100], ["rectal", "ANATOMY", 110, 116], ["nasogastric tubes", "OBSERVATION", 134, 151]]], ["66 Treatment of the pediatric patient with diarrhea centers on supportive care, with encouragement of fluids for mild to moderate cases, and in severe cases intravenous or nasogastric fluid replacement.", [["intravenous", "ANATOMY", 157, 168], ["nasogastric", "ANATOMY", 172, 183], ["diarrhea", "DISEASE", 43, 51], ["patient", "ORGANISM", 30, 37], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 168], ["patient", "SPECIES", 30, 37], ["diarrhea", "PROBLEM", 43, 51], ["supportive care", "TREATMENT", 63, 78], ["fluids", "TREATMENT", 102, 108], ["mild to moderate cases", "PROBLEM", 113, 135], ["severe cases intravenous", "TREATMENT", 144, 168], ["nasogastric fluid replacement", "TREATMENT", 172, 201], ["nasogastric", "OBSERVATION", 172, 183], ["fluid replacement", "OBSERVATION", 184, 201]]], ["Educating parents in the appropriate treatment of their child's diarrhea is crucial.", [["diarrhea", "DISEASE", 64, 72], ["child", "ORGANISM", 56, 61], ["diarrhea", "PROBLEM", 64, 72]]], ["Whereas 52% of parents treated their child's diarrhea with appropriate rehydration fluids and solutions, 13% of parents used treatments not recommended in the current Centers for Disease Control (CDC) guidelines, typically using antidiarrheal agents and fluids high in simple sugars.", [["diarrhea", "DISEASE", 45, 53], ["sugars", "CHEMICAL", 276, 282], ["parents", "ORGANISM", 15, 22], ["antidiarrheal agents", "SIMPLE_CHEMICAL", 229, 249], ["child", "SPECIES", 37, 42], ["diarrhea", "PROBLEM", 45, 53], ["appropriate rehydration fluids", "TREATMENT", 59, 89], ["solutions", "TREATMENT", 94, 103], ["treatments", "TREATMENT", 125, 135], ["Disease Control (CDC) guidelines", "TREATMENT", 179, 211], ["antidiarrheal agents", "TREATMENT", 229, 249], ["fluids", "TREATMENT", 254, 260]]], ["67 Vomiting, Diarrhea, Constipation, Gastroenteritis Developed in 1975, the WHO standard oral rehydration solution consists of a high content of sodium (90 mmol/L) and has been found to be effective in the treatment of dehydration from acute gastroenteritis regardless of the etiology of the diarrhea.", [["oral", "ANATOMY", 89, 93], ["Vomiting", "DISEASE", 3, 11], ["Diarrhea", "DISEASE", 13, 21], ["Constipation", "DISEASE", 23, 35], ["Gastroenteritis", "DISEASE", 37, 52], ["sodium", "CHEMICAL", 145, 151], ["dehydration", "DISEASE", 219, 230], ["gastroenteritis", "DISEASE", 242, 257], ["diarrhea", "DISEASE", 292, 300], ["sodium", "CHEMICAL", 145, 151], ["oral", "ORGANISM_SUBDIVISION", 89, 93], ["sodium", "SIMPLE_CHEMICAL", 145, 151], ["Vomiting", "PROBLEM", 3, 11], ["Diarrhea", "PROBLEM", 13, 21], ["Constipation", "PROBLEM", 23, 35], ["Gastroenteritis", "PROBLEM", 37, 52], ["the WHO standard oral rehydration solution", "TREATMENT", 72, 114], ["sodium", "TREATMENT", 145, 151], ["dehydration", "PROBLEM", 219, 230], ["acute gastroenteritis", "PROBLEM", 236, 257], ["the diarrhea", "PROBLEM", 288, 300], ["Diarrhea", "OBSERVATION", 13, 21], ["Constipation", "OBSERVATION", 23, 35], ["Gastroenteritis", "OBSERVATION", 37, 52], ["effective", "OBSERVATION_MODIFIER", 189, 198], ["dehydration", "OBSERVATION", 219, 230], ["acute", "OBSERVATION_MODIFIER", 236, 241], ["gastroenteritis", "OBSERVATION", 242, 257], ["diarrhea", "OBSERVATION", 292, 300]]], ["68 Several newer products with lower sodium levels, including the WHO revised formula (75 mmol/L) and Pedialyte (45 mmol/L), may be better tolerated among pediatric patients.", [["sodium", "CHEMICAL", 37, 43], ["Pedialyte", "CHEMICAL", 102, 111], ["sodium", "CHEMICAL", 37, 43], ["Pedialyte", "CHEMICAL", 102, 111], ["sodium", "SIMPLE_CHEMICAL", 37, 43], ["Pedialyte", "SIMPLE_CHEMICAL", 102, 111], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["lower sodium levels", "PROBLEM", 31, 50], ["Pedialyte", "TREATMENT", 102, 111]]], ["However, these products may not be appropriate for patients suffering from diarrhea caused by cholera, one of the most serious types of diarrheal disease that can cause rapid electrolyte loss.", [["diarrhea", "DISEASE", 75, 83], ["cholera", "DISEASE", 94, 101], ["diarrheal disease", "DISEASE", 136, 153], ["electrolyte loss", "DISEASE", 175, 191], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["diarrhea", "PROBLEM", 75, 83], ["cholera", "PROBLEM", 94, 101], ["diarrheal disease", "PROBLEM", 136, 153], ["rapid electrolyte loss", "PROBLEM", 169, 191], ["may not be", "UNCERTAINTY", 24, 34], ["diarrhea", "OBSERVATION", 75, 83], ["most serious", "OBSERVATION_MODIFIER", 114, 126], ["diarrheal disease", "OBSERVATION", 136, 153], ["rapid", "OBSERVATION_MODIFIER", 169, 174], ["electrolyte loss", "OBSERVATION", 175, 191]]], ["In an analysis of 7 trials of patients with cholera, the investigators found an increased number of patients with hyponatremia treated with hypoosmolar solutions compared with standard oral rehydration solutions, although the outcomes were similar.", [["oral", "ANATOMY", 185, 189], ["cholera", "DISEASE", 44, 51], ["hyponatremia", "DISEASE", 114, 126], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 100, 108], ["oral", "ORGANISM_SUBDIVISION", 185, 189], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 100, 108], ["an analysis", "TEST", 3, 14], ["cholera", "TREATMENT", 44, 51], ["hyponatremia", "PROBLEM", 114, 126], ["hypoosmolar solutions", "TREATMENT", 140, 161], ["standard oral rehydration solutions", "TREATMENT", 176, 211], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["number", "OBSERVATION_MODIFIER", 90, 96], ["hyponatremia", "OBSERVATION", 114, 126]]], ["69Elderly PatientsElderly patients afflicted with diarrhea tend to have longer hospital stays (7.4 days in patients older than 75 years versus 4.1 days in those patients 20 to 49 years old) and a higher mortality.", [["diarrhea", "DISEASE", 50, 58], ["Patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 161, 169], ["Patients", "SPECIES", 10, 18], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 161, 169], ["diarrhea", "PROBLEM", 50, 58], ["a higher mortality", "PROBLEM", 194, 212]]], ["70 Age greater than 65 years is also considered an independent C difficile risk factor.", [["C difficile", "ORGANISM", 63, 74], ["C difficile risk factor", "PROTEIN", 63, 86], ["C difficile", "SPECIES", 63, 74], ["C difficile", "SPECIES", 63, 74], ["an independent C difficile risk factor", "PROBLEM", 48, 86]]], ["71 In one ED-based study of 174 patients with diarrhea, it was found that age greater than 40 years with constant abdominal pain and diarrhea was predictive of a surgical etiology for their symptoms.", [["abdominal", "ANATOMY", 114, 123], ["diarrhea", "DISEASE", 46, 54], ["abdominal pain", "DISEASE", 114, 128], ["diarrhea", "DISEASE", 133, 141], ["patients", "ORGANISM", 32, 40], ["abdominal", "ORGANISM_SUBDIVISION", 114, 123], ["patients", "SPECIES", 32, 40], ["diarrhea", "PROBLEM", 46, 54], ["constant abdominal pain", "PROBLEM", 105, 128], ["diarrhea", "PROBLEM", 133, 141], ["their symptoms", "PROBLEM", 184, 198], ["abdominal", "ANATOMY", 114, 123], ["pain", "OBSERVATION", 124, 128], ["diarrhea", "OBSERVATION", 133, 141]]], ["72 Taken together, these factors should prompt the clinician to at times take a more aggressive and perhaps more comprehensive approach in attempting to search for the origin of diarrhea in the elderly patient.TreatmentRehydration and electrolyte replacement remain cornerstones of treatment for patients with diarrhea.", [["diarrhea", "DISEASE", 178, 186], ["diarrhea", "DISEASE", 310, 318], ["patient", "ORGANISM", 202, 209], ["patients", "ORGANISM", 296, 304], ["patient", "SPECIES", 202, 209], ["patients", "SPECIES", 296, 304], ["diarrhea", "PROBLEM", 178, 186], ["TreatmentRehydration", "TREATMENT", 210, 230], ["electrolyte replacement", "TREATMENT", 235, 258], ["treatment", "TREATMENT", 282, 291], ["diarrhea", "PROBLEM", 310, 318], ["diarrhea", "OBSERVATION", 178, 186]]], ["To accomplish this, the \"BRAT\" diet (bananas, rice, apple sauce, and toast) is often recommended, although evidence supporting its practice is limited.", [["bananas, rice, apple sauce", "CHEMICAL", 37, 63], ["bananas", "ORGANISM_SUBDIVISION", 37, 44], ["rice", "ORGANISM_SUBDIVISION", 46, 50], ["apple", "ORGANISM", 52, 57], ["sauce", "ORGANISM_SUBDIVISION", 58, 63], ["rice", "SPECIES", 46, 50], ["apple", "SPECIES", 52, 57], ["sauce", "SPECIES", 58, 63], ["bananas", "SPECIES", 37, 44], ["rice", "SPECIES", 46, 50], ["apple", "SPECIES", 52, 57], ["the \"BRAT\" diet (bananas, rice, apple sauce", "TREATMENT", 20, 63]]], ["Loperamide (Imodium) has been shown to be efficacious in reducing the symptoms of diarrhea in undifferentiated patients with mild symptoms 73 ; however, there is scant evidence regarding its safety profile in patients with moderate or severe diarrhea.", [["Loperamide", "CHEMICAL", 0, 10], ["Imodium", "CHEMICAL", 12, 19], ["diarrhea", "DISEASE", 82, 90], ["diarrhea", "DISEASE", 242, 250], ["Loperamide", "CHEMICAL", 0, 10], ["Imodium", "CHEMICAL", 12, 19], ["Loperamide", "SIMPLE_CHEMICAL", 0, 10], ["Imodium", "SIMPLE_CHEMICAL", 12, 19], ["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 209, 217], ["Loperamide (Imodium)", "TREATMENT", 0, 20], ["the symptoms", "PROBLEM", 66, 78], ["diarrhea", "PROBLEM", 82, 90], ["mild symptoms", "PROBLEM", 125, 138], ["moderate or severe diarrhea", "PROBLEM", 223, 250], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["moderate", "OBSERVATION_MODIFIER", 223, 231], ["severe", "OBSERVATION_MODIFIER", 235, 241], ["diarrhea", "OBSERVATION", 242, 250]]], ["74 A recent review did not find conclusive evidence supporting or refuting the usage of antimotility agents and adsorbents in controlling diarrhea in people with HIV/ AIDS, 75 thus reinforcing the need for adjunct treatments such as fluid replacement.", [["fluid", "ANATOMY", 233, 238], ["diarrhea", "DISEASE", 138, 146], ["HIV/ AIDS", "DISEASE", 162, 171], ["people", "ORGANISM", 150, 156], ["people", "SPECIES", 150, 156], ["HIV", "SPECIES", 162, 165], ["HIV", "SPECIES", 162, 165], ["antimotility agents", "TREATMENT", 88, 107], ["adsorbents", "TREATMENT", 112, 122], ["diarrhea", "PROBLEM", 138, 146], ["HIV/ AIDS", "PROBLEM", 162, 171], ["adjunct treatments", "TREATMENT", 206, 224], ["fluid replacement", "TREATMENT", 233, 250], ["fluid replacement", "OBSERVATION", 233, 250]]], ["Nevertheless, one meta-analysis found that when combined with antibiotic therapy, loperamide was more efficacious than antibiotics alone in decreasing illness duration for adult patients with traveler's diarrhea.", [["loperamide", "CHEMICAL", 82, 92], ["illness", "DISEASE", 151, 158], ["diarrhea", "DISEASE", 203, 211], ["loperamide", "CHEMICAL", 82, 92], ["loperamide", "SIMPLE_CHEMICAL", 82, 92], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["antibiotic therapy", "TREATMENT", 62, 80], ["loperamide", "TREATMENT", 82, 92], ["antibiotics", "TREATMENT", 119, 130], ["traveler's diarrhea", "PROBLEM", 192, 211]]], ["76 Antidiarrheal agents are not recommended in the treatment of pediatric patients with diarrhea, as they have potentially serious side effects in this population.", [["diarrhea", "DISEASE", 88, 96], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Antidiarrheal agents", "TREATMENT", 3, 23], ["diarrhea", "PROBLEM", 88, 96]]], ["77 Antibiotics are the mainstay of treatment for patients with a suspected bacterial cause for their diarrheal symptoms.", [["diarrheal symptoms", "DISEASE", 101, 119], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Antibiotics", "TREATMENT", 3, 14], ["treatment", "TREATMENT", 35, 44], ["a suspected bacterial cause", "PROBLEM", 63, 90], ["their diarrheal symptoms", "PROBLEM", 95, 119]]], ["A study of 139 patients presenting with severe diarrhea characterized by one of either profuse watery diarrhea with dehydration, passage of stools containing mucus and blood, temperature greater than 38.4 C, passage of more than 6 soft stools in 24 hours, duration of illness of more than 48 hours, severe abdominal pain in a patient older than 50, or diarrhea in the elderly, found single-dose quinolone therapy shortened the duration of symptoms and was equally efficacious when compared with a 5-day antibiotic regimen.", [["mucus", "ANATOMY", 158, 163], ["blood", "ANATOMY", 168, 173], ["abdominal", "ANATOMY", 306, 315], ["diarrhea", "DISEASE", 47, 55], ["watery diarrhea", "DISEASE", 95, 110], ["dehydration", "DISEASE", 116, 127], ["soft stools", "DISEASE", 231, 242], ["illness", "DISEASE", 268, 275], ["abdominal pain", "DISEASE", 306, 320], ["diarrhea", "DISEASE", 352, 360], ["quinolone", "CHEMICAL", 395, 404], ["quinolone", "CHEMICAL", 395, 404], ["patients", "ORGANISM", 15, 23], ["mucus", "ORGANISM_SUBSTANCE", 158, 163], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["abdominal", "ORGANISM_SUBDIVISION", 306, 315], ["patient", "ORGANISM", 326, 333], ["quinolone", "SIMPLE_CHEMICAL", 395, 404], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 326, 333], ["A study", "TEST", 0, 7], ["severe diarrhea", "PROBLEM", 40, 55], ["profuse watery diarrhea", "PROBLEM", 87, 110], ["dehydration", "PROBLEM", 116, 127], ["passage of stools containing mucus and blood", "PROBLEM", 129, 173], ["temperature", "TEST", 175, 186], ["6 soft stools", "PROBLEM", 229, 242], ["illness", "PROBLEM", 268, 275], ["severe abdominal pain", "PROBLEM", 299, 320], ["diarrhea", "PROBLEM", 352, 360], ["single-dose quinolone therapy", "TREATMENT", 383, 412], ["symptoms", "PROBLEM", 439, 447], ["a 5-day antibiotic regimen", "TREATMENT", 495, 521], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["diarrhea", "OBSERVATION", 47, 55], ["severe", "OBSERVATION_MODIFIER", 299, 305], ["abdominal", "ANATOMY", 306, 315], ["pain", "OBSERVATION", 316, 320]]], ["78 Probiotics, which are found in yogurts, fermented milks, and dietary supplements, may help treat diarrheal diseases.", [["yogurts", "ANATOMY", 34, 41], ["milks", "ANATOMY", 53, 58], ["diarrheal diseases", "DISEASE", 100, 118], ["milks", "ORGANISM_SUBDIVISION", 53, 58], ["Probiotics", "TREATMENT", 3, 13], ["dietary supplements", "TREATMENT", 64, 83], ["diarrheal diseases", "PROBLEM", 100, 118]]], ["In one randomized, double-blind, placebocontrolled study, consumption of a 100-g drink containing Lactobacillus casei, Lactobacillus bulgaricus, and Streptococcus thermophilus twice daily during a course of antibiotics and 1 week after the antibiotic was finished resulted in an absolute risk reduction of 21.6% for the occurrence of antibiotic-associated diarrhea.", [["Lactobacillus casei", "CHEMICAL", 98, 117], ["Lactobacillus bulgaricus", "CHEMICAL", 119, 143], ["diarrhea", "DISEASE", 356, 364], ["Lactobacillus casei", "ORGANISM", 98, 117], ["Lactobacillus bulgaricus", "ORGANISM", 119, 143], ["Streptococcus thermophilus", "ORGANISM", 149, 175], ["Lactobacillus casei", "SPECIES", 98, 117], ["Lactobacillus bulgaricus", "SPECIES", 119, 143], ["Streptococcus thermophilus", "SPECIES", 149, 175], ["Lactobacillus casei", "SPECIES", 98, 117], ["Lactobacillus bulgaricus", "SPECIES", 119, 143], ["Streptococcus thermophilus", "SPECIES", 149, 175], ["Lactobacillus casei", "TREATMENT", 98, 117], ["Lactobacillus bulgaricus", "TREATMENT", 119, 143], ["Streptococcus thermophilus", "TREATMENT", 149, 175], ["antibiotics", "TREATMENT", 207, 218], ["the antibiotic", "TREATMENT", 236, 250], ["an absolute risk reduction", "TREATMENT", 276, 302], ["antibiotic", "TREATMENT", 334, 344], ["associated diarrhea", "PROBLEM", 345, 364], ["diarrhea", "OBSERVATION", 356, 364]]], ["79 Another study noted probiotic organisms may be beneficial for 3 problems common in the elderly: undernutrition, constipation, and the capacity to resist infection.", [["undernutrition", "DISEASE", 99, 113], ["constipation", "DISEASE", 115, 127], ["infection", "DISEASE", 156, 165], ["Another study", "TEST", 3, 16], ["probiotic organisms", "PROBLEM", 23, 42], ["3 problems", "PROBLEM", 65, 75], ["undernutrition", "PROBLEM", 99, 113], ["constipation", "PROBLEM", 115, 127], ["the capacity", "PROBLEM", 133, 145], ["resist infection", "PROBLEM", 149, 165], ["undernutrition", "OBSERVATION", 99, 113], ["constipation", "OBSERVATION", 115, 127], ["infection", "OBSERVATION", 156, 165]]], ["80 A systematic review of the literature on probiotics, which examined 23 studies with 1917 participants, found probiotics reduced the risk of diarrhea at 3 days and the mean duration of diarrhea by 30 hours.", [["diarrhea", "DISEASE", 143, 151], ["diarrhea", "DISEASE", 187, 195], ["participants", "SPECIES", 92, 104], ["probiotics", "TREATMENT", 44, 54], ["diarrhea", "PROBLEM", 143, 151], ["diarrhea", "PROBLEM", 187, 195], ["diarrhea", "OBSERVATION", 143, 151]]], ["81 Prevention Most preventive measures aimed at limiting the spread of diarrheal diseases focus on improving the quality of available water sources.", [["diarrheal diseases", "DISEASE", 71, 89], ["preventive measures", "TREATMENT", 19, 38], ["diarrheal diseases", "PROBLEM", 71, 89]]], ["Two studies found the addition of household-based water filters reduced the prevalence of diarrhea by 60% in Columbia 82 and by 70% in rural Bolivia.", [["diarrhea", "DISEASE", 90, 98], ["Two studies", "TEST", 0, 11], ["household-based water filters", "TREATMENT", 34, 63], ["diarrhea", "PROBLEM", 90, 98]]], ["83 Further, one study found treating turbid water in rural Kenya with a disinfectant resulted in a 19% absolute reduction in the prevalence of diarrhea.", [["diarrhea", "DISEASE", 143, 151], ["one study", "TEST", 12, 21], ["a disinfectant", "TREATMENT", 70, 84], ["a 19% absolute reduction", "TREATMENT", 97, 121], ["diarrhea", "PROBLEM", 143, 151], ["diarrhea", "OBSERVATION", 143, 151]]], ["84 Communicable and diarrheal diseases are also major concerns for disaster-affected populations in camp settings.", [["diarrheal diseases", "DISEASE", 20, 38], ["diarrheal diseases", "PROBLEM", 20, 38], ["camp settings", "TREATMENT", 100, 113]]], ["In treated households in Liberia, disinfectants reduced diarrheal prevalence by 83% compared with control households.", [["diarrheal", "DISEASE", 56, 65]]], ["85 Other developing countries have instituted hand-washing campaigns.", [["hand", "ANATOMY", 46, 50]]], ["One, in urban squatter settlements in Pakistan, found campaigns promoting handwashing reduced the incidence of diarrhea by 53% among children younger than 15 years.", [["diarrhea", "DISEASE", 111, 119], ["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141], ["diarrhea", "PROBLEM", 111, 119]]], ["86 A recent review, which examined 33 trials with more than 53,000 participants, found that interventions focused on improving the quality of drinking water were effective in preventing diarrhea, with interventions aimed at the household level more effective than those aimed at the source.", [["diarrhea", "DISEASE", 186, 194], ["participants", "SPECIES", 67, 79], ["A recent review", "TEST", 3, 18], ["interventions", "TREATMENT", 92, 105], ["diarrhea", "PROBLEM", 186, 194], ["interventions", "TREATMENT", 201, 214]]], ["87CONSTIPATIONConstipation is the most common digestive complaint in the United States, affecting up to 27% of the North American population.", [["digestive", "ANATOMY", 46, 55], ["digestive", "ORGAN", 46, 55]]], ["Although constipation tends to be associated with increasing age, 88 children also may experience this problem.", [["constipation", "DISEASE", 9, 21], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["constipation", "PROBLEM", 9, 21], ["this problem", "PROBLEM", 98, 110]]], ["One review of 4157 children younger than 2 years found the prevalence of constipation was 2.9% in the first year of life and 10.1% in the second year of life.", [["constipation", "DISEASE", 73, 85], ["children", "ORGANISM", 19, 27], ["children", "SPECIES", 19, 27], ["constipation", "PROBLEM", 73, 85], ["constipation", "OBSERVATION", 73, 85]]], ["While the majority of these cases were diagnosed as functional constipation, in 1.6% of cases underlying disease was responsible.", [["functional constipation", "DISEASE", 52, 75], ["functional constipation", "PROBLEM", 52, 75], ["underlying disease", "PROBLEM", 94, 112], ["disease", "OBSERVATION", 105, 112]]], ["89 Constipation is also the most common cause of acute abdominal pain in children.", [["abdominal", "ANATOMY", 55, 64], ["Constipation", "DISEASE", 3, 15], ["abdominal pain", "DISEASE", 55, 69], ["abdominal", "ORGANISM_SUBDIVISION", 55, 64], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["Constipation", "PROBLEM", 3, 15], ["acute abdominal pain", "PROBLEM", 49, 69], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["abdominal", "ANATOMY", 55, 64], ["pain", "OBSERVATION", 65, 69]]], ["A study of 962 children seen in a pediatric office found 9% had a complaint of abdominal pain; chronic constipation was diagnosed in 35% of those patients and acute constipation was diagnosed in 13%.", [["abdominal", "ANATOMY", 79, 88], ["abdominal pain", "DISEASE", 79, 93], ["chronic constipation", "DISEASE", 95, 115], ["constipation", "DISEASE", 165, 177], ["children", "ORGANISM", 15, 23], ["abdominal", "ORGANISM_SUBDIVISION", 79, 88], ["patients", "ORGANISM", 146, 154], ["children", "SPECIES", 15, 23], ["patients", "SPECIES", 146, 154], ["A study", "TEST", 0, 7], ["abdominal pain", "PROBLEM", 79, 93], ["chronic constipation", "PROBLEM", 95, 115], ["acute constipation", "PROBLEM", 159, 177], ["abdominal", "ANATOMY", 79, 88], ["pain", "OBSERVATION", 89, 93], ["chronic", "OBSERVATION_MODIFIER", 95, 102], ["constipation", "OBSERVATION", 103, 115], ["acute", "OBSERVATION_MODIFIER", 159, 164], ["constipation", "OBSERVATION", 165, 177]]], ["A surgical condition was found in only 2% of the children with abdominal pain.", [["abdominal", "ANATOMY", 63, 72], ["abdominal pain", "DISEASE", 63, 77], ["children", "ORGANISM", 49, 57], ["abdominal", "ORGANISM_SUBDIVISION", 63, 72], ["children", "SPECIES", 49, 57], ["A surgical condition", "PROBLEM", 0, 20], ["abdominal pain", "PROBLEM", 63, 77], ["surgical", "OBSERVATION", 2, 10], ["abdominal", "ANATOMY", 63, 72], ["pain", "OBSERVATION", 73, 77]]], ["90 Furthermore, pregnant women are also disproportionately afflicted with constipation, with 25% of healthy women experiencing symptoms during their pregnancy and up to 3 months postpartum.", [["constipation", "DISEASE", 74, 86], ["women", "ORGANISM", 25, 30], ["women", "ORGANISM", 108, 113], ["women", "SPECIES", 25, 30], ["women", "SPECIES", 108, 113], ["constipation", "PROBLEM", 74, 86], ["symptoms", "PROBLEM", 127, 135]]], ["91EtiologyThe cause of constipation is often multifactorial.", [["91Etiology", "CHEMICAL", 0, 10], ["constipation", "DISEASE", 23, 35], ["constipation", "PROBLEM", 23, 35], ["constipation", "OBSERVATION", 23, 35]]], ["While a 2007 review revealed a small number of publications addressing the etiologic factors of this very common problem, 92 it was suggested that insufficient dietary fiber intake, inadequate fluid intake, decreased physical activity, side effects of drugs, hypothyroidism, sex hormones, and colorectal cancer obstruction may be responsible for constipation.", [["fluid", "ANATOMY", 193, 198], ["colorectal cancer", "ANATOMY", 293, 310], ["hypothyroidism", "DISEASE", 259, 273], ["colorectal cancer obstruction", "DISEASE", 293, 322], ["constipation", "DISEASE", 346, 358], ["fluid", "ORGANISM_SUBSTANCE", 193, 198], ["colorectal cancer", "CANCER", 293, 310], ["a small number of publications", "PROBLEM", 29, 59], ["inadequate fluid intake", "PROBLEM", 182, 205], ["decreased physical activity", "PROBLEM", 207, 234], ["drugs", "TREATMENT", 252, 257], ["hypothyroidism", "PROBLEM", 259, 273], ["sex hormones", "PROBLEM", 275, 287], ["colorectal cancer obstruction", "PROBLEM", 293, 322], ["constipation", "PROBLEM", 346, 358], ["small", "OBSERVATION_MODIFIER", 31, 36], ["number", "OBSERVATION_MODIFIER", 37, 43], ["hypothyroidism", "OBSERVATION", 259, 273], ["colorectal", "ANATOMY", 293, 303], ["cancer", "OBSERVATION", 304, 310]]], ["92 Furthermore, the cause of constipation may also be related to abnormal bowel motility, anatomical rectal disorders, neurological disorders, or psychosocial issues ( Table 3) .", [["bowel", "ANATOMY", 74, 79], ["rectal", "ANATOMY", 101, 107], ["neurological", "ANATOMY", 119, 131], ["constipation", "DISEASE", 29, 41], ["abnormal bowel motility", "DISEASE", 65, 88], ["rectal disorders", "DISEASE", 101, 117], ["neurological disorders", "DISEASE", 119, 141], ["bowel", "ORGAN", 74, 79], ["rectal", "MULTI-TISSUE_STRUCTURE", 101, 107], ["constipation", "PROBLEM", 29, 41], ["abnormal bowel motility", "PROBLEM", 65, 88], ["anatomical rectal disorders", "PROBLEM", 90, 117], ["neurological disorders", "PROBLEM", 119, 141], ["psychosocial issues", "PROBLEM", 146, 165], ["constipation", "OBSERVATION", 29, 41], ["may also be related to", "UNCERTAINTY", 42, 64], ["abnormal", "OBSERVATION_MODIFIER", 65, 73], ["bowel", "ANATOMY", 74, 79], ["motility", "OBSERVATION", 80, 88], ["rectal", "ANATOMY", 101, 107]]], ["A thorough review of the patient's medications is advisable, as there are many different medications that secondarily contribute to constipation, such as calcium and iron supplements, opioids, anticonvulsants, antipsychotics, and Vomiting, Diarrhea, Constipation, Gastroenteritis antihistamines.", [["constipation", "DISEASE", 132, 144], ["calcium", "CHEMICAL", 154, 161], ["iron", "CHEMICAL", 166, 170], ["Vomiting", "DISEASE", 230, 238], ["Diarrhea", "DISEASE", 240, 248], ["Constipation", "DISEASE", 250, 262], ["Gastroenteritis", "DISEASE", 264, 279], ["calcium", "CHEMICAL", 154, 161], ["iron", "CHEMICAL", 166, 170], ["patient", "ORGANISM", 25, 32], ["calcium", "SIMPLE_CHEMICAL", 154, 161], ["iron", "SIMPLE_CHEMICAL", 166, 170], ["opioids", "SIMPLE_CHEMICAL", 184, 191], ["patient", "SPECIES", 25, 32], ["the patient's medications", "TREATMENT", 21, 46], ["many different medications", "TREATMENT", 74, 100], ["constipation", "PROBLEM", 132, 144], ["calcium and iron supplements", "TREATMENT", 154, 182], ["opioids", "TREATMENT", 184, 191], ["anticonvulsants", "TREATMENT", 193, 208], ["antipsychotics", "TREATMENT", 210, 224], ["Vomiting", "PROBLEM", 230, 238], ["Diarrhea", "PROBLEM", 240, 248], ["Constipation", "PROBLEM", 250, 262], ["Gastroenteritis", "PROBLEM", 264, 279], ["antihistamines", "TREATMENT", 280, 294], ["constipation", "OBSERVATION", 132, 144]]], ["88 Constipation resistant to simple measures may be caused by painful anorectal conditions, irritable bowel syndrome (IBS), slow transit constipation, or obstructive defecation.", [["anorectal", "ANATOMY", 70, 79], ["bowel", "ANATOMY", 102, 107], ["Constipation", "DISEASE", 3, 15], ["irritable bowel syndrome", "DISEASE", 92, 116], ["IBS", "DISEASE", 118, 121], ["constipation", "DISEASE", 137, 149], ["obstructive defecation", "DISEASE", 154, 176], ["bowel", "ORGAN", 102, 107], ["Constipation", "PROBLEM", 3, 15], ["simple measures", "TREATMENT", 29, 44], ["painful anorectal conditions", "PROBLEM", 62, 90], ["irritable bowel syndrome", "PROBLEM", 92, 116], ["IBS", "PROBLEM", 118, 121], ["slow transit constipation", "PROBLEM", 124, 149], ["obstructive defecation", "PROBLEM", 154, 176], ["may be caused", "UNCERTAINTY", 45, 58], ["bowel", "ANATOMY", 102, 107], ["obstructive defecation", "OBSERVATION", 154, 176]]], ["Obstructed defecation is a broad term used to describe the inability to empty stool from the rectum, which may result from functional, metabolic, mechanical, or anatomical problems.", [["stool", "ANATOMY", 78, 83], ["rectum", "ANATOMY", 93, 99], ["Obstructed defecation", "DISEASE", 0, 21], ["stool", "ORGANISM_SUBSTANCE", 78, 83], ["rectum", "ORGAN", 93, 99], ["Obstructed defecation", "PROBLEM", 0, 21], ["a broad term", "PROBLEM", 25, 37], ["the inability to empty stool from the rectum", "PROBLEM", 55, 99], ["functional, metabolic, mechanical, or anatomical problems", "PROBLEM", 123, 180], ["defecation", "OBSERVATION", 11, 21], ["rectum", "ANATOMY", 93, 99]]], ["93 Mechanical and anatomical disorders causing obstructive defecation include Hirschsprung disease, rectocele, rectoanal intussusception, enterocele, sigmoidocele, and rectal prolapse.", [["rectoanal", "ANATOMY", 111, 120], ["enterocele", "ANATOMY", 138, 148], ["sigmoidocele", "ANATOMY", 150, 162], ["rectal", "ANATOMY", 168, 174], ["obstructive defecation", "DISEASE", 47, 69], ["Hirschsprung disease", "DISEASE", 78, 98], ["rectocele", "DISEASE", 100, 109], ["rectoanal intussusception", "DISEASE", 111, 136], ["enterocele", "DISEASE", 138, 148], ["sigmoidocele", "DISEASE", 150, 162], ["rectal prolapse", "DISEASE", 168, 183], ["rectal", "ORGAN", 168, 174], ["Mechanical and anatomical disorders", "PROBLEM", 3, 38], ["obstructive defecation", "PROBLEM", 47, 69], ["Hirschsprung disease", "PROBLEM", 78, 98], ["rectocele", "PROBLEM", 100, 109], ["rectoanal intussusception", "PROBLEM", 111, 136], ["enterocele", "PROBLEM", 138, 148], ["sigmoidocele", "PROBLEM", 150, 162], ["rectal prolapse", "PROBLEM", 168, 183], ["obstructive", "OBSERVATION_MODIFIER", 47, 58], ["Hirschsprung disease", "OBSERVATION", 78, 98], ["rectocele", "OBSERVATION", 100, 109], ["rectoanal", "ANATOMY", 111, 120], ["intussusception", "OBSERVATION", 121, 136], ["enterocele", "OBSERVATION", 138, 148], ["sigmoidocele", "ANATOMY", 150, 162], ["rectal", "ANATOMY", 168, 174], ["prolapse", "OBSERVATION", 175, 183]]], ["94 Studies have found that obstructive defecation is a significant problem for middle-aged women.", [["obstructive defecation", "DISEASE", 27, 49], ["women", "ORGANISM", 91, 96], ["women", "SPECIES", 91, 96], ["obstructive defecation", "PROBLEM", 27, 49], ["obstructive", "OBSERVATION_MODIFIER", 27, 38], ["defecation", "OBSERVATION", 39, 49], ["significant", "OBSERVATION_MODIFIER", 55, 66]]], ["Obstructive defecation was self-reported and defined by difficulty in passing stool, hard stool, straining for more than 15 minutes, or incomplete evacuation, occurring at least weekly.", [["stool", "ANATOMY", 78, 83], ["Obstructive defecation", "DISEASE", 0, 22], ["stool", "ORGANISM_SUBSTANCE", 78, 83], ["Obstructive defecation", "PROBLEM", 0, 22], ["difficulty in passing stool", "PROBLEM", 56, 83], ["hard stool", "PROBLEM", 85, 95], ["straining", "PROBLEM", 97, 106], ["incomplete evacuation", "PROBLEM", 136, 157], ["defecation", "OBSERVATION", 12, 22], ["evacuation", "OBSERVATION", 147, 157]]], ["In this study of 2109 subjects, 12.3% of women reported obstructive defecation at least once weekly.", [["obstructive defecation", "DISEASE", 56, 78], ["women", "ORGANISM", 41, 46], ["women", "SPECIES", 41, 46], ["this study", "TEST", 3, 13], ["women reported obstructive defecation", "PROBLEM", 41, 78], ["obstructive", "OBSERVATION_MODIFIER", 56, 67], ["defecation", "OBSERVATION", 68, 78]]], ["Risk factors correlated with patients developing obstructive defecation included a history of IBS, vaginal or laparoscopic hysterectomy, unemployment, use of 3 or more medications, symptomatic pelvic organ prolapse, history of urinary incontinence surgery, or other pelvic surgeries.", [["vaginal", "ANATOMY", 99, 106], ["pelvic organ", "ANATOMY", 193, 205], ["urinary", "ANATOMY", 227, 234], ["pelvic", "ANATOMY", 266, 272], ["obstructive defecation", "DISEASE", 49, 71], ["IBS", "DISEASE", 94, 97], ["pelvic organ prolapse", "DISEASE", 193, 214], ["urinary incontinence", "DISEASE", 227, 247], ["patients", "ORGANISM", 29, 37], ["organ", "ORGAN", 200, 205], ["urinary", "ORGANISM_SUBDIVISION", 227, 234], ["pelvic", "ORGAN", 266, 272], ["patients", "SPECIES", 29, 37], ["Risk factors", "PROBLEM", 0, 12], ["patients developing obstructive defecation", "PROBLEM", 29, 71], ["IBS", "PROBLEM", 94, 97], ["vaginal", "TREATMENT", 99, 106], ["laparoscopic hysterectomy", "TREATMENT", 110, 135], ["medications", "TREATMENT", 168, 179], ["symptomatic pelvic organ prolapse", "PROBLEM", 181, 214], ["urinary incontinence surgery", "TREATMENT", 227, 255], ["other pelvic surgeries", "TREATMENT", 260, 282], ["obstructive defecation", "OBSERVATION", 49, 71], ["vaginal", "ANATOMY", 99, 106], ["laparoscopic", "OBSERVATION_MODIFIER", 110, 122], ["hysterectomy", "OBSERVATION", 123, 135], ["pelvic organ", "ANATOMY", 193, 205], ["prolapse", "OBSERVATION", 206, 214], ["urinary", "ANATOMY", 227, 234], ["incontinence", "OBSERVATION", 235, 247], ["pelvic", "ANATOMY", 266, 272], ["surgeries", "OBSERVATION", 273, 282]]], ["95 IBS, characterized by chronic abdominal pain and altered bowel habits without a clearly defined organic cause, 96 affects 10% to 15% of North Americans.", [["abdominal", "ANATOMY", 33, 42], ["bowel", "ANATOMY", 60, 65], ["IBS", "DISEASE", 3, 6], ["chronic abdominal pain", "DISEASE", 25, 47], ["abdominal", "ORGANISM_SUBDIVISION", 33, 42], ["bowel", "ORGAN", 60, 65], ["IBS", "PROBLEM", 3, 6], ["chronic abdominal pain", "PROBLEM", 25, 47], ["altered bowel habits", "PROBLEM", 52, 72], ["a clearly defined organic cause", "PROBLEM", 81, 112], ["IBS", "OBSERVATION", 3, 6], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["abdominal", "ANATOMY", 33, 42], ["pain", "OBSERVATION", 43, 47], ["bowel", "ANATOMY", 60, 65], ["organic cause", "OBSERVATION", 99, 112]]], ["97, 98 Attempts to standardize the diagnosis of IBS have been made, and the American Gastroenterology Association recommends clinicians use the Rome III criteria, last revised in 2005, to diagnose IBS.", [["IBS", "DISEASE", 48, 51], ["IBS", "DISEASE", 197, 200], ["IBS", "PROBLEM", 48, 51], ["IBS", "PROBLEM", 197, 200], ["IBS", "OBSERVATION", 48, 51]]], ["99 These criteria require the presence of recurrent abdominal pain or discomfort at least 3 days per month as well as 2 or more of the following: improvement with defecation, onset associated with a change in form of stool, or onset associated with a change in frequency of stool.", [["abdominal", "ANATOMY", 52, 61], ["abdominal pain", "DISEASE", 52, 66], ["defecation", "DISEASE", 163, 173], ["abdominal", "ORGANISM_SUBDIVISION", 52, 61], ["stool", "ORGANISM_SUBSTANCE", 274, 279], ["recurrent abdominal pain", "PROBLEM", 42, 66], ["discomfort", "PROBLEM", 70, 80], ["defecation", "PROBLEM", 163, 173], ["a change in form of stool", "PROBLEM", 197, 222], ["a change in frequency of stool", "PROBLEM", 249, 279], ["recurrent", "OBSERVATION_MODIFIER", 42, 51], ["abdominal", "ANATOMY", 52, 61], ["pain", "OBSERVATION", 62, 66], ["stool", "OBSERVATION", 217, 222], ["stool", "OBSERVATION", 274, 279]]], ["The Rome III diagnostic criteria for IBS must be fulfilled for 3 consecutive months with symptom onset at least 6 months before diagnosis.", [["IBS", "DISEASE", 37, 40], ["IBS", "PROBLEM", 37, 40]]], ["100 Other symptoms that are not part of the Rome criteria but support the diagnosis of IBS include defecation straining, urgency, a feeling of incomplete bowel movement, passing mucus, and bloating.", [["bowel", "ANATOMY", 154, 159], ["mucus", "ANATOMY", 178, 183], ["IBS", "DISEASE", 87, 90], ["defecation straining", "DISEASE", 99, 119], ["bloating", "DISEASE", 189, 197], ["bowel", "ORGAN", 154, 159], ["mucus", "MULTI-TISSUE_STRUCTURE", 178, 183], ["Other symptoms", "PROBLEM", 4, 18], ["IBS", "PROBLEM", 87, 90], ["defecation straining", "PROBLEM", 99, 119], ["urgency", "PROBLEM", 121, 128], ["incomplete bowel movement", "PROBLEM", 143, 168], ["passing mucus", "PROBLEM", 170, 183], ["bloating", "PROBLEM", 189, 197], ["bowel", "ANATOMY", 154, 159], ["movement", "OBSERVATION", 160, 168], ["bloating", "OBSERVATION", 189, 197]]], ["Four subtypes of IBS are recognized: IBS with constipation (hard stools 25% and loose stools <25% of bowel movements), IBS with diarrhea (loose stools 25% and hard stools <25% of bowel movements), mixed IBS (hard stools 25% and loose stools 25% of bowel movements), and unsubtyped IBS (insufficient abnormality of stool consistency to meet the other subtypes).EtiologyPharmacologic intervention must be tailored to the specific subtype of IBS.", [["bowel", "ANATOMY", 101, 106], ["bowel", "ANATOMY", 179, 184], ["bowel", "ANATOMY", 248, 253], ["IBS", "DISEASE", 17, 20], ["IBS", "DISEASE", 37, 40], ["constipation", "DISEASE", 46, 58], ["bowel movements", "DISEASE", 101, 116], ["IBS", "DISEASE", 119, 122], ["diarrhea", "DISEASE", 128, 136], ["bowel movements", "DISEASE", 179, 194], ["IBS", "DISEASE", 203, 206], ["bowel movements", "DISEASE", 248, 263], ["IBS", "DISEASE", 281, 284], ["IBS", "DISEASE", 439, 442], ["bowel", "ORGAN", 101, 106], ["bowel", "ORGAN", 179, 184], ["bowel", "ORGAN", 248, 253], ["IBS", "PROBLEM", 17, 20], ["IBS", "PROBLEM", 37, 40], ["constipation", "PROBLEM", 46, 58], ["hard stools", "PROBLEM", 60, 71], ["loose stools", "PROBLEM", 80, 92], ["bowel movements", "TEST", 101, 116], ["IBS", "PROBLEM", 119, 122], ["diarrhea", "PROBLEM", 128, 136], ["loose stools", "PROBLEM", 138, 150], ["hard stools", "PROBLEM", 159, 170], ["bowel movements", "TEST", 179, 194], ["mixed IBS", "PROBLEM", 197, 206], ["hard stools", "PROBLEM", 208, 219], ["loose stools", "PROBLEM", 228, 240], ["bowel movements", "TEST", 248, 263], ["unsubtyped IBS", "PROBLEM", 270, 284], ["insufficient abnormality of stool consistency", "PROBLEM", 286, 331], ["Pharmacologic intervention", "TREATMENT", 368, 394], ["IBS", "PROBLEM", 439, 442], ["subtypes", "OBSERVATION_MODIFIER", 5, 13], ["IBS", "OBSERVATION", 17, 20], ["IBS", "OBSERVATION", 37, 40], ["constipation", "OBSERVATION", 46, 58], ["bowel", "ANATOMY", 101, 106], ["IBS", "ANATOMY", 119, 122], ["diarrhea", "OBSERVATION", 128, 136], ["bowel", "ANATOMY", 179, 184], ["bowel", "ANATOMY", 248, 253], ["IBS", "OBSERVATION", 439, 442]]], ["While antidepressant therapy has been explored as treatment for IBS, a trial of 51 patients randomized to placebo, imipramine, or citalopram found none of these agents significantly improved global IBS end points.", [["antidepressant", "CHEMICAL", 6, 20], ["IBS", "DISEASE", 64, 67], ["imipramine", "CHEMICAL", 115, 125], ["citalopram", "CHEMICAL", 130, 140], ["imipramine", "CHEMICAL", 115, 125], ["citalopram", "CHEMICAL", 130, 140], ["patients", "ORGANISM", 83, 91], ["imipramine", "SIMPLE_CHEMICAL", 115, 125], ["citalopram", "SIMPLE_CHEMICAL", 130, 140], ["patients", "SPECIES", 83, 91], ["antidepressant therapy", "TREATMENT", 6, 28], ["treatment", "TREATMENT", 50, 59], ["IBS", "PROBLEM", 64, 67], ["placebo", "TREATMENT", 106, 113], ["imipramine", "TREATMENT", 115, 125], ["citalopram", "TREATMENT", 130, 140], ["IBS", "OBSERVATION", 198, 201]]], ["101 Antibiotics, specifically rifaximin, have also been tried in the treatment of IBS.", [["rifaximin", "CHEMICAL", 30, 39], ["IBS", "DISEASE", 82, 85], ["rifaximin", "CHEMICAL", 30, 39], ["rifaximin", "SIMPLE_CHEMICAL", 30, 39], ["Antibiotics", "TREATMENT", 4, 15], ["rifaximin", "TREATMENT", 30, 39], ["IBS", "PROBLEM", 82, 85], ["IBS", "OBSERVATION", 82, 85]]], ["A recent study of 80 patients randomized to rifaximin or placebo for 10 days found the group that received rifaximin had a greater improvement of IBS symptoms and a lower bloating score.", [["rifaximin", "CHEMICAL", 44, 53], ["rifaximin", "CHEMICAL", 107, 116], ["IBS", "DISEASE", 146, 149], ["bloating", "DISEASE", 171, 179], ["rifaximin", "CHEMICAL", 44, 53], ["rifaximin", "CHEMICAL", 107, 116], ["patients", "ORGANISM", 21, 29], ["rifaximin", "SIMPLE_CHEMICAL", 44, 53], ["rifaximin", "SIMPLE_CHEMICAL", 107, 116], ["patients", "SPECIES", 21, 29], ["A recent study", "TEST", 0, 14], ["rifaximin", "TREATMENT", 44, 53], ["placebo", "TREATMENT", 57, 64], ["rifaximin", "TREATMENT", 107, 116], ["IBS symptoms", "PROBLEM", 146, 158], ["a lower bloating score", "PROBLEM", 163, 185], ["IBS", "OBSERVATION", 146, 149]]], ["102Presenting Signs and SymptomsStudies show a discrepancy among how physicians and patients define constipation, although they have a similar understanding of the symptoms.", [["constipation", "DISEASE", 100, 112], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["constipation", "PROBLEM", 100, 112], ["the symptoms", "PROBLEM", 160, 172]]], ["88 Patients typically describe constipation as straining to have bowel movements, lumpy or hard stools, incomplete evacuation, anorectal obstruction, and a decreased frequency of bowel movements.", [["bowel", "ANATOMY", 65, 70], ["anorectal", "ANATOMY", 127, 136], ["bowel", "ANATOMY", 179, 184], ["constipation", "DISEASE", 31, 43], ["bowel movements", "DISEASE", 65, 80], ["anorectal obstruction", "DISEASE", 127, 148], ["bowel movements", "DISEASE", 179, 194], ["Patients", "ORGANISM", 3, 11], ["bowel", "ORGAN", 65, 70], ["bowel", "ORGAN", 179, 184], ["Patients", "SPECIES", 3, 11], ["constipation", "PROBLEM", 31, 43], ["bowel movements", "PROBLEM", 65, 80], ["lumpy", "PROBLEM", 82, 87], ["hard stools", "PROBLEM", 91, 102], ["incomplete evacuation", "PROBLEM", 104, 125], ["anorectal obstruction", "PROBLEM", 127, 148], ["a decreased frequency of bowel movements", "PROBLEM", 154, 194], ["constipation", "OBSERVATION", 31, 43], ["bowel", "ANATOMY", 65, 70], ["evacuation", "OBSERVATION", 115, 125], ["anorectal", "ANATOMY", 127, 136], ["obstruction", "OBSERVATION", 137, 148], ["decreased", "OBSERVATION_MODIFIER", 156, 165], ["bowel", "ANATOMY", 179, 184], ["movements", "OBSERVATION", 185, 194]]], ["To establish a standard for defining constipation, the Rome III criteria were created by a consortium of representatives from 18 countries.", [["constipation", "DISEASE", 37, 49], ["constipation", "PROBLEM", 37, 49]]], ["88, 100 These criteria include the aforementioned signs and symptoms frequently described by patients, while requiring at least 2 of the following over 3 months' duration: fewer than 3 bowel movements per week, at least 25% of bowel movements involving manual maneuvers to disimpact, straining, passing hard stools, or a sensation of anorectal obstruction.", [["bowel", "ANATOMY", 185, 190], ["bowel", "ANATOMY", 227, 232], ["anorectal", "ANATOMY", 334, 343], ["bowel movements", "DISEASE", 227, 242], ["anorectal obstruction", "DISEASE", 334, 355], ["patients", "ORGANISM", 93, 101], ["bowel", "ORGAN", 185, 190], ["bowel", "ORGAN", 227, 232], ["anorectal obstruction", "PATHOLOGICAL_FORMATION", 334, 355], ["patients", "SPECIES", 93, 101], ["symptoms", "PROBLEM", 60, 68], ["manual maneuvers", "TREATMENT", 253, 269], ["straining", "PROBLEM", 284, 293], ["passing hard stools", "PROBLEM", 295, 314], ["anorectal obstruction", "PROBLEM", 334, 355], ["bowel", "ANATOMY", 227, 232], ["anorectal", "ANATOMY", 334, 343], ["obstruction", "OBSERVATION", 344, 355]]], ["The Rome criteria excludes patients with loose stools as well as those meeting diagnostic criteria for IBS, given that there are separate Rome criteria for the diagnosis of IBS as mentioned previously.Diagnostic EvaluationThe physical examination may include a digital rectal examination to determine presence of stool impaction or blood in the stool.", [["rectal", "ANATOMY", 269, 275], ["stool", "ANATOMY", 313, 318], ["blood", "ANATOMY", 332, 337], ["stool", "ANATOMY", 345, 350], ["IBS", "DISEASE", 103, 106], ["IBS", "DISEASE", 173, 176], ["stool impaction", "DISEASE", 313, 328], ["patients", "ORGANISM", 27, 35], ["rectal", "ORGAN", 269, 275], ["stool", "ORGANISM_SUBDIVISION", 313, 318], ["blood", "ORGANISM_SUBSTANCE", 332, 337], ["stool", "ORGANISM_SUBSTANCE", 345, 350], ["patients", "SPECIES", 27, 35], ["loose stools", "PROBLEM", 41, 53], ["IBS", "PROBLEM", 103, 106], ["IBS", "PROBLEM", 173, 176], ["Diagnostic Evaluation", "TEST", 201, 222], ["The physical examination", "TEST", 222, 246], ["a digital rectal examination", "TEST", 259, 287], ["stool impaction", "PROBLEM", 313, 328], ["blood in the stool", "PROBLEM", 332, 350], ["IBS", "OBSERVATION", 173, 176], ["rectal", "ANATOMY", 269, 275], ["stool", "OBSERVATION", 313, 318], ["stool", "OBSERVATION", 345, 350]]], ["The clinician should be aware of what the American College of Gastroenterology (ACG) refers to as \"alarm\" signs or symptoms, which include fever, nausea, vomiting, weight loss of more than 10 pounds, anorexia, blood in stool, anemia, family history of colon cancer, onset of constipation after the age of 50 years, or acute onset of constipation in the elderly.", [["blood", "ANATOMY", 210, 215], ["stool", "ANATOMY", 219, 224], ["colon cancer", "ANATOMY", 252, 264], ["fever", "DISEASE", 139, 144], ["nausea", "DISEASE", 146, 152], ["vomiting", "DISEASE", 154, 162], ["weight loss", "DISEASE", 164, 175], ["anorexia", "DISEASE", 200, 208], ["anemia", "DISEASE", 226, 232], ["colon cancer", "DISEASE", 252, 264], ["constipation", "DISEASE", 275, 287], ["constipation", "DISEASE", 333, 345], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["stool", "ORGANISM_SUBSTANCE", 219, 224], ["colon cancer", "CANCER", 252, 264], ["signs", "PROBLEM", 106, 111], ["symptoms", "PROBLEM", 115, 123], ["fever", "PROBLEM", 139, 144], ["nausea", "PROBLEM", 146, 152], ["vomiting", "PROBLEM", 154, 162], ["weight loss", "PROBLEM", 164, 175], ["anorexia", "PROBLEM", 200, 208], ["blood in stool", "PROBLEM", 210, 224], ["anemia", "PROBLEM", 226, 232], ["colon cancer", "PROBLEM", 252, 264], ["constipation", "PROBLEM", 275, 287], ["constipation", "PROBLEM", 333, 345], ["stool", "ANATOMY", 219, 224], ["anemia", "OBSERVATION", 226, 232], ["colon", "ANATOMY", 252, 257], ["cancer", "OBSERVATION", 258, 264], ["constipation", "OBSERVATION", 275, 287], ["acute", "OBSERVATION_MODIFIER", 318, 323], ["constipation", "OBSERVATION", 333, 345]]], ["88, 103 If any of these symptoms are present a workup is advised, including a complete blood count, basic metabolic panel, thyroid tests, and possibly colonoscopy.", [["blood", "ANATOMY", 87, 92], ["thyroid", "ANATOMY", 123, 130], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["thyroid", "ORGAN", 123, 130], ["these symptoms", "PROBLEM", 18, 32], ["a workup", "TEST", 45, 53], ["a complete blood count", "TEST", 76, 98], ["basic metabolic panel", "TEST", 100, 121], ["thyroid tests", "TEST", 123, 136], ["colonoscopy", "TEST", 151, 162], ["thyroid", "ANATOMY", 123, 130]]], ["If these signs are absent, the ACG recommends empiric treatment of the constipation.", [["constipation", "DISEASE", 71, 83], ["these signs", "TEST", 3, 14], ["empiric treatment", "TREATMENT", 46, 63], ["the constipation", "PROBLEM", 67, 83], ["constipation", "OBSERVATION", 71, 83]]], ["88, 103 Radiographic studies are sometimes used to help determine the etiology of constipation.", [["constipation", "DISEASE", 82, 94], ["Radiographic studies", "TEST", 8, 28], ["constipation", "PROBLEM", 82, 94], ["constipation", "OBSERVATION", 82, 94]]], ["However, in a 2005 review article of the pediatric literature, the investigators found conflicting evidence for an association between a clinical and a radiographic diagnosis of constipation.", [["constipation", "DISEASE", 178, 190], ["constipation", "PROBLEM", 178, 190], ["constipation", "OBSERVATION", 178, 190]]], ["The investigators therefore do not recommend performing routine abdominal films on pediatric patients presenting with constipation.", [["abdominal", "ANATOMY", 64, 73], ["constipation", "DISEASE", 118, 130], ["abdominal", "ORGANISM_SUBDIVISION", 64, 73], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["routine abdominal films", "TEST", 56, 79], ["constipation", "PROBLEM", 118, 130], ["abdominal", "ANATOMY", 64, 73]]], ["104Management and TreatmentThe management of constipation depends on the degree to which the symptoms affect the patient's daily life, patient preference for type of treatment, efficacy of treatments tried in the past, and the provider's clinical judgment.", [["constipation", "DISEASE", 45, 57], ["patient", "ORGANISM", 113, 120], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 113, 120], ["patient", "SPECIES", 135, 142], ["Treatment", "TREATMENT", 18, 27], ["constipation", "PROBLEM", 45, 57], ["the symptoms", "PROBLEM", 89, 101], ["treatment", "TREATMENT", 166, 175], ["treatments", "TREATMENT", 189, 199], ["constipation", "OBSERVATION", 45, 57]]], ["If, for example, the patient is impacted then an enema or manual disimpaction is indicated.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["an enema", "TREATMENT", 46, 54], ["manual disimpaction", "TREATMENT", 58, 77]]], ["The ACG Chronic Constipation Task Force guidelines state exercise may help patients with constipation by reducing gastrointestinal transit time.", [["gastrointestinal", "ANATOMY", 114, 130], ["Constipation", "DISEASE", 16, 28], ["constipation", "DISEASE", 89, 101], ["patients", "ORGANISM", 75, 83], ["gastrointestinal", "ORGANISM_SUBDIVISION", 114, 130], ["patients", "SPECIES", 75, 83], ["The ACG Chronic Constipation", "PROBLEM", 0, 28], ["constipation", "PROBLEM", 89, 101], ["Chronic", "OBSERVATION_MODIFIER", 8, 15], ["Constipation", "OBSERVATION", 16, 28]]], ["Further, increasing water and fiber in the diet can increase frequency of bowel movements.", [["bowel", "ANATOMY", 74, 79], ["bowel movements", "DISEASE", 74, 89], ["water", "SIMPLE_CHEMICAL", 20, 25], ["bowel", "ORGAN", 74, 79], ["increasing water and fiber in the diet", "TREATMENT", 9, 47], ["bowel", "ANATOMY", 74, 79]]], ["92, 103, 105 However, patient satisfaction surveys show dissatisfaction with initial treatment regimens of lifestyle and dietary changes for chronic constipation, 105 which highlights the importance of a multipronged approach in treating constipation.Management and TreatmentWhen lifestyle changes fail, the options for medical treatment include bulking agents, osmotic agents, stimulant laxatives, and enemas ( Table 4 ).", [["chronic constipation", "DISEASE", 141, 161], ["constipation", "DISEASE", 238, 250], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["initial treatment regimens", "TREATMENT", 77, 103], ["lifestyle", "TREATMENT", 107, 116], ["dietary changes", "TREATMENT", 121, 136], ["chronic constipation", "PROBLEM", 141, 161], ["a multipronged approach", "TREATMENT", 202, 225], ["constipation", "PROBLEM", 238, 250], ["Management", "TREATMENT", 251, 261], ["TreatmentWhen lifestyle changes", "TREATMENT", 266, 297], ["medical treatment", "TREATMENT", 320, 337], ["bulking agents", "TREATMENT", 346, 360], ["osmotic agents", "TREATMENT", 362, 376], ["stimulant laxatives", "TREATMENT", 378, 397], ["enemas", "TREATMENT", 403, 409]]], ["Stool softeners are surface-acting agents that function as detergents, allowing water to interact Vomiting, Diarrhea, Constipation, Gastroenteritis more effectively with stool.", [["Stool", "ANATOMY", 0, 5], ["surface", "ANATOMY", 20, 27], ["Vomiting", "DISEASE", 98, 106], ["Diarrhea", "DISEASE", 108, 116], ["Constipation", "DISEASE", 118, 130], ["Gastroenteritis", "DISEASE", 132, 147], ["stool", "ORGANISM_SUBSTANCE", 170, 175], ["Stool softeners", "TREATMENT", 0, 15], ["surface-acting agents", "TREATMENT", 20, 41], ["Vomiting", "PROBLEM", 98, 106], ["Diarrhea", "PROBLEM", 108, 116], ["Constipation", "PROBLEM", 118, 130], ["Gastroenteritis", "PROBLEM", 132, 147], ["Gastroenteritis", "OBSERVATION", 132, 147]]], ["Docusate sodium (Colace) is a stool softener that is frequently prescribed for the treatment of chronic constipation; however, there are insufficient data to support its use.", [["Docusate sodium", "CHEMICAL", 0, 15], ["Colace", "CHEMICAL", 17, 23], ["chronic constipation", "DISEASE", 96, 116], ["Docusate sodium", "CHEMICAL", 0, 15], ["Colace", "CHEMICAL", 17, 23], ["Docusate sodium", "SIMPLE_CHEMICAL", 0, 15], ["Colace", "SIMPLE_CHEMICAL", 17, 23], ["Docusate sodium (Colace)", "TREATMENT", 0, 24], ["a stool softener", "TREATMENT", 28, 44], ["chronic constipation", "PROBLEM", 96, 116], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["constipation", "OBSERVATION", 104, 116]]], ["106 One placebo-controlled crossover trial of docusate calcium (Surfak) versus placebo demonstrated no differences in stool consistency or frequency between the 2 groups.", [["stool", "ANATOMY", 118, 123], ["docusate", "CHEMICAL", 46, 54], ["calcium", "CHEMICAL", 55, 62], ["Surfak", "CHEMICAL", 64, 70], ["docusate calcium", "CHEMICAL", 46, 62], ["Surfak", "CHEMICAL", 64, 70], ["docusate", "SIMPLE_CHEMICAL", 46, 54], ["calcium", "SIMPLE_CHEMICAL", 55, 62], ["Surfak", "SIMPLE_CHEMICAL", 64, 70], ["stool", "ORGANISM_SUBSTANCE", 118, 123], ["docusate calcium (Surfak)", "TREATMENT", 46, 71], ["placebo", "TREATMENT", 79, 86], ["differences in stool consistency", "PROBLEM", 103, 135], ["no", "UNCERTAINTY", 100, 102]]], ["107 Another trial, which was a multicenter, randomized, double-blind study of 170 patients with chronic constipation, found psyllium was superior to docusate sodium for increasing the stool water content and frequency of bowel movements.", [["bowel", "ANATOMY", 221, 226], ["chronic constipation", "DISEASE", 96, 116], ["psyllium", "CHEMICAL", 124, 132], ["docusate sodium", "CHEMICAL", 149, 164], ["bowel movements", "DISEASE", 221, 236], ["docusate sodium", "CHEMICAL", 149, 164], ["patients", "ORGANISM", 82, 90], ["psyllium", "SIMPLE_CHEMICAL", 124, 132], ["docusate sodium", "SIMPLE_CHEMICAL", 149, 164], ["bowel", "ORGAN", 221, 226], ["patients", "SPECIES", 82, 90], ["double-blind study", "TEST", 56, 74], ["chronic constipation", "PROBLEM", 96, 116], ["psyllium", "TREATMENT", 124, 132], ["docusate sodium", "TREATMENT", 149, 164], ["increasing the stool water content", "PROBLEM", 169, 203], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["constipation", "OBSERVATION", 104, 116], ["stool", "OBSERVATION", 184, 189], ["bowel", "ANATOMY", 221, 226]]], ["108 Nevertheless, the ACG recommends osmotic laxatives to treat constipation if an increase in water and dietary fiber fails.", [["constipation", "DISEASE", 64, 76], ["water", "SIMPLE_CHEMICAL", 95, 100], ["osmotic laxatives", "TREATMENT", 37, 54], ["constipation", "PROBLEM", 64, 76], ["dietary fiber fails", "TREATMENT", 105, 124]]], ["103, 109 One double-blind, multicenter study randomized 100 patients who presented with chronic medication-induced constipation to receive either polyethylene glycol (PEG) 3350 (Miralax) or placebo for 28 days.", [["constipation", "DISEASE", 115, 127], ["polyethylene glycol", "CHEMICAL", 146, 165], ["PEG) 3350", "CHEMICAL", 167, 176], ["Miralax", "CHEMICAL", 178, 185], ["polyethylene glycol", "CHEMICAL", 146, 165], ["PEG) 3350", "CHEMICAL", 167, 176], ["patients", "ORGANISM", 60, 68], ["polyethylene glycol", "SIMPLE_CHEMICAL", 146, 165], ["PEG) 3350", "SIMPLE_CHEMICAL", 167, 176], ["Miralax", "SIMPLE_CHEMICAL", 178, 185], ["patients", "SPECIES", 60, 68], ["multicenter study", "TEST", 27, 44], ["chronic medication-induced constipation", "PROBLEM", 88, 127], ["polyethylene glycol (PEG)", "TREATMENT", 146, 171], ["Miralax", "TREATMENT", 178, 185], ["placebo", "TREATMENT", 190, 197]]], ["The standard dosing of PEG, 17 g mixed with 8 ounces of water daily, was given to patients in the treatment group.", [["PEG", "CHEMICAL", 23, 26], ["PEG", "CHEMICAL", 23, 26], ["PEG", "SIMPLE_CHEMICAL", 23, 26], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["The standard dosing of PEG", "TREATMENT", 0, 26], ["the treatment group", "TREATMENT", 94, 113]]], ["PEG 3350 was found to be superior to placebo (78.3% vs 39.1%) in relieving constipation.", [["PEG 3350", "CHEMICAL", 0, 8], ["constipation", "DISEASE", 75, 87], ["PEG 3350", "CHEMICAL", 0, 8], ["PEG 3350", "SIMPLE_CHEMICAL", 0, 8], ["PEG", "TREATMENT", 0, 3], ["placebo", "TEST", 37, 44], ["relieving constipation", "PROBLEM", 65, 87], ["constipation", "OBSERVATION", 75, 87]]], ["Diarrhea and flatulence occurred more frequently with PEG treatment, although not to a statistically significant extent from placebo.", [["Diarrhea", "DISEASE", 0, 8], ["flatulence", "DISEASE", 13, 23], ["PEG", "CHEMICAL", 54, 57], ["PEG", "CHEMICAL", 54, 57], ["PEG", "SIMPLE_CHEMICAL", 54, 57], ["Diarrhea", "PROBLEM", 0, 8], ["flatulence", "PROBLEM", 13, 23], ["PEG treatment", "TREATMENT", 54, 67], ["placebo", "TREATMENT", 125, 132], ["flatulence", "OBSERVATION", 13, 23]]], ["110 Based on this study and others supporting PEG's efficacy at improving stool frequency and consistency, the ACG Task Force gave PEG as well as lactulose (Cholac) grade A recommendations.", [["PEG", "CHEMICAL", 46, 49], ["PEG", "CHEMICAL", 131, 134], ["lactulose", "CHEMICAL", 146, 155], ["PEG", "CHEMICAL", 46, 49], ["PEG", "CHEMICAL", 131, 134], ["lactulose", "CHEMICAL", 146, 155], ["PEG", "SIMPLE_CHEMICAL", 46, 49], ["stool", "ORGANISM_SUBSTANCE", 74, 79], ["lactulose", "SIMPLE_CHEMICAL", 146, 155], ["this study", "TEST", 13, 23], ["PEG's efficacy", "TREATMENT", 46, 60], ["PEG", "TREATMENT", 131, 134], ["lactulose (Cholac)", "TREATMENT", 146, 164]]], ["103, 105 Nevertheless, when osmotic laxatives fail to provide relief of symptoms of constipation, stimulant laxatives may be prescribed.", [["constipation", "DISEASE", 84, 96], ["osmotic laxatives", "TREATMENT", 28, 45], ["symptoms", "PROBLEM", 72, 80], ["constipation", "PROBLEM", 84, 96], ["stimulant laxatives", "TREATMENT", 98, 117]]], ["Stimulant laxatives include compounds containing senna or bisacodyl, and are thought to act by stimulating the sensory nerve endings of the colonic mucosa.", [["sensory nerve endings", "ANATOMY", 111, 132], ["colonic mucosa", "ANATOMY", 140, 154], ["bisacodyl", "CHEMICAL", 58, 67], ["bisacodyl", "CHEMICAL", 58, 67], ["senna", "SIMPLE_CHEMICAL", 49, 54], ["bisacodyl", "SIMPLE_CHEMICAL", 58, 67], ["nerve endings", "MULTI-TISSUE_STRUCTURE", 119, 132], ["colonic mucosa", "MULTI-TISSUE_STRUCTURE", 140, 154], ["Stimulant laxatives", "TREATMENT", 0, 19], ["compounds", "TREATMENT", 28, 37], ["senna", "TREATMENT", 49, 54], ["bisacodyl", "TREATMENT", 58, 67], ["sensory nerve", "ANATOMY", 111, 124], ["colonic mucosa", "ANATOMY", 140, 154]]], ["The FDA has approved these agents for treatment of occasional constipation; however, they should be used only as needed and for a brief time (<1 week), due to concerns regarding side effects with chronic use such as abdominal cramping, fecal incontinence, electrolyte imbalances, and reduced colonic motility.", [["abdominal", "ANATOMY", 216, 225], ["fecal", "ANATOMY", 236, 241], ["colonic", "ANATOMY", 292, 299], ["constipation", "DISEASE", 62, 74], ["abdominal cramping", "DISEASE", 216, 234], ["fecal incontinence", "DISEASE", 236, 254], ["abdominal", "ORGANISM_SUBDIVISION", 216, 225], ["fecal", "ORGANISM_SUBDIVISION", 236, 241], ["colonic", "ORGAN", 292, 299], ["these agents", "TREATMENT", 21, 33], ["occasional constipation", "PROBLEM", 51, 74], ["side effects", "PROBLEM", 178, 190], ["abdominal cramping", "PROBLEM", 216, 234], ["fecal incontinence", "PROBLEM", 236, 254], ["electrolyte imbalances", "PROBLEM", 256, 278], ["reduced colonic motility", "PROBLEM", 284, 308], ["constipation", "OBSERVATION", 62, 74], ["abdominal", "ANATOMY", 216, 225], ["cramping", "OBSERVATION", 226, 234], ["fecal", "ANATOMY", 236, 241], ["incontinence", "OBSERVATION", 242, 254], ["electrolyte imbalances", "OBSERVATION", 256, 278], ["reduced", "OBSERVATION_MODIFIER", 284, 291], ["colonic motility", "OBSERVATION", 292, 308]]], ["88, 105 One study, which evaluated sennosides (Sennakot) alone versus sennosides plus docusate sodium in the treatment of hospitalized oncologic patients, found that the sennosides group required fewer alternative laxative therapies (40% in the sennosides group versus 57% in the sennosides plus docusate sodium group) to treat constipation.", [["sennosides", "CHEMICAL", 35, 45], ["Sennakot", "CHEMICAL", 47, 55], ["sennosides", "CHEMICAL", 70, 80], ["docusate sodium", "CHEMICAL", 86, 101], ["sennosides", "CHEMICAL", 170, 180], ["sennosides", "CHEMICAL", 245, 255], ["sennosides", "CHEMICAL", 280, 290], ["docusate sodium", "CHEMICAL", 296, 311], ["constipation", "DISEASE", 328, 340], ["sennosides", "CHEMICAL", 35, 45], ["Sennakot", "CHEMICAL", 47, 55], ["sennosides", "CHEMICAL", 70, 80], ["docusate sodium", "CHEMICAL", 86, 101], ["sennosides", "CHEMICAL", 170, 180], ["docusate sodium", "CHEMICAL", 296, 311], ["sennosides", "SIMPLE_CHEMICAL", 35, 45], ["Sennakot", "SIMPLE_CHEMICAL", 47, 55], ["sennosides", "SIMPLE_CHEMICAL", 70, 80], ["docusate sodium", "SIMPLE_CHEMICAL", 86, 101], ["patients", "ORGANISM", 145, 153], ["sennosides", "SIMPLE_CHEMICAL", 170, 180], ["sennosides", "SIMPLE_CHEMICAL", 280, 290], ["docusate sodium", "SIMPLE_CHEMICAL", 296, 311], ["patients", "SPECIES", 145, 153], ["One study", "TEST", 8, 17], ["sennosides (Sennakot)", "TREATMENT", 35, 56], ["sennosides", "TREATMENT", 70, 80], ["docusate sodium", "TREATMENT", 86, 101], ["the sennosides group", "TREATMENT", 166, 186], ["alternative laxative therapies", "TREATMENT", 202, 232], ["docusate sodium group)", "TREATMENT", 296, 318], ["constipation", "PROBLEM", 328, 340]]], ["111 As there are no placebo-controlled trials of stimulant laxatives, insufficient data exist to make a recommendation about the effectiveness of stimulant laxatives in patients with chronic constipation.", [["chronic constipation", "DISEASE", 183, 203], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["placebo", "TREATMENT", 20, 27], ["stimulant laxatives", "TREATMENT", 49, 68], ["stimulant laxatives", "TREATMENT", 146, 165], ["chronic constipation", "PROBLEM", 183, 203], ["no", "UNCERTAINTY", 17, 19], ["chronic", "OBSERVATION_MODIFIER", 183, 190], ["constipation", "OBSERVATION", 191, 203]]], ["106 A drug that has recently emerged for the treatment of chronic constipation is lubiprostone (Amitiza), which works by activating chloride channels that in turn increase secretion of intestinal fluid.", [["intestinal fluid", "ANATOMY", 185, 201], ["constipation", "DISEASE", 66, 78], ["lubiprostone", "CHEMICAL", 82, 94], ["Amitiza", "CHEMICAL", 96, 103], ["chloride", "CHEMICAL", 132, 140], ["lubiprostone", "CHEMICAL", 82, 94], ["chloride", "CHEMICAL", 132, 140], ["lubiprostone", "SIMPLE_CHEMICAL", 82, 94], ["Amitiza", "SIMPLE_CHEMICAL", 96, 103], ["chloride", "SIMPLE_CHEMICAL", 132, 140], ["intestinal fluid", "ORGANISM_SUBSTANCE", 185, 201], ["chloride channels", "PROTEIN", 132, 149], ["chronic constipation", "PROBLEM", 58, 78], ["lubiprostone (Amitiza", "TREATMENT", 82, 103], ["activating chloride channels", "TREATMENT", 121, 149], ["intestinal fluid", "PROBLEM", 185, 201], ["chronic", "OBSERVATION_MODIFIER", 58, 65], ["constipation", "OBSERVATION", 66, 78], ["intestinal", "ANATOMY", 185, 195], ["fluid", "OBSERVATION", 196, 201]]], ["105, 109 Patients treated with lubiprostone in phase 3 clinical trials experienced a median increase of 3 or 4 spontaneous bowel movements per week after 1 month of treatment.", [["bowel", "ANATOMY", 123, 128], ["lubiprostone", "CHEMICAL", 31, 43], ["bowel movements", "DISEASE", 123, 138], ["lubiprostone", "CHEMICAL", 31, 43], ["Patients", "ORGANISM", 9, 17], ["lubiprostone", "SIMPLE_CHEMICAL", 31, 43], ["bowel", "ORGAN", 123, 128], ["Patients", "SPECIES", 9, 17], ["lubiprostone in phase", "TREATMENT", 31, 52], ["treatment", "TREATMENT", 165, 174], ["bowel", "ANATOMY", 123, 128]]], ["112 Treating constipation in pediatric patients is also challenging, although studies have demonstrated superior efficacy of PEG in this population as well.", [["constipation", "DISEASE", 13, 25], ["PEG", "CHEMICAL", 125, 128], ["PEG", "CHEMICAL", 125, 128], ["patients", "ORGANISM", 39, 47], ["PEG", "SIMPLE_CHEMICAL", 125, 128], ["patients", "SPECIES", 39, 47], ["constipation", "PROBLEM", 13, 25], ["studies", "TEST", 78, 85], ["PEG", "TREATMENT", 125, 128], ["PEG", "OBSERVATION", 125, 128]]], ["[113] [114] [115] [116] [117] In one study of 100 children aged 6 months to 15 years with constipation who received PEG or lactulose for 8 weeks, the investigators found a significant increase in the mean number of defecations per week in both groups.", [["constipation", "DISEASE", 90, 102], ["PEG", "CHEMICAL", 116, 119], ["lactulose", "CHEMICAL", 123, 132], ["PEG", "CHEMICAL", 116, 119], ["lactulose", "CHEMICAL", 123, 132], ["[113] [114", "SIMPLE_CHEMICAL", 0, 10], ["children", "ORGANISM", 50, 58], ["PEG", "SIMPLE_CHEMICAL", 116, 119], ["lactulose", "SIMPLE_CHEMICAL", 123, 132], ["children", "SPECIES", 50, 58], ["constipation", "PROBLEM", 90, 102], ["PEG", "TREATMENT", 116, 119], ["lactulose", "TREATMENT", 123, 132], ["significant", "OBSERVATION_MODIFIER", 172, 183], ["increase", "OBSERVATION_MODIFIER", 184, 192]]], ["In terms of complete relief of symptoms after 18 weeks, however, 56% of patients who received PEG 3350 were successfully treated compared with 29% of patients who received lactulose.", [["PEG 3350", "CHEMICAL", 94, 102], ["lactulose", "CHEMICAL", 172, 181], ["PEG", "CHEMICAL", 94, 97], ["lactulose", "CHEMICAL", 172, 181], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 150, 158], ["lactulose", "SIMPLE_CHEMICAL", 172, 181], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 150, 158], ["symptoms", "PROBLEM", 31, 39], ["PEG", "TREATMENT", 94, 97], ["lactulose", "TREATMENT", 172, 181], ["relief", "OBSERVATION_MODIFIER", 21, 27]]], ["114 Other studies have been performed to establish the most effective dose of PEG.", [["PEG", "CHEMICAL", 78, 81], ["PEG", "CHEMICAL", 78, 81], ["PEG", "SIMPLE_CHEMICAL", 78, 81], ["Other studies", "TEST", 4, 17], ["PEG", "TREATMENT", 78, 81], ["PEG", "OBSERVATION", 78, 81]]], ["108, 109 The results showed that 95% of patients receiving a higher dose (1-1.5 g/kg/d) achieved disimpaction versus 55% of patients receiving a lower dose (0.25-0.50 g/kg/d).", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 124, 132], ["a higher dose", "TREATMENT", 59, 72], ["disimpaction", "TREATMENT", 97, 109], ["a lower dose", "TREATMENT", 143, 155]]], ["However, diarrhea and bloating were more common in the higher-dose group.", [["diarrhea", "DISEASE", 9, 17], ["bloating", "DISEASE", 22, 30], ["diarrhea", "PROBLEM", 9, 17], ["bloating", "PROBLEM", 22, 30], ["diarrhea", "OBSERVATION", 9, 17], ["bloating", "OBSERVATION", 22, 30]]], ["117 A second study on PEG for children with constipation found low-dose PEG (0.2 g/kg/d) was successful in 77% of patients, mid-dose PEG (0.4 g/kg/d) was successful in 74% of patients, and highdose PEG (0.8 g/kg/d) was successful in 73% of patients.", [["PEG", "CHEMICAL", 22, 25], ["constipation", "DISEASE", 44, 56], ["PEG", "CHEMICAL", 72, 75], ["PEG", "CHEMICAL", 133, 136], ["PEG", "CHEMICAL", 198, 201], ["PEG", "CHEMICAL", 22, 25], ["PEG", "CHEMICAL", 72, 75], ["PEG", "CHEMICAL", 133, 136], ["PEG", "CHEMICAL", 198, 201], ["PEG", "SIMPLE_CHEMICAL", 22, 25], ["children", "ORGANISM", 30, 38], ["PEG", "SIMPLE_CHEMICAL", 72, 75], ["patients", "ORGANISM", 114, 122], ["PEG", "SIMPLE_CHEMICAL", 133, 136], ["patients", "ORGANISM", 175, 183], ["highdose PEG", "SIMPLE_CHEMICAL", 189, 201], ["patients", "ORGANISM", 240, 248], ["children", "SPECIES", 30, 38], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 240, 248], ["A second study", "TEST", 4, 18], ["PEG", "TREATMENT", 22, 25], ["constipation", "PROBLEM", 44, 56], ["low-dose PEG", "TREATMENT", 63, 75], ["mid-dose PEG", "TREATMENT", 124, 136], ["highdose PEG", "TREATMENT", 189, 201]]], ["All were more successful than placebo (42% success rate).", [["placebo", "TREATMENT", 30, 37]]], ["118 Nevertheless, a recent review stated that even though PEG achieved more treatment success compared with other laxatives, the studies were not of high enough quality to suggest laxative treatment is better than placebo in children with constipation.", [["PEG", "CHEMICAL", 58, 61], ["constipation", "DISEASE", 239, 251], ["PEG", "CHEMICAL", 58, 61], ["PEG", "SIMPLE_CHEMICAL", 58, 61], ["children", "ORGANISM", 225, 233], ["children", "SPECIES", 225, 233], ["PEG", "TREATMENT", 58, 61], ["other laxatives", "TREATMENT", 108, 123], ["the studies", "TEST", 125, 136], ["laxative treatment", "TREATMENT", 180, 198], ["constipation", "PROBLEM", 239, 251]]], ["119GASTROENTERITISGastroenteritis is defined as a syndrome of vomiting, diarrhea, or the combination of both, that begins abruptly in otherwise healthy individuals.", [["vomiting", "DISEASE", 62, 70], ["diarrhea", "DISEASE", 72, 80], ["a syndrome of vomiting", "PROBLEM", 48, 70], ["diarrhea", "PROBLEM", 72, 80]]], ["120 Although the symptoms of vomiting and diarrhea convey a broad differential, it is clinically important to consider the diagnosis of gastroenteritis in patients with these symptoms for public health reasons.", [["vomiting", "DISEASE", 29, 37], ["diarrhea", "DISEASE", 42, 50], ["gastroenteritis", "DISEASE", 136, 151], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["the symptoms", "PROBLEM", 13, 25], ["vomiting", "PROBLEM", 29, 37], ["diarrhea", "PROBLEM", 42, 50], ["gastroenteritis", "PROBLEM", 136, 151], ["these symptoms", "PROBLEM", 169, 183], ["gastroenteritis", "OBSERVATION", 136, 151]]], ["Worldwide, infectious gastroenteritis is a leading cause of morbidity and mortality.", [["infectious gastroenteritis", "DISEASE", 11, 37], ["infectious gastroenteritis", "PROBLEM", 11, 37], ["morbidity", "PROBLEM", 60, 69], ["infectious", "OBSERVATION_MODIFIER", 11, 21], ["morbidity", "OBSERVATION", 60, 69]]], ["120 In the United States, the highest incidence of infectious gastroenteritis is in patients younger than 5 years, whereas severe disease leading to hospitalization and resulting in mortality is most frequently observed in patients older than 60 years.", [["infectious gastroenteritis", "DISEASE", 51, 77], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 223, 231], ["infectious gastroenteritis", "PROBLEM", 51, 77], ["severe disease", "PROBLEM", 123, 137], ["infectious", "OBSERVATION_MODIFIER", 51, 61], ["gastroenteritis", "OBSERVATION", 62, 77], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["disease", "OBSERVATION", 130, 137]]], ["121 Even so, approximately 10% of hospitalizations in children younger than 5 years are caused by gastroenteritis and dehydration, accounting for nearly 220,000 hospitalizations yearly.", [["gastroenteritis", "DISEASE", 98, 113], ["dehydration", "DISEASE", 118, 129], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["gastroenteritis", "PROBLEM", 98, 113], ["dehydration", "PROBLEM", 118, 129], ["gastroenteritis", "OBSERVATION", 98, 113], ["dehydration", "OBSERVATION", 118, 129]]], ["122 Gastroenteritis has many causes, including viral, bacterial, parasitic, and noninfectious ( Table 5) .Norwalk VirusThe most prominent cause of acute gastroenteritis is viruses.", [["Gastroenteritis", "DISEASE", 4, 19], ["viral, bacterial, parasitic, and noninfectious", "DISEASE", 47, 93], ["gastroenteritis", "DISEASE", 153, 168], ["Norwalk Virus", "ORGANISM", 106, 119], ["Gastroenteritis", "PROBLEM", 4, 19], ["viral, bacterial, parasitic", "PROBLEM", 47, 74], ["Norwalk Virus", "PROBLEM", 106, 119], ["acute gastroenteritis", "PROBLEM", 147, 168], ["viruses", "PROBLEM", 172, 179], ["Gastroenteritis", "OBSERVATION", 4, 19], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["bacterial", "OBSERVATION_MODIFIER", 54, 63], ["parasitic", "OBSERVATION_MODIFIER", 65, 74], ["noninfectious", "OBSERVATION_MODIFIER", 80, 93], ["Virus", "OBSERVATION", 114, 119], ["most prominent", "OBSERVATION_MODIFIER", 123, 137], ["acute", "OBSERVATION_MODIFIER", 147, 152], ["gastroenteritis", "OBSERVATION", 153, 168], ["viruses", "OBSERVATION", 172, 179]]], ["Noroviruses account for more than 90% of the outbreaks in the United States, and affect both children and adults.", [["Noroviruses", "DISEASE", 0, 11], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["Noroviruses", "PROBLEM", 0, 11]]], ["123, 124 Outbreaks occur more commonly in cold-weather climates and in places where people are closely confined, such as schools, nursing homes, hospitals, and Vomiting, Diarrhea, Constipation, Gastroenteritis cruise ships.", [["Vomiting", "DISEASE", 160, 168], ["Diarrhea", "DISEASE", 170, 178], ["Constipation", "DISEASE", 180, 192], ["Gastroenteritis", "DISEASE", 194, 209], ["people", "ORGANISM", 84, 90], ["people", "SPECIES", 84, 90], ["Vomiting", "PROBLEM", 160, 168], ["Diarrhea", "PROBLEM", 170, 178], ["Constipation", "PROBLEM", 180, 192], ["Gastroenteritis", "PROBLEM", 194, 209], ["Gastroenteritis", "OBSERVATION", 194, 209]]], ["125 The primary mode of transmission is through fecal-oral spread, but the virus can also be transmitted by respiratory droplet contact or ingestion of contaminated food or water.", [["oral", "ANATOMY", 54, 58], ["respiratory droplet", "ANATOMY", 108, 127], ["fecal", "ORGANISM_SUBDIVISION", 48, 53], ["oral", "ORGANISM_SUBDIVISION", 54, 58], ["fecal-oral spread", "PROBLEM", 48, 65], ["the virus", "PROBLEM", 71, 80], ["fecal", "ANATOMY", 48, 53]]], ["Up to 30% of exposed individuals shed the virus before developing the illness, and patients with underlying illnesses or immunocompromised states may continue to do so long after the illness resolves.", [["illness", "DISEASE", 70, 77], ["illness", "DISEASE", 183, 190], ["individuals", "ORGANISM", 21, 32], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["the virus", "PROBLEM", 38, 47], ["the illness", "PROBLEM", 66, 77], ["underlying illnesses", "PROBLEM", 97, 117], ["immunocompromised states", "PROBLEM", 121, 145], ["the illness", "PROBLEM", 179, 190]]], ["126 Noroviruses survive in a variety of temperatures, remaining live on environmental surfaces, in recreational and drinking water, and on raw fruits and vegetables.", [["fruits", "ANATOMY", 143, 149], ["vegetables", "ANATOMY", 154, 164], ["fruits", "ORGANISM_SUBDIVISION", 143, 149], ["vegetables", "ORGANISM_SUBDIVISION", 154, 164], ["Noroviruses", "PROBLEM", 4, 15], ["Noroviruses", "OBSERVATION", 4, 15]]], ["Although patients may develop illness year-round, outbreaks tend to peak during periods of cold weather.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["illness", "PROBLEM", 30, 37], ["outbreaks", "PROBLEM", 50, 59], ["cold weather", "PROBLEM", 91, 103]]], ["124 Norovirus illness usually presents with both vomiting and diarrhea, as well as abdominal cramps, malaise, myalgias, and chills.", [["abdominal", "ANATOMY", 83, 92], ["Norovirus illness", "DISEASE", 4, 21], ["vomiting", "DISEASE", 49, 57], ["diarrhea", "DISEASE", 62, 70], ["abdominal cramps", "DISEASE", 83, 99], ["myalgias", "DISEASE", 110, 118], ["chills", "DISEASE", 124, 130], ["abdominal", "ORGANISM_SUBDIVISION", 83, 92], ["Norovirus illness", "PROBLEM", 4, 21], ["vomiting", "PROBLEM", 49, 57], ["diarrhea", "PROBLEM", 62, 70], ["abdominal cramps", "PROBLEM", 83, 99], ["malaise", "PROBLEM", 101, 108], ["myalgias", "PROBLEM", 110, 118], ["chills", "PROBLEM", 124, 130], ["Norovirus", "OBSERVATION", 4, 13], ["diarrhea", "OBSERVATION", 62, 70], ["abdominal", "ANATOMY", 83, 92], ["cramps", "OBSERVATION", 93, 99], ["malaise", "OBSERVATION", 101, 108], ["myalgias", "OBSERVATION", 110, 118], ["chills", "OBSERVATION", 124, 130]]], ["Symptom onset is sudden, with vomiting being more common in children and diarrhea more common in adults.", [["vomiting", "DISEASE", 30, 38], ["diarrhea", "DISEASE", 73, 81], ["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["Symptom onset", "PROBLEM", 0, 13], ["sudden", "PROBLEM", 17, 23], ["vomiting", "PROBLEM", 30, 38], ["diarrhea", "PROBLEM", 73, 81]]], ["124 Fever, which is typically low grade, is present in 50% of patients.", [["Fever", "DISEASE", 4, 9], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["Fever", "PROBLEM", 4, 9], ["Fever", "OBSERVATION", 4, 9], ["low grade", "OBSERVATION_MODIFIER", 30, 39]]], ["Symptoms usually last 24 to 60 hours and are typically mild and self-limited, while severe disease may develop in debilitated, elderly, or immunocompromised individuals.", [["Symptoms", "PROBLEM", 0, 8], ["severe disease", "PROBLEM", 84, 98], ["immunocompromised individuals", "PROBLEM", 139, 168], ["mild", "OBSERVATION_MODIFIER", 55, 59], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["disease", "OBSERVATION", 91, 98]]], ["123 Of particular concern, noroviruses may be associated with necrotizing enterocolitis (NEC).", [["noroviruses", "DISEASE", 27, 38], ["necrotizing enterocolitis", "DISEASE", 62, 87], ["NEC", "DISEASE", 89, 92], ["noroviruses", "ORGANISM", 27, 38], ["necrotizing enterocolitis", "PATHOLOGICAL_FORMATION", 62, 87], ["NEC", "PATHOLOGICAL_FORMATION", 89, 92], ["noroviruses", "PROBLEM", 27, 38], ["necrotizing enterocolitis", "PROBLEM", 62, 87], ["NEC", "PROBLEM", 89, 92], ["noroviruses", "OBSERVATION", 27, 38], ["may be associated with", "UNCERTAINTY", 39, 61], ["necrotizing", "OBSERVATION_MODIFIER", 62, 73], ["enterocolitis", "OBSERVATION", 74, 87], ["NEC", "OBSERVATION_MODIFIER", 89, 92]]], ["In one study of an outbreak of 8 infants with NEC in a neonatal intensive care unit, investigators found 4 (50%) of the infants had stool samples that tested positive for norovirus.", [["stool samples", "ANATOMY", 132, 145], ["NEC", "DISEASE", 46, 49], ["norovirus", "DISEASE", 171, 180], ["infants", "ORGANISM", 33, 40], ["infants", "ORGANISM", 120, 127], ["stool", "ORGANISM", 132, 137], ["norovirus", "ORGANISM", 171, 180], ["infants", "SPECIES", 33, 40], ["infants", "SPECIES", 120, 127], ["NEC", "PROBLEM", 46, 49], ["stool samples", "TEST", 132, 145], ["norovirus", "PROBLEM", 171, 180]]], ["127RotavirusAlthough norovirus infection is the most common cause of gastroenteritis outbreaks in people of all ages worldwide, group A rotavirus is the leading cause of diarrheal illness in children younger than 5 years.", [["Rotavirus", "DISEASE", 3, 12], ["norovirus infection", "DISEASE", 21, 40], ["gastroenteritis", "DISEASE", 69, 84], ["rotavirus", "DISEASE", 136, 145], ["diarrheal illness", "DISEASE", 170, 187], ["people", "ORGANISM", 98, 104], ["A rotavirus", "ORGANISM", 134, 145], ["children", "ORGANISM", 191, 199], ["people", "SPECIES", 98, 104], ["children", "SPECIES", 191, 199], ["A rotavirus", "SPECIES", 134, 145], ["Rotavirus", "PROBLEM", 3, 12], ["norovirus infection", "PROBLEM", 21, 40], ["gastroenteritis", "PROBLEM", 69, 84], ["diarrheal illness", "PROBLEM", 170, 187], ["norovirus", "OBSERVATION", 21, 30], ["most common", "OBSERVATION_MODIFIER", 48, 59], ["gastroenteritis", "OBSERVATION", 69, 84]]], ["128 A cohort study from Europe of 2928 children younger than 5 years with more than 3 loose stools per day for more than 2 weeks found 43.4% of stool samples were positive for rotavirus.", [["stool samples", "ANATOMY", 144, 157], ["rotavirus", "DISEASE", 176, 185], ["children", "ORGANISM", 39, 47], ["stool", "ORGANISM", 144, 149], ["samples", "CANCER", 150, 157], ["rotavirus", "ORGANISM", 176, 185], ["children", "SPECIES", 39, 47], ["rotavirus", "SPECIES", 176, 185], ["A cohort study", "TEST", 4, 18], ["3 loose stools", "PROBLEM", 84, 98], ["stool samples", "TEST", 144, 157], ["rotavirus", "PROBLEM", 176, 185]]], ["In a study of 516 children younger than 3 years with acute gastroenteritis, the investigators found 44% had rotavirus-positive stool samples.", [["stool samples", "ANATOMY", 127, 140], ["acute gastroenteritis", "DISEASE", 53, 74], ["rotavirus-positive stool", "DISEASE", 108, 132], ["children", "ORGANISM", 18, 26], ["rotavirus", "ORGANISM", 108, 117], ["stool", "ORGANISM", 127, 132], ["children", "SPECIES", 18, 26], ["rotavirus", "SPECIES", 108, 117], ["acute gastroenteritis", "PROBLEM", 53, 74], ["the investigators", "TEST", 76, 93], ["rotavirus", "PROBLEM", 108, 117], ["positive stool samples", "PROBLEM", 118, 140], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["gastroenteritis", "OBSERVATION", 59, 74]]], ["130 Although rotavirus is more common in children, it can also affect adults.", [["rotavirus", "DISEASE", 13, 22], ["rotavirus", "ORGANISM", 13, 22], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["rotavirus", "SPECIES", 13, 22], ["rotavirus", "PROBLEM", 13, 22], ["rotavirus", "OBSERVATION", 13, 22], ["more common", "OBSERVATION_MODIFIER", 26, 37]]], ["In a 4-year prospective study of 683 adults with acute diarrhea, 14% of subjects tested positive for rotavirus.", [["acute diarrhea", "DISEASE", 49, 63], ["rotavirus", "DISEASE", 101, 110], ["adults", "ORGANISM", 37, 43], ["subjects", "ORGANISM", 72, 80], ["rotavirus", "ORGANISM", 101, 110], ["rotavirus", "SPECIES", 101, 110], ["prospective study", "TEST", 12, 29], ["acute diarrhea", "PROBLEM", 49, 63], ["rotavirus", "PROBLEM", 101, 110], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["diarrhea", "OBSERVATION", 55, 63]]], ["131 There is a wide spectrum of disease severity for adults presenting with rotavirus, from mild vomiting, diarrhea, or both, to dehydration and severe systemic disease.", [["vomiting", "DISEASE", 97, 105], ["diarrhea", "DISEASE", 107, 115], ["dehydration", "DISEASE", 129, 140], ["systemic disease", "DISEASE", 152, 168], ["rotavirus", "SPECIES", 76, 85], ["a wide spectrum of disease severity", "PROBLEM", 13, 48], ["rotavirus", "PROBLEM", 76, 85], ["mild vomiting", "PROBLEM", 92, 105], ["diarrhea", "PROBLEM", 107, 115], ["dehydration", "PROBLEM", 129, 140], ["severe systemic disease", "PROBLEM", 145, 168], ["wide", "OBSERVATION_MODIFIER", 15, 19], ["disease", "OBSERVATION", 32, 39], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["vomiting", "OBSERVATION", 97, 105], ["diarrhea", "OBSERVATION", 107, 115], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["systemic", "OBSERVATION_MODIFIER", 152, 160], ["disease", "OBSERVATION", 161, 168]]], ["Vomiting is present in 90% of cases and 30% of patients have a fever (>39.0 C).", [["Vomiting", "DISEASE", 0, 8], ["fever", "DISEASE", 63, 68], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["Vomiting", "PROBLEM", 0, 8], ["a fever", "PROBLEM", 61, 68]]], ["Finally, while the illness is usually worst in the first 24 hours it is typically mild and self-limited in immunocompetent adults.", [["illness", "DISEASE", 19, 26], ["adults", "ORGANISM", 123, 129], ["mild", "OBSERVATION_MODIFIER", 82, 86]]], ["132 Salmonella Salmonella infection is the most common cause of bacterial gastroenteritis in the United States, with more than 95% of subjects infected by contaminated food.", [["Salmonella infection", "DISEASE", 15, 35], ["bacterial gastroenteritis", "DISEASE", 64, 89], ["Salmonella Salmonella", "ORGANISM", 4, 25], ["Salmonella Salmonella", "SPECIES", 4, 25], ["Salmonella Salmonella infection", "PROBLEM", 4, 35], ["bacterial gastroenteritis", "PROBLEM", 64, 89], ["Salmonella infection", "OBSERVATION", 15, 35], ["most common", "OBSERVATION_MODIFIER", 43, 54], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["gastroenteritis", "OBSERVATION", 74, 89]]], ["Usually the source is raw or undercooked eggs, but the bacteria may also be found in meats, unpasteurized dairy products, fruits, vegetables, and peanuts.", [["eggs", "ANATOMY", 41, 45], ["meats", "ANATOMY", 85, 90], ["fruits", "ANATOMY", 122, 128], ["vegetables", "ANATOMY", 130, 140], ["meats", "ORGANISM_SUBDIVISION", 85, 90], ["fruits", "ORGANISM_SUBDIVISION", 122, 128], ["vegetables", "ORGANISM_SUBDIVISION", 130, 140], ["peanuts", "ORGANISM_SUBDIVISION", 146, 153], ["peanuts", "SPECIES", 146, 153], ["undercooked eggs", "PROBLEM", 29, 45], ["the bacteria", "PROBLEM", 51, 63]]], ["[133] [134] [135] [136] [137] Transmission may also occur via contact with infected animals, such as turtles.", [["[133] [134] [135] [136] [137", "SIMPLE_CHEMICAL", 0, 28]]], ["138 Salmonella infection has a short incubation period of approximately 6 to 48 hours.", [["Salmonella infection", "DISEASE", 4, 24], ["Salmonella", "SPECIES", 4, 14], ["Salmonella infection", "PROBLEM", 4, 24], ["infection", "OBSERVATION", 15, 24], ["short incubation", "OBSERVATION_MODIFIER", 31, 47]]], ["Symptoms typically persist for 24 hours to 1 week and may include vomiting, diarrhea, crampy abdominal pain, and fever.", [["abdominal", "ANATOMY", 93, 102], ["vomiting", "DISEASE", 66, 74], ["diarrhea", "DISEASE", 76, 84], ["crampy abdominal pain", "DISEASE", 86, 107], ["fever", "DISEASE", 113, 118], ["abdominal", "ORGANISM_SUBDIVISION", 93, 102], ["Symptoms", "PROBLEM", 0, 8], ["vomiting", "PROBLEM", 66, 74], ["diarrhea", "PROBLEM", 76, 84], ["crampy abdominal pain", "PROBLEM", 86, 107], ["fever", "PROBLEM", 113, 118], ["abdominal", "ANATOMY", 93, 102], ["pain", "OBSERVATION", 103, 107], ["fever", "OBSERVATION", 113, 118]]], ["In patients infected with Salmonella, resistance can be a problem and susceptibility testing is recommended.", [["Salmonella", "CHEMICAL", 26, 36], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["Salmonella", "SPECIES", 26, 36], ["Salmonella", "PROBLEM", 26, 36], ["susceptibility testing", "TEST", 70, 92], ["infected", "OBSERVATION_MODIFIER", 12, 20], ["Salmonella", "OBSERVATION", 26, 36]]], ["While antibiotics are thought to increase carrier states in patients with Salmonella infection, in selected patients, or in patients with severe illness, recommended antibiotics include third-generation cephalosporins or fluoroquinolones.", [["Salmonella infection", "DISEASE", 74, 94], ["cephalosporins", "CHEMICAL", 203, 217], ["fluoroquinolones", "CHEMICAL", 221, 237], ["cephalosporins", "CHEMICAL", 203, 217], ["fluoroquinolones", "CHEMICAL", 221, 237], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 124, 132], ["third-generation cephalosporins", "SIMPLE_CHEMICAL", 186, 217], ["fluoroquinolones", "SIMPLE_CHEMICAL", 221, 237], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 124, 132], ["Salmonella", "SPECIES", 74, 84], ["antibiotics", "TREATMENT", 6, 17], ["Salmonella infection", "PROBLEM", 74, 94], ["severe illness", "PROBLEM", 138, 152], ["antibiotics", "TREATMENT", 166, 177], ["third-generation cephalosporins", "TREATMENT", 186, 217], ["fluoroquinolones", "TREATMENT", 221, 237], ["infection", "OBSERVATION", 85, 94]]], ["139 Campylobacter jejuni C jejuni is the most common cause of bacterial gastroenteritis worldwide and the second most common in the United States after Salmonella infection.", [["Campylobacter jejuni C jejuni", "DISEASE", 4, 33], ["bacterial gastroenteritis", "DISEASE", 62, 87], ["Salmonella infection", "DISEASE", 152, 172], ["Campylobacter jejuni C jejuni", "ORGANISM", 4, 33], ["Campylobacter jejuni", "SPECIES", 4, 24], ["C jejuni", "SPECIES", 25, 33], ["Campylobacter jejuni", "SPECIES", 4, 24], ["C jejuni", "SPECIES", 25, 33], ["Salmonella", "SPECIES", 152, 162], ["Campylobacter jejuni C jejuni", "PROBLEM", 4, 33], ["bacterial gastroenteritis", "PROBLEM", 62, 87], ["Salmonella infection", "PROBLEM", 152, 172], ["Campylobacter jejuni", "OBSERVATION", 4, 24], ["most common", "OBSERVATION_MODIFIER", 41, 52], ["bacterial", "OBSERVATION_MODIFIER", 62, 71], ["gastroenteritis", "OBSERVATION", 72, 87], ["infection", "OBSERVATION", 163, 172]]], ["The CDC reported an incidence of C jejuni infection of 13.02 per 100,000 persons in 2009.", [["C jejuni infection", "DISEASE", 33, 51], ["C jejuni", "ORGANISM", 33, 41], ["C jejuni", "SPECIES", 33, 41], ["persons", "SPECIES", 73, 80], ["C jejuni", "SPECIES", 33, 41], ["C jejuni infection", "PROBLEM", 33, 51], ["jejuni infection", "OBSERVATION", 35, 51]]], ["140 The highest incidence of disease is among children younger than 5 years.", [["140", "CHEMICAL", 0, 3], ["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["disease", "PROBLEM", 29, 36], ["highest", "OBSERVATION_MODIFIER", 8, 15], ["disease", "OBSERVATION", 29, 36]]], ["Although C jejuni infection may be acquired from contaminated drinking water or exposure to infected farm or domestic animals, 50% of cases are associated with the handling and consumption of undercooked poultry.", [["C jejuni infection", "DISEASE", 9, 27], ["undercooked poultry", "DISEASE", 192, 211], ["C jejuni", "ORGANISM", 9, 17], ["C jejuni", "SPECIES", 9, 17], ["C jejuni", "SPECIES", 9, 17], ["C jejuni infection", "PROBLEM", 9, 27], ["jejuni", "OBSERVATION_MODIFIER", 11, 17], ["infection", "OBSERVATION", 18, 27], ["infected", "OBSERVATION_MODIFIER", 92, 100]]], ["141 Campylobacter infection develops 1 to 10 days postexposure.", [["Campylobacter infection", "DISEASE", 4, 27], ["Campylobacter infection", "PROBLEM", 4, 27], ["Campylobacter", "OBSERVATION_MODIFIER", 4, 17], ["infection", "OBSERVATION", 18, 27]]], ["The illness may start with a prodrome of fever, malaise, chills, and headache before the onset of abdominal symptoms, which include watery but sometimes bloody diarrhea, abdominal pain, nausea, and vomiting.", [["abdominal", "ANATOMY", 98, 107], ["abdominal", "ANATOMY", 170, 179], ["illness", "DISEASE", 4, 11], ["fever", "DISEASE", 41, 46], ["chills", "DISEASE", 57, 63], ["headache", "DISEASE", 69, 77], ["abdominal symptoms", "DISEASE", 98, 116], ["watery", "DISEASE", 132, 138], ["diarrhea", "DISEASE", 160, 168], ["abdominal pain", "DISEASE", 170, 184], ["nausea", "DISEASE", 186, 192], ["vomiting", "DISEASE", 198, 206], ["abdominal", "ORGANISM_SUBDIVISION", 98, 107], ["watery", "ORGANISM_SUBDIVISION", 132, 138], ["abdominal", "ORGANISM_SUBDIVISION", 170, 179], ["fever", "PROBLEM", 41, 46], ["malaise", "PROBLEM", 48, 55], ["chills", "PROBLEM", 57, 63], ["headache", "PROBLEM", 69, 77], ["abdominal symptoms", "PROBLEM", 98, 116], ["watery", "PROBLEM", 132, 138], ["bloody diarrhea", "PROBLEM", 153, 168], ["abdominal pain", "PROBLEM", 170, 184], ["nausea", "PROBLEM", 186, 192], ["vomiting", "PROBLEM", 198, 206], ["abdominal", "ANATOMY", 98, 107], ["symptoms", "OBSERVATION", 108, 116], ["abdominal", "ANATOMY", 170, 179], ["pain", "OBSERVATION", 180, 184], ["nausea", "OBSERVATION", 186, 192]]], ["Symptoms typically resolve within 5 days, but in some cases may persist for several weeks.", [["Symptoms", "PROBLEM", 0, 8]]], ["141 For patients infected with C jejuni, treatment with erythromycin (Erythrocin) or azithromycin (Zithromax) is recommended.", [["erythromycin", "CHEMICAL", 56, 68], ["Erythrocin", "CHEMICAL", 70, 80], ["azithromycin", "CHEMICAL", 85, 97], ["Zithromax", "CHEMICAL", 99, 108], ["erythromycin", "CHEMICAL", 56, 68], ["Erythrocin", "CHEMICAL", 70, 80], ["azithromycin", "CHEMICAL", 85, 97], ["Zithromax", "CHEMICAL", 99, 108], ["patients", "ORGANISM", 8, 16], ["C jejuni", "ORGANISM", 31, 39], ["erythromycin", "SIMPLE_CHEMICAL", 56, 68], ["Erythrocin", "SIMPLE_CHEMICAL", 70, 80], ["azithromycin", "SIMPLE_CHEMICAL", 85, 97], ["Zithromax", "SIMPLE_CHEMICAL", 99, 108], ["patients", "SPECIES", 8, 16], ["C jejuni", "SPECIES", 31, 39], ["C jejuni", "SPECIES", 31, 39], ["C jejuni", "TREATMENT", 31, 39], ["treatment", "TREATMENT", 41, 50], ["erythromycin (Erythrocin)", "TREATMENT", 56, 81], ["azithromycin", "TREATMENT", 85, 97], ["Zithromax", "TREATMENT", 99, 108]]], ["Fluoroquinolones are no longer advised as there have been increasing resistance patterns, possibly resulting from the usage of fluoroquinolones for farm animals.", [["Fluoroquinolones", "CHEMICAL", 0, 16], ["fluoroquinolones", "CHEMICAL", 127, 143], ["Fluoroquinolones", "CHEMICAL", 0, 16], ["fluoroquinolones", "CHEMICAL", 127, 143], ["Fluoroquinolones", "SIMPLE_CHEMICAL", 0, 16], ["fluoroquinolones", "SIMPLE_CHEMICAL", 127, 143], ["Fluoroquinolones", "TREATMENT", 0, 16], ["increasing resistance patterns", "PROBLEM", 58, 88], ["fluoroquinolones", "TREATMENT", 127, 143], ["no longer", "UNCERTAINTY", 21, 30], ["increasing", "OBSERVATION_MODIFIER", 58, 68], ["resistance", "OBSERVATION", 69, 79]]], ["141, 142 Campylobacter infection has also been associated with the development of postinfectious Guillain-Barr\u00e9 Syndrome (GBS), with an incidence of 1 per 1000 individuals.", [["Campylobacter infection", "DISEASE", 9, 32], ["Guillain-Barr\u00e9 Syndrome", "DISEASE", 97, 120], ["GBS", "DISEASE", 122, 125], ["Guillain-Barr\u00e9", "ORGANISM", 97, 111], ["Guillain-Barr\u00e9 Syndrome (GBS)", "SPECIES", 97, 126], ["Campylobacter infection", "PROBLEM", 9, 32], ["postinfectious Guillain-Barr\u00e9 Syndrome", "PROBLEM", 82, 120], ["GBS", "TEST", 122, 125], ["Campylobacter infection", "OBSERVATION", 9, 32], ["postinfectious", "OBSERVATION_MODIFIER", 82, 96], ["Barr\u00e9 Syndrome", "OBSERVATION", 106, 120]]], ["Serological surveys have found anti-C jejuni antibodies in patients with GBS, a finding consistent with recent infection.", [["GBS", "DISEASE", 73, 76], ["infection", "DISEASE", 111, 120], ["anti-C jejuni antibodies", "GENE_OR_GENE_PRODUCT", 31, 55], ["patients", "ORGANISM", 59, 67], ["anti-C jejuni antibodies", "PROTEIN", 31, 55], ["anti-C jejuni", "SPECIES", 31, 44], ["patients", "SPECIES", 59, 67], ["anti-C jejuni", "SPECIES", 31, 44], ["Serological surveys", "TEST", 0, 19], ["anti-C jejuni antibodies", "PROBLEM", 31, 55], ["GBS", "PROBLEM", 73, 76], ["recent infection", "PROBLEM", 104, 120], ["anti-C jejuni antibodies", "OBSERVATION", 31, 55], ["GBS", "OBSERVATION", 73, 76], ["consistent with", "UNCERTAINTY", 88, 103], ["infection", "OBSERVATION", 111, 120]]], ["Further, a high proportion of patients have C jejuni in their stools when they develop GBS.", [["stools", "ANATOMY", 62, 68], ["GBS", "DISEASE", 87, 90], ["patients", "ORGANISM", 30, 38], ["C jejuni", "ORGANISM", 44, 52], ["stools", "ORGANISM_SUBSTANCE", 62, 68], ["patients", "SPECIES", 30, 38], ["C jejuni", "SPECIES", 44, 52], ["C jejuni", "SPECIES", 44, 52], ["C jejuni in their stools", "PROBLEM", 44, 68], ["GBS", "PROBLEM", 87, 90], ["GBS", "OBSERVATION", 87, 90]]], ["Finally, GBS has been shown to be more severe and more likely to be irreversible when it is preceded by C jejuni infection.", [["GBS", "DISEASE", 9, 12], ["C jejuni infection", "DISEASE", 104, 122], ["C jejuni", "ORGANISM", 104, 112], ["C jejuni", "SPECIES", 104, 112], ["C jejuni", "SPECIES", 104, 112], ["GBS", "TEST", 9, 12], ["C jejuni infection", "PROBLEM", 104, 122], ["GBS", "OBSERVATION", 9, 12], ["more severe", "OBSERVATION_MODIFIER", 34, 45], ["more likely to be", "UNCERTAINTY", 50, 67], ["irreversible", "OBSERVATION", 68, 80], ["jejuni", "OBSERVATION_MODIFIER", 106, 112], ["infection", "OBSERVATION", 113, 122]]], ["143Vibrio parahaemolyticusWhereas gastroenteritis caused by the organism Vibrio parahaemolyticus is common in Japan, the CDC reports a total of just 4500 cases per year in the United States.", [["Vibrio parahaemolyticus", "DISEASE", 3, 26], ["gastroenteritis", "DISEASE", 34, 49], ["Vibrio parahaemolyticus", "DISEASE", 73, 96], ["Vibrio parahaemolyticus", "ORGANISM", 3, 26], ["Vibrio parahaemolyticus", "ORGANISM", 73, 96], ["Vibrio parahaemolyticus", "SPECIES", 3, 26], ["Vibrio parahaemolyticus", "SPECIES", 73, 96], ["Vibrio parahaemolyticus", "SPECIES", 3, 26], ["Vibrio parahaemolyticus", "SPECIES", 73, 96], ["Vibrio parahaemolyticus", "PROBLEM", 3, 26], ["gastroenteritis", "PROBLEM", 34, 49], ["the organism Vibrio parahaemolyticus", "PROBLEM", 60, 96], ["parahaemolyticus", "OBSERVATION", 10, 26], ["gastroenteritis", "OBSERVATION", 34, 49]]], ["140 The organism lives in oysters, clams, and crabs, and is transmitted by the ingestion of Vomiting, Diarrhea, Constipation, Gastroenteritis contaminated saltwater seafood or direct exposure of an open wound to seawater.", [["wound", "ANATOMY", 203, 208], ["140", "CHEMICAL", 0, 3], ["Vomiting", "DISEASE", 92, 100], ["Diarrhea", "DISEASE", 102, 110], ["Constipation", "DISEASE", 112, 124], ["Gastroenteritis", "DISEASE", 126, 141], ["crabs", "ORGANISM_SUBDIVISION", 46, 51], ["wound", "PATHOLOGICAL_FORMATION", 203, 208], ["Vomiting", "PROBLEM", 92, 100], ["Diarrhea", "PROBLEM", 102, 110], ["Constipation", "PROBLEM", 112, 124], ["Gastroenteritis", "PROBLEM", 126, 141], ["an open wound", "PROBLEM", 195, 208], ["wound", "OBSERVATION", 203, 208]]], ["144 V parahaemolyticus has a 6-hour to 4-day incubation period and presents with the sudden onset of severe watery diarrhea, vomiting, abdominal cramping, and fever.", [["abdominal", "ANATOMY", 135, 144], ["watery diarrhea", "DISEASE", 108, 123], ["vomiting", "DISEASE", 125, 133], ["abdominal cramping", "DISEASE", 135, 153], ["fever", "DISEASE", 159, 164], ["144 V parahaemolyticus", "ORGANISM", 0, 22], ["abdominal", "ORGANISM_SUBDIVISION", 135, 144], ["V parahaemolyticus", "SPECIES", 4, 22], ["V parahaemolyticus", "SPECIES", 4, 22], ["severe watery diarrhea", "PROBLEM", 101, 123], ["vomiting", "PROBLEM", 125, 133], ["abdominal cramping", "PROBLEM", 135, 153], ["fever", "PROBLEM", 159, 164], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["watery", "OBSERVATION_MODIFIER", 108, 114], ["diarrhea", "OBSERVATION", 115, 123], ["abdominal", "ANATOMY", 135, 144], ["cramping", "OBSERVATION", 145, 153], ["fever", "OBSERVATION", 159, 164]]], ["Based on susceptibility testing of an outbreak of 10,000 patients infected with V parahaemolyticus in Chile in 2005, it is best treated with tetracycline (Sumycin), ciprofloxacin, or chloramphenicol.", [["infected with V parahaemolyticus", "DISEASE", 66, 98], ["tetracycline", "CHEMICAL", 141, 153], ["Sumycin", "CHEMICAL", 155, 162], ["ciprofloxacin", "CHEMICAL", 165, 178], ["chloramphenicol", "CHEMICAL", 183, 198], ["tetracycline", "CHEMICAL", 141, 153], ["Sumycin", "CHEMICAL", 155, 162], ["ciprofloxacin", "CHEMICAL", 165, 178], ["chloramphenicol", "CHEMICAL", 183, 198], ["patients", "ORGANISM", 57, 65], ["V parahaemolyticus", "ORGANISM", 80, 98], ["tetracycline", "SIMPLE_CHEMICAL", 141, 153], ["Sumycin", "SIMPLE_CHEMICAL", 155, 162], ["ciprofloxacin", "SIMPLE_CHEMICAL", 165, 178], ["chloramphenicol", "SIMPLE_CHEMICAL", 183, 198], ["patients", "SPECIES", 57, 65], ["V parahaemolyticus", "SPECIES", 80, 98], ["V parahaemolyticus", "SPECIES", 80, 98], ["susceptibility testing", "TEST", 9, 31], ["tetracycline (Sumycin)", "TREATMENT", 141, 163], ["ciprofloxacin", "TREATMENT", 165, 178], ["chloramphenicol", "TREATMENT", 183, 198]]], ["Of note, investigators found the organism was universally resistant to ampicillin.", [["ampicillin", "CHEMICAL", 71, 81], ["ampicillin", "CHEMICAL", 71, 81], ["ampicillin", "SIMPLE_CHEMICAL", 71, 81], ["the organism", "PROBLEM", 29, 41], ["ampicillin", "TREATMENT", 71, 81]]], ["145 Shigella Shigella infection primarily affects people in developing countries, and the majority of cases are in children younger than 5 years.", [["Shigella infection", "DISEASE", 13, 31], ["Shigella Shigella", "ORGANISM", 4, 21], ["people", "ORGANISM", 50, 56], ["children", "ORGANISM", 115, 123], ["Shigella Shigella", "SPECIES", 4, 21], ["people", "SPECIES", 50, 56], ["children", "SPECIES", 115, 123], ["Shigella Shigella infection", "PROBLEM", 4, 31], ["Shigella", "OBSERVATION_MODIFIER", 4, 12], ["Shigella", "OBSERVATION_MODIFIER", 13, 21], ["infection", "OBSERVATION", 22, 31]]], ["146 The incidence of Shigella in the United States in 2009 was 3.99 per 100,000.", [["Shigella", "PROBLEM", 21, 29], ["Shigella", "OBSERVATION_MODIFIER", 21, 29]]], ["140 The bacteria are transmitted mainly through person-to-person contact but may also be acquired from food, water, flies, and feces.", [["140", "CHEMICAL", 0, 3], ["feces", "ORGANISM_SUBDIVISION", 127, 132], ["person", "SPECIES", 48, 54], ["person", "SPECIES", 58, 64], ["The bacteria", "PROBLEM", 4, 16], ["bacteria", "OBSERVATION", 8, 16]]], ["Shigella invades the cells of the colonic epithelium, and the shiga toxin induces local inflammation, which in turn produces hemorrhagic colitis.", [["cells", "ANATOMY", 21, 26], ["colonic epithelium", "ANATOMY", 34, 52], ["inflammation", "DISEASE", 88, 100], ["hemorrhagic colitis", "DISEASE", 125, 144], ["Shigella", "ORGANISM", 0, 8], ["cells", "CELL", 21, 26], ["colonic epithelium", "TISSUE", 34, 52], ["shiga toxin", "GENE_OR_GENE_PRODUCT", 62, 73], ["colitis", "PATHOLOGICAL_FORMATION", 137, 144], ["Shigella", "PROBLEM", 0, 8], ["the shiga toxin", "PROBLEM", 58, 73], ["local inflammation", "PROBLEM", 82, 100], ["hemorrhagic colitis", "PROBLEM", 125, 144], ["cells", "OBSERVATION_MODIFIER", 21, 26], ["colonic epithelium", "ANATOMY", 34, 52], ["local", "OBSERVATION_MODIFIER", 82, 87], ["inflammation", "OBSERVATION", 88, 100], ["hemorrhagic", "OBSERVATION_MODIFIER", 125, 136], ["colitis", "OBSERVATION", 137, 144]]], ["Following an incubation period from 1 to 6 days, patients develop fever, crampy abdominal pain, and diarrhea, which often contains blood and mucus.", [["abdominal", "ANATOMY", 80, 89], ["blood", "ANATOMY", 131, 136], ["mucus", "ANATOMY", 141, 146], ["fever", "DISEASE", 66, 71], ["crampy abdominal pain", "DISEASE", 73, 94], ["diarrhea", "DISEASE", 100, 108], ["patients", "ORGANISM", 49, 57], ["abdominal", "ORGANISM_SUBDIVISION", 80, 89], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["mucus", "ORGANISM_SUBSTANCE", 141, 146], ["patients", "SPECIES", 49, 57], ["fever", "PROBLEM", 66, 71], ["crampy abdominal pain", "PROBLEM", 73, 94], ["diarrhea", "PROBLEM", 100, 108], ["fever", "OBSERVATION", 66, 71], ["crampy", "OBSERVATION_MODIFIER", 73, 79], ["abdominal", "ANATOMY", 80, 89], ["pain", "OBSERVATION", 90, 94], ["diarrhea", "OBSERVATION", 100, 108], ["mucus", "OBSERVATION", 141, 146]]], ["Infants, on the other hand, present more often with nonbloody stool and lack of fever.", [["fever", "DISEASE", 80, 85], ["Infants", "ORGANISM", 0, 7], ["stool", "ORGANISM_SUBSTANCE", 62, 67], ["Infants", "SPECIES", 0, 7], ["nonbloody stool", "PROBLEM", 52, 67], ["fever", "PROBLEM", 80, 85], ["fever", "OBSERVATION", 80, 85]]], ["147 Although symptoms caused by Shigella infection are typically self-limiting and resolve within 2 to 3 days, most clinicians treat Shigella with antibiotic therapy.", [["Shigella infection", "DISEASE", 32, 50], ["symptoms", "PROBLEM", 13, 21], ["Shigella infection", "PROBLEM", 32, 50], ["Shigella", "PROBLEM", 133, 141], ["antibiotic therapy", "TREATMENT", 147, 165], ["Shigella", "OBSERVATION_MODIFIER", 32, 40], ["infection", "OBSERVATION", 41, 50]]], ["Fluoroquinolones are the mainstays of therapy, while azithromycin, trimethoprim-sulfamethoxazole (Bactrim), ampicillin, and ceftriaxone (Rocephin) are other options.YersiniaYersinia is a prominent infection worldwide, but caused only 0.32 cases per 100,000 persons in the United States in 2009.", [["Fluoroquinolones", "CHEMICAL", 0, 16], ["azithromycin", "CHEMICAL", 53, 65], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 67, 96], ["Bactrim", "CHEMICAL", 98, 105], ["ampicillin", "CHEMICAL", 108, 118], ["ceftriaxone", "CHEMICAL", 124, 135], ["Rocephin", "CHEMICAL", 137, 145], ["YersiniaYersinia", "CHEMICAL", 165, 181], ["infection", "DISEASE", 197, 206], ["Fluoroquinolones", "CHEMICAL", 0, 16], ["azithromycin", "CHEMICAL", 53, 65], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 67, 96], ["Bactrim", "CHEMICAL", 98, 105], ["ampicillin", "CHEMICAL", 108, 118], ["ceftriaxone", "CHEMICAL", 124, 135], ["Rocephin", "CHEMICAL", 137, 145], ["Fluoroquinolones", "SIMPLE_CHEMICAL", 0, 16], ["azithromycin", "SIMPLE_CHEMICAL", 53, 65], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 67, 96], ["Bactrim", "SIMPLE_CHEMICAL", 98, 105], ["ampicillin", "SIMPLE_CHEMICAL", 108, 118], ["ceftriaxone", "SIMPLE_CHEMICAL", 124, 135], ["Rocephin", "SIMPLE_CHEMICAL", 137, 145], ["persons", "SPECIES", 257, 264], ["Fluoroquinolones", "TREATMENT", 0, 16], ["therapy", "TREATMENT", 38, 45], ["azithromycin", "TREATMENT", 53, 65], ["trimethoprim", "TREATMENT", 67, 79], ["sulfamethoxazole", "TREATMENT", 80, 96], ["(Bactrim)", "TREATMENT", 97, 106], ["ampicillin", "TREATMENT", 108, 118], ["ceftriaxone", "TREATMENT", 124, 135], ["Rocephin", "TREATMENT", 137, 145], ["a prominent infection", "PROBLEM", 185, 206], ["prominent", "OBSERVATION_MODIFIER", 187, 196], ["infection", "OBSERVATION", 197, 206]]], ["140 A primary risk factor for acquiring Yersinia is the consumption of contaminated foods, in particular raw pork.", [["140", "CHEMICAL", 0, 3], ["Yersinia", "DISEASE", 40, 48], ["pork", "ORGANISM_SUBDIVISION", 109, 113], ["pork", "SPECIES", 109, 113], ["A primary risk factor", "PROBLEM", 4, 25], ["acquiring Yersinia", "PROBLEM", 30, 48]]], ["148 Yersinia infection presents with a gradual onset of symptoms from several days to 1 week, which include bloody diarrhea, fever, vomiting, and severe right lower quadrant abdominal pain that may mimic appendicitis.", [["right lower quadrant abdominal", "ANATOMY", 153, 183], ["Yersinia infection", "DISEASE", 4, 22], ["bloody diarrhea", "DISEASE", 108, 123], ["fever", "DISEASE", 125, 130], ["vomiting", "DISEASE", 132, 140], ["abdominal pain", "DISEASE", 174, 188], ["appendicitis", "DISEASE", 204, 216], ["abdominal", "ORGANISM_SUBDIVISION", 174, 183], ["Yersinia infection", "PROBLEM", 4, 22], ["symptoms", "PROBLEM", 56, 64], ["bloody diarrhea", "PROBLEM", 108, 123], ["fever", "PROBLEM", 125, 130], ["vomiting", "PROBLEM", 132, 140], ["severe right lower quadrant abdominal pain", "PROBLEM", 146, 188], ["appendicitis", "PROBLEM", 204, 216], ["Yersinia", "OBSERVATION_MODIFIER", 4, 12], ["infection", "OBSERVATION", 13, 22], ["bloody diarrhea", "OBSERVATION", 108, 123], ["fever", "OBSERVATION", 125, 130], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["right", "ANATOMY_MODIFIER", 153, 158], ["lower", "ANATOMY_MODIFIER", 159, 164], ["quadrant", "ANATOMY_MODIFIER", 165, 173], ["abdominal", "ANATOMY", 174, 183], ["pain", "OBSERVATION", 184, 188], ["appendicitis", "OBSERVATION", 204, 216]]], ["Approximately 20% of patients also present with pharyngitis.", [["pharyngitis", "DISEASE", 48, 59], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["pharyngitis", "PROBLEM", 48, 59], ["pharyngitis", "OBSERVATION", 48, 59]]], ["149 Treatment regimens for Yersinia include trimethoprim-sulfamethoxazole, fluoroquinolones, gentamycin, tobramycin, amikacin (Amikin), or cefotaxime (Claforan).", [["trimethoprim-sulfamethoxazole", "CHEMICAL", 44, 73], ["fluoroquinolones", "CHEMICAL", 75, 91], ["gentamycin", "CHEMICAL", 93, 103], ["tobramycin", "CHEMICAL", 105, 115], ["amikacin", "CHEMICAL", 117, 125], ["Amikin", "CHEMICAL", 127, 133], ["cefotaxime", "CHEMICAL", 139, 149], ["Claforan", "CHEMICAL", 151, 159], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 44, 73], ["fluoroquinolones", "CHEMICAL", 75, 91], ["gentamycin", "CHEMICAL", 93, 103], ["tobramycin", "CHEMICAL", 105, 115], ["amikacin", "CHEMICAL", 117, 125], ["Amikin", "CHEMICAL", 127, 133], ["cefotaxime", "CHEMICAL", 139, 149], ["Claforan", "CHEMICAL", 151, 159], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 44, 73], ["fluoroquinolones", "SIMPLE_CHEMICAL", 75, 91], ["gentamycin", "SIMPLE_CHEMICAL", 93, 103], ["tobramycin", "SIMPLE_CHEMICAL", 105, 115], ["amikacin", "SIMPLE_CHEMICAL", 117, 125], ["Amikin", "SIMPLE_CHEMICAL", 127, 133], ["cefotaxime", "SIMPLE_CHEMICAL", 139, 149], ["Claforan", "SIMPLE_CHEMICAL", 151, 159], ["Treatment regimens", "TREATMENT", 4, 22], ["Yersinia", "PROBLEM", 27, 35], ["trimethoprim", "TREATMENT", 44, 56], ["sulfamethoxazole", "TREATMENT", 57, 73], ["fluoroquinolones", "TREATMENT", 75, 91], ["gentamycin", "TREATMENT", 93, 103], ["tobramycin", "TREATMENT", 105, 115], ["amikacin (Amikin)", "TREATMENT", 117, 134], ["cefotaxime", "TREATMENT", 139, 149], ["Claforan", "TREATMENT", 151, 159]]], ["Yersiniainfected individuals have a risk of developing bacteremia, liver or spleen abscesses, suppurative appendicitis, peritonitis, intussusception, and toxic megacolon.Escherichia coliE coli infections are categorized as enterohemorrhagic (O157:H7), enterotoxigenic (traveler's diarrhea), enteropathogenic (nontoxin mediated, uses an adhesin to attach and efface intestinal cells), or enteroinvasive.", [["liver", "ANATOMY", 67, 72], ["spleen abscesses", "ANATOMY", 76, 92], ["efface intestinal cells", "ANATOMY", 358, 381], ["bacteremia", "DISEASE", 55, 65], ["liver or spleen abscesses", "DISEASE", 67, 92], ["appendicitis", "DISEASE", 106, 118], ["peritonitis", "DISEASE", 120, 131], ["intussusception", "DISEASE", 133, 148], ["toxic megacolon", "DISEASE", 154, 169], ["coliE coli infections", "DISEASE", 182, 203], ["diarrhea", "DISEASE", 280, 288], ["liver", "ORGAN", 67, 72], ["spleen", "ORGAN", 76, 82], ["megacolon", "PATHOLOGICAL_FORMATION", 160, 169], ["Escherichia coliE coli", "ORGANISM", 170, 192], ["O157:H7", "ORGANISM", 242, 249], ["intestinal cells", "CELL", 365, 381], ["adhesin", "PROTEIN", 336, 343], ["efface intestinal cells", "CELL_TYPE", 358, 381], ["Escherichia coliE coli", "SPECIES", 170, 192], ["Escherichia coliE coli", "SPECIES", 170, 192], ["O157:H7", "SPECIES", 242, 249], ["developing bacteremia", "PROBLEM", 44, 65], ["liver or spleen abscesses", "PROBLEM", 67, 92], ["suppurative appendicitis", "PROBLEM", 94, 118], ["peritonitis", "PROBLEM", 120, 131], ["intussusception", "PROBLEM", 133, 148], ["toxic megacolon", "PROBLEM", 154, 169], ["Escherichia coliE coli infections", "PROBLEM", 170, 203], ["enterohemorrhagic", "PROBLEM", 223, 240], ["enterotoxigenic", "PROBLEM", 252, 267], ["diarrhea", "PROBLEM", 280, 288], ["enteropathogenic (nontoxin mediated", "PROBLEM", 291, 326], ["an adhesin", "TREATMENT", 333, 343], ["intestinal cells", "PROBLEM", 365, 381], ["enteroinvasive", "PROBLEM", 387, 401], ["risk of", "UNCERTAINTY", 36, 43], ["developing", "OBSERVATION_MODIFIER", 44, 54], ["bacteremia", "OBSERVATION", 55, 65], ["liver", "ANATOMY", 67, 72], ["spleen", "ANATOMY", 76, 82], ["abscesses", "OBSERVATION", 83, 92], ["suppurative", "OBSERVATION_MODIFIER", 94, 105], ["appendicitis", "OBSERVATION", 106, 118], ["peritonitis", "OBSERVATION", 120, 131], ["intussusception", "OBSERVATION", 133, 148], ["toxic", "OBSERVATION_MODIFIER", 154, 159], ["megacolon", "OBSERVATION", 160, 169], ["coliE coli infections", "OBSERVATION", 182, 203], ["enterohemorrhagic", "OBSERVATION_MODIFIER", 223, 240], ["intestinal cells", "ANATOMY", 365, 381]]], ["E coli 0157:H7 primarily affects children younger than 10 years and elderly patients, with an incidence of 0.99 per 100,000 persons in the United States in 2009.", [["E coli 0157:H7", "CHEMICAL", 0, 14], ["E coli 0157:H7", "ORGANISM", 0, 14], ["children", "ORGANISM", 33, 41], ["patients", "ORGANISM", 76, 84], ["E coli", "SPECIES", 0, 6], ["children", "SPECIES", 33, 41], ["patients", "SPECIES", 76, 84], ["persons", "SPECIES", 124, 131], ["E coli 0157:H7", "SPECIES", 0, 14], ["coli", "OBSERVATION", 2, 6]]], ["140 Transmission has been linked to the consumption of undercooked beef, contaminated drinking water, unpasteurized milk, 150, 151 and from fecal contamination of raw vegetables and unpasteurized apple juice.", [["milk", "ANATOMY", 116, 120], ["vegetables", "ANATOMY", 167, 177], ["juice", "ANATOMY", 202, 207], ["undercooked beef", "DISEASE", 55, 71], ["beef", "ORGANISM_SUBDIVISION", 67, 71], ["milk", "ORGANISM_SUBSTANCE", 116, 120], ["fecal", "ORGANISM_SUBSTANCE", 140, 145], ["vegetables", "ORGANISM_SUBDIVISION", 167, 177], ["apple juice", "ORGANISM_SUBSTANCE", 196, 207], ["beef", "SPECIES", 67, 71], ["apple", "SPECIES", 196, 201], ["beef", "SPECIES", 67, 71], ["apple", "SPECIES", 196, 201], ["fecal", "ANATOMY", 140, 145]]], ["152,153 E coli 0157:H7 bacteria cause a hemorrhagic colitis due to a shiga-like cytotoxin that destroys the colonic microvilli.", [["colonic microvilli", "ANATOMY", 108, 126], ["hemorrhagic colitis", "DISEASE", 40, 59], ["colitis", "PATHOLOGICAL_FORMATION", 52, 59], ["colonic microvilli", "MULTI-TISSUE_STRUCTURE", 108, 126], ["shiga-like cytotoxin", "PROTEIN", 69, 89], ["E coli", "SPECIES", 8, 14], ["E coli", "SPECIES", 8, 14], ["E coli", "TEST", 8, 14], ["bacteria", "PROBLEM", 23, 31], ["a hemorrhagic colitis", "PROBLEM", 38, 59], ["a shiga-like cytotoxin", "PROBLEM", 67, 89], ["hemorrhagic", "OBSERVATION_MODIFIER", 40, 51], ["colitis", "OBSERVATION", 52, 59], ["colonic", "ANATOMY", 108, 115], ["microvilli", "ANATOMY_MODIFIER", 116, 126]]], ["Patients infected with E coli may develop an acute onset of watery diarrhea, which may progress to bloody diarrhea, abdominal cramps, and vomiting.", [["abdominal", "ANATOMY", 116, 125], ["watery diarrhea", "DISEASE", 60, 75], ["diarrhea", "DISEASE", 106, 114], ["abdominal cramps", "DISEASE", 116, 132], ["vomiting", "DISEASE", 138, 146], ["Patients", "ORGANISM", 0, 8], ["E coli", "ORGANISM", 23, 29], ["abdominal", "ORGANISM_SUBDIVISION", 116, 125], ["Patients", "SPECIES", 0, 8], ["E coli", "SPECIES", 23, 29], ["E coli", "SPECIES", 23, 29], ["E coli", "PROBLEM", 23, 29], ["watery diarrhea", "PROBLEM", 60, 75], ["bloody diarrhea", "PROBLEM", 99, 114], ["abdominal cramps", "PROBLEM", 116, 132], ["vomiting", "PROBLEM", 138, 146], ["infected", "OBSERVATION", 9, 17], ["E coli", "OBSERVATION_MODIFIER", 23, 29], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["watery", "OBSERVATION_MODIFIER", 60, 66], ["diarrhea", "OBSERVATION", 67, 75], ["abdominal", "ANATOMY", 116, 125], ["cramps", "OBSERVATION", 126, 132]]], ["Fever is typically absent or low grade.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["low grade", "PROBLEM", 29, 38], ["low grade", "OBSERVATION_MODIFIER", 29, 38]]], ["Approximately 6% of patients with E coli 0157:H7 infection, particularly those younger than 5 years and elderly patients, develop hemolytic uremic syndrome.", [["infection", "DISEASE", 49, 58], ["hemolytic uremic syndrome", "DISEASE", 130, 155], ["patients", "ORGANISM", 20, 28], ["E coli 0157:H7", "ORGANISM", 34, 48], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 20, 28], ["E coli", "SPECIES", 34, 40], ["patients", "SPECIES", 112, 120], ["E coli", "SPECIES", 34, 40], ["E coli", "PROBLEM", 34, 40], ["infection", "PROBLEM", 49, 58], ["hemolytic uremic syndrome", "PROBLEM", 130, 155], ["E coli", "OBSERVATION_MODIFIER", 34, 40], ["infection", "OBSERVATION", 49, 58], ["hemolytic", "OBSERVATION_MODIFIER", 130, 139], ["uremic syndrome", "OBSERVATION", 140, 155]]], ["154 This risk is increased with bloody diarrhea, leukocytosis, fever, and possibly the use of antimotility agents.", [["diarrhea", "DISEASE", 39, 47], ["leukocytosis", "DISEASE", 49, 61], ["fever", "DISEASE", 63, 68], ["antimotility agents", "SIMPLE_CHEMICAL", 94, 113], ["bloody diarrhea", "PROBLEM", 32, 47], ["leukocytosis", "PROBLEM", 49, 61], ["fever", "PROBLEM", 63, 68], ["antimotility agents", "TREATMENT", 94, 113], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["leukocytosis", "OBSERVATION", 49, 61]]], ["155, 156 Outbreaks Gastroenteritis outbreaks have been studied to determine their causes.", [["Gastroenteritis", "DISEASE", 19, 34], ["Outbreaks Gastroenteritis outbreaks", "PROBLEM", 9, 44]]], ["One study examined patients hospitalized with community-acquired gastroenteritis in Berlin, Germany.", [["gastroenteritis", "DISEASE", 65, 80], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["One study", "TEST", 0, 9], ["acquired gastroenteritis", "PROBLEM", 56, 80], ["gastroenteritis", "OBSERVATION", 65, 80]]], ["The investigators found Campylobacter in 35% of specimens, norovirus in 23%, Salmonella in 20%, rotavirus in 15%, and a noninfectious cause in 8% of patients, supporting the need to remain diligent in looking for other causes of diarrhea even in an outbreak.", [["specimens", "ANATOMY", 48, 57], ["norovirus", "DISEASE", 59, 68], ["rotavirus", "DISEASE", 96, 105], ["diarrhea", "DISEASE", 229, 237], ["specimens", "CANCER", 48, 57], ["norovirus", "ORGANISM", 59, 68], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Salmonella", "SPECIES", 77, 87], ["rotavirus", "SPECIES", 96, 105], ["The investigators", "TEST", 0, 17], ["Campylobacter", "PROBLEM", 24, 37], ["specimens", "TEST", 48, 57], ["norovirus", "TEST", 59, 68], ["Salmonella", "TEST", 77, 87], ["rotavirus", "PROBLEM", 96, 105], ["a noninfectious cause", "PROBLEM", 118, 139], ["diarrhea", "PROBLEM", 229, 237], ["Campylobacter", "OBSERVATION", 24, 37], ["noninfectious", "OBSERVATION", 120, 133], ["diarrhea", "OBSERVATION", 229, 237]]], ["In this study, length of hospital stay (median: 5.5 days) was independent of the pathogen, but was associated with patients who had underlying medical conditions.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["this study", "TEST", 3, 13], ["underlying medical conditions", "PROBLEM", 132, 161]]], ["157 Another study evaluated 29 acute gastroenteritis outbreaks in childcare centers.", [["gastroenteritis", "DISEASE", 37, 52], ["Another study", "TEST", 4, 17], ["acute gastroenteritis", "PROBLEM", 31, 52], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["gastroenteritis", "OBSERVATION", 37, 52]]], ["Stool specimens from symptomatic children and environmental surface swabs found offending pathogens included rotavirus (17% of outbreaks), norovirus (10%), astrovirus (10%), and sapovirus (7%).", [["Stool specimens", "ANATOMY", 0, 15], ["surface swabs", "ANATOMY", 60, 73], ["rotavirus", "DISEASE", 109, 118], ["norovirus", "DISEASE", 139, 148], ["astrovirus", "DISEASE", 156, 166], ["sapovirus", "DISEASE", 178, 187], ["Stool specimens", "CANCER", 0, 15], ["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["rotavirus", "SPECIES", 109, 118], ["Stool specimens", "TEST", 0, 15], ["environmental surface swabs", "TEST", 46, 73], ["offending pathogens", "PROBLEM", 80, 99], ["rotavirus", "PROBLEM", 109, 118], ["outbreaks", "PROBLEM", 127, 136], ["norovirus", "PROBLEM", 139, 148], ["astrovirus", "PROBLEM", 156, 166], ["sapovirus", "PROBLEM", 178, 187], ["symptomatic", "OBSERVATION_MODIFIER", 21, 32]]], ["In 3 of the outbreaks, 10% of patients were found to have multiple viruses responsible for their infection, highlighting the importance of surveillance monitoring during these occurrences.", [["infection", "DISEASE", 97, 106], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["multiple viruses", "PROBLEM", 58, 74], ["their infection", "PROBLEM", 91, 106], ["surveillance monitoring", "TEST", 139, 162], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["viruses", "OBSERVATION", 67, 74], ["infection", "OBSERVATION", 97, 106]]], ["128Assessment and Diagnostic EvaluationThe duration and severity of the patient's diarrhea and vomiting should be assessed, along with their fluid intake, urine output, and overall mental status.", [["fluid", "ANATOMY", 141, 146], ["urine", "ANATOMY", 155, 160], ["diarrhea", "DISEASE", 82, 90], ["vomiting", "DISEASE", 95, 103], ["patient", "ORGANISM", 72, 79], ["urine", "ORGANISM_SUBSTANCE", 155, 160], ["patient", "SPECIES", 72, 79], ["Diagnostic Evaluation", "TEST", 18, 39], ["the patient's diarrhea", "PROBLEM", 68, 90], ["vomiting", "PROBLEM", 95, 103], ["their fluid intake", "TEST", 135, 153], ["urine output", "TEST", 155, 167]]], ["Malnourished and immunocompromised patients are more likely to have serious outcomes.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["Malnourished", "PROBLEM", 0, 12], ["immunocompromised", "PROBLEM", 17, 34], ["immunocompromised", "OBSERVATION", 17, 34]]], ["Stool cultures in the ED are typically reserved for patients with severe illness or for patients presenting with diarrhea in times of community-wide outbreaks.", [["Stool cultures", "ANATOMY", 0, 14], ["diarrhea", "DISEASE", 113, 121], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 88, 96], ["Stool cultures", "TEST", 0, 14], ["severe illness", "PROBLEM", 66, 80], ["diarrhea", "PROBLEM", 113, 121]]], ["While fecal leukocytes are 70% sensitive and 50% specific for detecting inflammation in studies examining the infectious etiology of diarrhea, white blood cells in the stool may also be present in other conditions such as ulcerative colitis and Crohn disease.", [["fecal leukocytes", "ANATOMY", 6, 22], ["white blood cells", "ANATOMY", 143, 160], ["stool", "ANATOMY", 168, 173], ["ulcerative", "ANATOMY", 222, 232], ["inflammation", "DISEASE", 72, 84], ["diarrhea", "DISEASE", 133, 141], ["ulcerative colitis", "DISEASE", 222, 240], ["Crohn disease", "DISEASE", 245, 258], ["fecal leukocytes", "CELL", 6, 22], ["white blood cells", "CELL", 143, 160], ["stool", "ORGANISM_SUBSTANCE", 168, 173], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 222, 240], ["fecal leukocytes", "CELL_TYPE", 6, 22], ["white blood cells", "CELL_TYPE", 143, 160], ["fecal leukocytes", "TEST", 6, 22], ["inflammation in studies", "PROBLEM", 72, 95], ["diarrhea", "PROBLEM", 133, 141], ["white blood cells in the stool", "PROBLEM", 143, 173], ["ulcerative colitis", "PROBLEM", 222, 240], ["Crohn disease", "PROBLEM", 245, 258], ["fecal leukocytes", "ANATOMY", 6, 22], ["inflammation", "OBSERVATION", 72, 84], ["infectious", "OBSERVATION_MODIFIER", 110, 120], ["stool", "ANATOMY", 168, 173], ["may also be", "UNCERTAINTY", 174, 185], ["ulcerative", "OBSERVATION_MODIFIER", 222, 232], ["colitis", "OBSERVATION", 233, 240], ["Crohn disease", "OBSERVATION", 245, 258]]], ["158 Sensitivities can be increased to 83% by testing for fecal calprotectin.", [["calprotectin", "GENE_OR_GENE_PRODUCT", 63, 75], ["fecal calprotectin", "PROTEIN", 57, 75], ["Sensitivities", "TEST", 4, 17], ["fecal calprotectin", "TEST", 57, 75]]], ["159 Nonetheless, clinicians may consider sending a stool sample if there is blood or mucus in the stool, persistent diarrhea of more than 2 weeks' duration, or to help exclude an intestinal infection.Assessment and Diagnostic EvaluationLaboratory testing for patients with vomiting and diarrhea caused by viral illnesses is typically not helpful, as these patients may not demonstrate markers of infection in their blood work or stool cultures.", [["blood", "ANATOMY", 76, 81], ["mucus", "ANATOMY", 85, 90], ["stool", "ANATOMY", 98, 103], ["intestinal", "ANATOMY", 179, 189], ["blood", "ANATOMY", 415, 420], ["diarrhea", "DISEASE", 116, 124], ["intestinal infection", "DISEASE", 179, 199], ["vomiting", "DISEASE", 273, 281], ["diarrhea", "DISEASE", 286, 294], ["viral illnesses", "DISEASE", 305, 320], ["infection", "DISEASE", 396, 405], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["mucus", "ORGANISM_SUBSTANCE", 85, 90], ["stool", "ORGANISM_SUBSTANCE", 98, 103], ["intestinal", "ORGAN", 179, 189], ["patients", "ORGANISM", 259, 267], ["patients", "ORGANISM", 356, 364], ["blood", "ORGANISM_SUBSTANCE", 415, 420], ["patients", "SPECIES", 259, 267], ["patients", "SPECIES", 356, 364], ["a stool sample", "TEST", 49, 63], ["blood", "PROBLEM", 76, 81], ["mucus in the stool", "PROBLEM", 85, 103], ["persistent diarrhea", "PROBLEM", 105, 124], ["an intestinal infection", "PROBLEM", 176, 199], ["Assessment", "TEST", 200, 210], ["Diagnostic EvaluationLaboratory testing", "TEST", 215, 254], ["vomiting", "PROBLEM", 273, 281], ["diarrhea", "PROBLEM", 286, 294], ["viral illnesses", "PROBLEM", 305, 320], ["infection", "PROBLEM", 396, 405], ["their blood work", "TEST", 409, 425], ["stool cultures", "TEST", 429, 443], ["stool", "ANATOMY", 98, 103], ["intestinal", "ANATOMY", 179, 189], ["infection", "OBSERVATION", 190, 199], ["infection", "OBSERVATION", 396, 405]]], ["However, in one study of patients with known norovirus illness, investigators found leukocytosis with a neutrophil predominance was common.", [["neutrophil", "ANATOMY", 104, 114], ["norovirus illness", "DISEASE", 45, 62], ["leukocytosis", "DISEASE", 84, 96], ["patients", "ORGANISM", 25, 33], ["neutrophil", "CELL", 104, 114], ["patients", "SPECIES", 25, 33], ["one study", "TEST", 12, 21], ["known norovirus illness", "PROBLEM", 39, 62], ["leukocytosis", "PROBLEM", 84, 96], ["a neutrophil predominance", "PROBLEM", 102, 127], ["norovirus", "OBSERVATION", 45, 54], ["leukocytosis", "OBSERVATION", 84, 96], ["neutrophil predominance", "OBSERVATION", 104, 127]]], ["Furthermore, 64% of subjects tested positive for fecal leukocytes.", [["fecal leukocytes", "ANATOMY", 49, 65], ["subjects", "ORGANISM", 20, 28], ["fecal leukocytes", "CELL", 49, 65], ["fecal leukocytes", "CELL_TYPE", 49, 65], ["fecal leukocytes", "PROBLEM", 49, 65], ["fecal leukocytes", "ANATOMY", 49, 65]]], ["This finding was surprising, as it had been thought that leukocytosis and stool leukocytes were rare in patients with norovirus-induced gastroenteritis.", [["stool leukocytes", "ANATOMY", 74, 90], ["leukocytosis", "DISEASE", 57, 69], ["norovirus-induced gastroenteritis", "DISEASE", 118, 151], ["stool leukocytes", "CELL", 74, 90], ["patients", "ORGANISM", 104, 112], ["stool leukocytes", "CELL_TYPE", 74, 90], ["patients", "SPECIES", 104, 112], ["leukocytosis", "PROBLEM", 57, 69], ["stool leukocytes", "PROBLEM", 74, 90], ["norovirus", "PROBLEM", 118, 127], ["gastroenteritis", "PROBLEM", 136, 151], ["leukocytosis", "OBSERVATION", 57, 69], ["stool leukocytes", "OBSERVATION", 74, 90], ["norovirus", "OBSERVATION", 118, 127], ["gastroenteritis", "OBSERVATION", 136, 151]]], ["160ManagementThe mainstay of therapy for acute gastroenteritis is supportive care.", [["gastroenteritis", "DISEASE", 47, 62], ["therapy", "TREATMENT", 29, 36], ["acute gastroenteritis", "PROBLEM", 41, 62], ["supportive care", "TREATMENT", 66, 81], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["gastroenteritis", "OBSERVATION", 47, 62]]], ["No specific antiviral therapy exists for viral gastroenteritis.", [["viral gastroenteritis", "DISEASE", 41, 62], ["specific antiviral therapy", "TREATMENT", 3, 29], ["viral gastroenteritis", "PROBLEM", 41, 62], ["antiviral therapy", "OBSERVATION", 12, 29], ["viral gastroenteritis", "OBSERVATION", 41, 62]]], ["Rehydration and electrolyte replacement are the most important aspects of treatment.", [["Rehydration", "DISEASE", 0, 11], ["Rehydration", "TREATMENT", 0, 11], ["electrolyte replacement", "TREATMENT", 16, 39], ["treatment", "TREATMENT", 74, 83], ["electrolyte replacement", "OBSERVATION", 16, 39]]], ["Severely ill, immunocompromised, or very young children with suspected bacterial infections should receive empiric treatment with antibiotics.", [["Severely ill", "DISEASE", 0, 12], ["bacterial infections", "DISEASE", 71, 91], ["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["Severely ill", "PROBLEM", 0, 12], ["immunocompromised", "PROBLEM", 14, 31], ["suspected bacterial infections", "PROBLEM", 61, 91], ["empiric treatment", "TREATMENT", 107, 124], ["antibiotics", "TREATMENT", 130, 141], ["ill", "OBSERVATION_MODIFIER", 9, 12], ["immunocompromised", "OBSERVATION", 14, 31], ["bacterial", "OBSERVATION_MODIFIER", 71, 80], ["infections", "OBSERVATION", 81, 91]]], ["161 To help estimate the degree of fluid loss in children, investigators in Canada have created the Clinical Dehydration Scale (CDS) to identify pediatric patients with severe dehydration.", [["fluid", "ANATOMY", 35, 40], ["fluid loss", "DISEASE", 35, 45], ["dehydration", "DISEASE", 176, 187], ["fluid", "ORGANISM_SUBSTANCE", 35, 40], ["children", "ORGANISM", 49, 57], ["patients", "ORGANISM", 155, 163], ["children", "SPECIES", 49, 57], ["patients", "SPECIES", 155, 163], ["fluid loss", "PROBLEM", 35, 45], ["severe dehydration", "PROBLEM", 169, 187], ["fluid loss", "OBSERVATION", 35, 45], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["dehydration", "OBSERVATION", 176, 187]]], ["The scale assesses 4 characteristics: general appearance, eyes, mucous membranes, and tears.", [["eyes", "ANATOMY", 58, 62], ["mucous membranes", "ANATOMY", 64, 80], ["eyes", "ORGAN", 58, 62], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 64, 80], ["The scale assesses", "TEST", 0, 18], ["tears", "PROBLEM", 86, 91], ["eyes", "ANATOMY", 58, 62], ["mucous membranes", "ANATOMY", 64, 80], ["tears", "OBSERVATION", 86, 91]]], ["If all of these are normal, the score is zero, and the child is determined to have no dehydration.", [["dehydration", "DISEASE", 86, 97], ["dehydration", "PROBLEM", 86, 97], ["normal", "OBSERVATION", 20, 26], ["no", "UNCERTAINTY", 83, 85], ["dehydration", "OBSERVATION", 86, 97]]], ["A score of 1 is given in each category if the child appears thirsty or restless, has slightly sunken eyes, sticky mucous membranes, or decreased tears.", [["eyes", "ANATOMY", 101, 105], ["mucous membranes", "ANATOMY", 114, 130], ["decreased tears", "DISEASE", 135, 150], ["child", "ORGANISM", 46, 51], ["eyes", "ORGAN", 101, 105], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 114, 130], ["restless", "PROBLEM", 71, 79], ["slightly sunken eyes", "PROBLEM", 85, 105], ["sticky mucous membranes", "PROBLEM", 107, 130], ["decreased tears", "PROBLEM", 135, 150], ["mucous membranes", "ANATOMY", 114, 130], ["decreased tears", "OBSERVATION", 135, 150]]], ["A score of 2 is given in each category if the child has a drowsy, limp, cold, or sweaty appearance, has very sunken eyes, dry Vomiting, Diarrhea, Constipation, Gastroenteritis mucous membranes, or absent tears.", [["eyes", "ANATOMY", 116, 120], ["mucous membranes", "ANATOMY", 176, 192], ["limp", "DISEASE", 66, 70], ["dry Vomiting", "DISEASE", 122, 134], ["Diarrhea", "DISEASE", 136, 144], ["Constipation", "DISEASE", 146, 158], ["Gastroenteritis", "DISEASE", 160, 175], ["absent tears", "DISEASE", 197, 209], ["child", "ORGANISM", 46, 51], ["eyes", "ORGAN", 116, 120], ["tears", "PATHOLOGICAL_FORMATION", 204, 209], ["a drowsy", "PROBLEM", 56, 64], ["limp", "PROBLEM", 66, 70], ["cold", "PROBLEM", 72, 76], ["sweaty appearance", "PROBLEM", 81, 98], ["very sunken eyes", "PROBLEM", 104, 120], ["dry Vomiting", "PROBLEM", 122, 134], ["Diarrhea", "PROBLEM", 136, 144], ["Constipation", "PROBLEM", 146, 158], ["Gastroenteritis mucous membranes", "PROBLEM", 160, 192], ["absent tears", "PROBLEM", 197, 209], ["Constipation", "OBSERVATION", 146, 158], ["Gastroenteritis", "OBSERVATION", 160, 175], ["mucous membranes", "ANATOMY", 176, 192], ["absent", "OBSERVATION_MODIFIER", 197, 203], ["tears", "OBSERVATION", 204, 209]]], ["A CDS score of 1 to 4 indicates some dehydration, whereas a score of 5 to 8 indicates moderate to severe dehydration.", [["dehydration", "DISEASE", 37, 48], ["dehydration", "DISEASE", 105, 116], ["A CDS score", "TEST", 0, 11], ["some dehydration", "PROBLEM", 32, 48], ["a score", "TEST", 58, 65], ["moderate to severe dehydration", "PROBLEM", 86, 116], ["dehydration", "OBSERVATION", 37, 48], ["moderate", "OBSERVATION_MODIFIER", 86, 94], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["dehydration", "OBSERVATION", 105, 116]]], ["162 According to the CDC, children weighing less than 10 kg should receive 60 to 120 mL of oral rehydration solution per episode of vomiting or diarrheal stool, and those weighing more than 10 kg should receive 120 to 240 mL oral rehydration solution in addition to their daily requirements.", [["oral", "ANATOMY", 91, 95], ["stool", "ANATOMY", 154, 159], ["oral", "ANATOMY", 225, 229], ["vomiting", "DISEASE", 132, 140], ["diarrheal stool", "DISEASE", 144, 159], ["children", "ORGANISM", 26, 34], ["oral", "ORGANISM_SUBDIVISION", 91, 95], ["stool", "ORGANISM_SUBSTANCE", 154, 159], ["oral", "ORGANISM_SUBDIVISION", 225, 229], ["children", "SPECIES", 26, 34], ["oral rehydration solution", "TREATMENT", 91, 116], ["vomiting", "PROBLEM", 132, 140], ["diarrheal stool", "PROBLEM", 144, 159], ["oral rehydration solution", "TREATMENT", 225, 250]]], ["28, 132 The original standard WHO oral rehydration solution had an osmolality of 311 mOsm/kg; however, in 2002 the formulation was changed to a lower osmolality solution (245 mOsm/kg) with lower concentrations of glucose (75 mmol/L) and sodium (75 mEq/L) based on several studies demonstrating a reduced osmolality solution, diminished stool volume, and the duration of diarrhea.", [["oral", "ANATOMY", 34, 38], ["stool", "ANATOMY", 336, 341], ["glucose", "CHEMICAL", 213, 220], ["sodium", "CHEMICAL", 237, 243], ["diarrhea", "DISEASE", 370, 378], ["glucose", "CHEMICAL", 213, 220], ["sodium", "CHEMICAL", 237, 243], ["oral", "ORGANISM_SUBDIVISION", 34, 38], ["glucose", "SIMPLE_CHEMICAL", 213, 220], ["sodium", "SIMPLE_CHEMICAL", 237, 243], ["stool", "ORGANISM_SUBSTANCE", 336, 341], ["The original standard WHO oral rehydration solution", "TREATMENT", 8, 59], ["an osmolality", "TEST", 64, 77], ["a lower osmolality solution", "TREATMENT", 142, 169], ["glucose", "TEST", 213, 220], ["sodium", "TEST", 237, 243], ["several studies", "TEST", 264, 279], ["a reduced osmolality solution", "PROBLEM", 294, 323], ["diminished stool volume", "PROBLEM", 325, 348], ["diarrhea", "PROBLEM", 370, 378], ["diminished", "OBSERVATION_MODIFIER", 325, 335], ["stool volume", "OBSERVATION", 336, 348]]], ["163 Most commercial oral rehydration solutions contain 2% to 3% carbohydrate.", [["oral", "ANATOMY", 20, 24], ["carbohydrate", "CHEMICAL", 64, 76], ["oral", "ORGANISM_SUBDIVISION", 20, 24], ["carbohydrate", "SIMPLE_CHEMICAL", 64, 76], ["Most commercial oral rehydration solutions", "TREATMENT", 4, 46]]], ["Common household fluids such as tea, fruit juice, sports drinks, and soft drinks have too little sodium along with a higher carbohydrate and osmolality content than suggested, and should therefore be avoided when attempting to hydrate a child with diarrhea.", [["tea", "ANATOMY", 32, 35], ["fruit juice", "ANATOMY", 37, 48], ["sodium", "CHEMICAL", 97, 103], ["diarrhea", "DISEASE", 248, 256], ["sodium", "CHEMICAL", 97, 103], ["carbohydrate", "CHEMICAL", 124, 136], ["tea", "ORGANISM_SUBDIVISION", 32, 35], ["juice", "ORGANISM_SUBSTANCE", 43, 48], ["sodium", "SIMPLE_CHEMICAL", 97, 103], ["carbohydrate", "SIMPLE_CHEMICAL", 124, 136], ["fruit", "SPECIES", 37, 42], ["too little sodium", "PROBLEM", 86, 103], ["a higher carbohydrate and osmolality content", "PROBLEM", 115, 159], ["diarrhea", "PROBLEM", 248, 256], ["fluids", "OBSERVATION", 17, 23]]], ["28, 29 In children with severe dehydration (more than 10% body weight loss), intravenous fluids are recommended.", [["body", "ANATOMY", 58, 62], ["intravenous", "ANATOMY", 77, 88], ["dehydration", "DISEASE", 31, 42], ["weight loss", "DISEASE", 63, 74], ["children", "ORGANISM", 10, 18], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 88], ["children", "SPECIES", 10, 18], ["severe dehydration", "PROBLEM", 24, 42], ["body weight loss", "PROBLEM", 58, 74], ["intravenous fluids", "TREATMENT", 77, 95], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["dehydration", "OBSERVATION", 31, 42]]], ["A 20 mL/kg bolus of intravenous fluid is suggested except in the case of a malnourished infant, where 10 mL/kg as a starting resuscitative amount is recommended to avoid overhydration or heart failure.", [["intravenous", "ANATOMY", 20, 31], ["heart", "ANATOMY", 187, 192], ["overhydration", "DISEASE", 170, 183], ["heart failure", "DISEASE", 187, 200], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 31], ["infant", "ORGANISM", 88, 94], ["heart", "ORGAN", 187, 192], ["A 20 mL/kg bolus of intravenous fluid", "TREATMENT", 0, 37], ["a starting resuscitative amount", "TREATMENT", 114, 145], ["overhydration", "PROBLEM", 170, 183], ["heart failure", "PROBLEM", 187, 200], ["overhydration", "OBSERVATION", 170, 183], ["heart", "ANATOMY", 187, 192], ["failure", "OBSERVATION", 193, 200]]], ["After the initial intravenous therapy, 100 mL/kg oral rehydration solution over 4 hours or D5\u00bdNS (dextrose 5% in 0.45% normal saline) intravenously at a rate of twice maintenance may be administered.ManagementSuggested indications for hospital admission for children with gastroenteritis include severe dehydration, neurological involvement, toxic state or shock, inability to tolerate oral rehydration, potential for surgery, failure of treatment despite oral rehydration therapy, or uncertain diagnosis.", [["intravenous", "ANATOMY", 18, 29], ["oral", "ANATOMY", 49, 53], ["neurological", "ANATOMY", 316, 328], ["oral", "ANATOMY", 386, 390], ["oral", "ANATOMY", 456, 460], ["dextrose", "CHEMICAL", 98, 106], ["gastroenteritis", "DISEASE", 272, 287], ["dehydration", "DISEASE", 303, 314], ["shock", "DISEASE", 357, 362], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 29], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["saline", "SIMPLE_CHEMICAL", 126, 132], ["children", "ORGANISM", 258, 266], ["oral", "ORGANISM_SUBDIVISION", 386, 390], ["oral", "ORGANISM_SUBDIVISION", 456, 460], ["children", "SPECIES", 258, 266], ["the initial intravenous therapy", "TREATMENT", 6, 37], ["oral rehydration solution", "TREATMENT", 49, 74], ["D5", "TREATMENT", 91, 93], ["NS (dextrose", "TREATMENT", 94, 106], ["gastroenteritis", "PROBLEM", 272, 287], ["severe dehydration", "PROBLEM", 296, 314], ["neurological involvement", "PROBLEM", 316, 340], ["toxic state", "PROBLEM", 342, 353], ["shock", "PROBLEM", 357, 362], ["oral rehydration", "TREATMENT", 386, 402], ["surgery", "TREATMENT", 418, 425], ["treatment", "TREATMENT", 438, 447], ["oral rehydration therapy", "TREATMENT", 456, 480], ["severe", "OBSERVATION_MODIFIER", 296, 302], ["dehydration", "OBSERVATION", 303, 314]]], ["Providers should also consider admission for children younger than 2 months, febrile infants younger than 6 months with bloody stool, children with immunodeficiency or malnutrition, or if there is an inability to take care of the child at home.", [["febrile", "DISEASE", 77, 84], ["bloody stool", "DISEASE", 120, 132], ["immunodeficiency", "DISEASE", 148, 164], ["malnutrition", "DISEASE", 168, 180], ["children", "ORGANISM", 45, 53], ["infants", "ORGANISM", 85, 92], ["children", "ORGANISM", 134, 142], ["children", "SPECIES", 45, 53], ["infants", "SPECIES", 85, 92], ["children", "SPECIES", 134, 142], ["febrile", "PROBLEM", 77, 84], ["bloody stool", "PROBLEM", 120, 132], ["immunodeficiency", "PROBLEM", 148, 164], ["malnutrition", "PROBLEM", 168, 180]]], ["132SUMMARYPatients commonly present to the ED with symptoms of vomiting, diarrhea, constipation, and gastroenteritis.", [["vomiting", "DISEASE", 63, 71], ["diarrhea", "DISEASE", 73, 81], ["constipation", "DISEASE", 83, 95], ["gastroenteritis", "DISEASE", 101, 116], ["symptoms", "PROBLEM", 51, 59], ["vomiting", "PROBLEM", 63, 71], ["diarrhea", "PROBLEM", 73, 81], ["constipation", "PROBLEM", 83, 95], ["gastroenteritis", "PROBLEM", 101, 116], ["diarrhea", "OBSERVATION", 73, 81], ["constipation", "OBSERVATION", 83, 95], ["gastroenteritis", "OBSERVATION", 101, 116]]], ["While management focuses largely on supportive care, the clinician needs to be aware that some patients, particularly infants, the elderly, and immunocompromised individuals, may need more aggressive care.", [["patients", "ORGANISM", 95, 103], ["infants", "ORGANISM", 118, 125], ["patients", "SPECIES", 95, 103], ["infants", "SPECIES", 118, 125], ["supportive care", "TREATMENT", 36, 51], ["immunocompromised individuals", "PROBLEM", 144, 173], ["aggressive care", "TREATMENT", 189, 204]]], ["New medications and treatment modalities continue to be developed for these conditions, with the latest pharmaceuticals offering promise in terms of their efficacy and side effect profiles.", [["New medications", "TREATMENT", 0, 15], ["treatment modalities", "TREATMENT", 20, 40], ["the latest pharmaceuticals", "TREATMENT", 93, 119], ["side effect profiles", "PROBLEM", 168, 188]]]]}